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Abstract 
 
A primary focus of the Molecular Neuropathobiology laboratory is the 
investigation of the long range trafficking of neurotrophins and neurotrophin receptors 
in motor neurons (MNs). The goal of my project was to deepen our understanding of the 
nature of the cellular machinery controlling long-range neurotrophin trafficking in 
MNs, by discovering new players involved in this process. In order to achieve this goal 
I performed an siRNA screen in MNs derived from mouse ES cells to monitor the cell 
surface binding and internalization of two fluorescently tagged reporters: the binding 
fragment of the Tetanus neurotoxin (HC), which enters an axonal transport compartment 
shared with neurotrophins and their receptors, and an antibody directed against the 
extracellular domain of the neurotrophin receptor p75NTR. A high-throughput, lipid-
based siRNA transfection method was optimised for ES cell-derived MNs and used to 
screen a library of siRNAs directed against a pool of genes involved in endocytosis and 
membrane trafficking. The primary candidate genes were subsequently validated, and 
one gene in particular, Bicaudal D homolog 1 (BICD1), was selected for further 
analyses.  
BICD1 is a member of the Bicaudal D family, whose members function as 
molecular motor adaptors with pleiotropic roles in intracellular trafficking. Bicd1 
expression at E12.5 and 13.5 was restricted to the nervous system, suggesting an 
important role for BICD1 in neurons. I used gene-trapped ES cells to derive MNs 
depleted of the BICD1 protein (Bicd1gt/gt MNs), which, when challenged with either HC 
or the p75NTR antibody, displayed an increased intracellular accumulation of both 
probes. Furthermore, I found that the level of neurotrophin receptors exposed at the 
plasma membrane was increased in these cells compared to their wild type counterparts, 
suggesting that BICD1 might be involved in the regulation of neurotrophin receptor 
dynamics in mammalian neurons. I also found that TrkB signalling upon stimulation 
with the brain-derived neurotrophic factor (BDNF) in Bicd1gt/gt MNs, was impaired. 
This suggests that the depletion of BICD1 not only affects the trafficking of 
neurotrophin receptors, but also their signalling capabilities. 
In conclusion, this thesis work has demonstrated that the concept of high 
throughput screening can be applied to cells notoriously difficult to handle and 
transfect, such as MNs. This approach was successful in unravelling a new role for 
BICD1 in neurons, where it appears to regulate the intracellular trafficking and 
signalling of neurotrophin receptors. Taken together with the in vivo expression data, 
these data suggest that BICD1 plays an important role in the development and function 
of the nervous system. 
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Chapter 1. Introduction 
1.1 Tetanus Neurotoxin 
 One of the probes used extensively in this thesis work to study the intracellular 
trafficking of neurotrophins and neurotrophin receptors is the HC fragment of the 
Clostridium tetani toxin of Clostridium tetani is able to produce a potent neurotoxin, 
called Tetanus Neurotoxin (TeNT), which was identified as the sole causative agent of 
tetanus, an often-fatal pathology characterised by spastic paralysis which can result in 
cardiovascular or respiratory failure.  
 TeNT is one of the most toxic virulence factors known, with an LD50 in mouse 
between 0.1 and 1 ng/kg of body weight. It is produced by the bacteria in lesions 
contaminated with toxigenic strains of C. tetani. In anaerobic conditions, these spores 
germinate, giving rise to the vegetative form of the bacteria, which synthesises TeNT. 
The toxin is released into the blood circulation, and is then able to bind with high 
affinity to the presynaptic membrane of motor neurons (MNs) at the neuromuscular 
junction (NMJ) (Montecucco and Schiavo, 1994). TeNT is then internalised and 
targeted to an axonal retrograde transport route, which enables the toxin to reach the 
MN soma, located in the spinal cord. Here TeNT is sorted and redirected to a 
transcytotic route, which results in its release into the extracellular space, where it binds 
to and is internalised into inhibitory interneurons. TeNT induces a block of 
neurotransmitter release from inhibitory interneurons, which results in the spastic 
paralysis characteristic of the disease (Montecucco and Schiavo, 1994).  
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1.1.1 Structure of Tetanus Neurotoxin 
 TeNT is initially synthesised by Clostridium tetani as an inactive polypeptide of 
150 kDa, which is then cleaved by specific bacterial or host proteases into two 
fragments, a 100 kDa heavy chain (HC) and a 50 kDa light chain (LC) (Figure 1.1 A) 
(Montecucco and Schiavo, 1994). The two chains remain associated via a single 
disulfide bond and non-covalent interactions. The LC is a zinc endoprotease and it is 
responsible for the block of neurotransmitter release. Once in the cytosol of inhibitory 
interneurons, the LC cleaves a unique peptide bond in the vesicle associated membrane 
protein 2 (VAMP2/synaptobrevin) (Schiavo et al., 1992a) (Schiavo et al., 1992b), which 
is a member of the soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) family of proteins. Different sets of SNAREs constitute the core 
machinery providing the driving force for membrane fusion in different cellular 
compartments (Jahn and Scheller, 2006). VAMP2 is involved in the fusion of synaptic 
vesicles (SVs), which contain the neurotransmitters, with the plasma membrane. 
Therefore its cleavage by TeNT prevents the fusion of SVs and results in the block of 
neurotransmitter release by the inhibitory interneurons. 
 The LC needs to be linked to the HC in order to gain access to the neuronal 
cytosol and cleave VAMP2. HC is, in fact, responsible for the binding to the neuronal 
surface and the translocation of TeNT into the cytoplasm (Lalli et al., 1999, Herreros et 
al., 2001), where LC cleaves its substrate. HC can be divided into two functional 
regions, a 50 kDa N-terminal (HN) and a 50 kDa C-terminal fragment (HC), which can 
be further subdivided in another 2 fragments of 25 kDa each, HCN and HCC (Figure 1.1 
A). HN has a loop that interacts with LC and two long α-helices and it is responsible for 
the translocation of LC through the endosomal membrane. Once inside the endosomal 
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compartment, the acidic pH is believed to cause a conformational change in HN, which 
rearranges to form a membrane pore, through which the LC translocates out of the 
endosome and into the cytoplasm.  
 The precise role of the HCN fragment is still unknown; however, it does not seem 
to play a role in the binding of TeNT to the neuronal membrane since it does not bind to 
rat dorsal root ganglionic cells (DRG) (Figueiredo et al., 1995) or to differentiated 
phaechromocytoma cells (PC12) (Herreros et al., 2001). HCC, however, has a well-
defined role: it is the main determinant in mediating the highly specific binding of 
TeNT to MN nerve terminals (Dolly et al., 1984) (Herreros et al., 2001) (Rummel et al., 
2003).  
1.1.2 Neurospecific binding of Tetanus Neurotoxin 
 TeNT binding in vivo is restricted to the presynaptic terminal of cholinergic 
nerves and to sympathetic adrenergic nerve fibers (Habermann and Dreyer, 1986). This 
binding has a very high affinity (sub-nanomolar range) and it is virtually irreversible. 
Since pre-treatment with an excess of HC is enough to counteract the paralysis induced 
by the whole toxin, this fragment bears the minimum determinant for the physiological 
binding of TeNT (Lalli et al., 1999). 
 The most important binding partners of TeNT on the neuronal plasma 
membrane (PM) identified so far are the polysialogangliosides of the G1b series (GD1b, 
GT1b and GQ1b), for which the HCC domain has two oligosaccharide-binding sites 
(Rummel et al., 2003). These gangliosides are essential for the binding and therefore the 
activity of the TeNT. Impairment of ganglioside biosynthesis, for example, decreases 
the activity of the toxin in vivo (Kitamura et al., 1999) (Williamson et al., 1999).  
Chapter 1. Introduction 
17 
 Montecucco (1986) has formulated a dual receptor model for the binding of 
TeNT. This model would involve a two-step process, where the initial binding is 
determined by the gangliosides, which are abundant on the neuronal surface and act as 
low affinity receptors. Once bound to gangliosides, TeNT could then come into contact 
with a putative high affinity protein receptor, which might mediate the subsequent 
endocytosis of the toxin (Montecucco, 1986, Binz and Rummel, 2009). This hypothesis 
is supported by the observation that TeNT has been found to be able to bind to one or 
more GPI-anchored protein(s) of 15 kDa (Herreros et al., 2000), and the cleavage of 
such GPI-anchored proteins has a protective effect on TeNT intoxication in neurons 
(Munro et al., 2001) (Herreros et al., 2001). One such GPI-anchored protein was 
identified as Thy-1 in NGF-differentiated PC12 cells, but this is unlikely to be the main 
protein receptor in vivo, since Thy1 knock-out mice are still sensitive to TeNT 
intoxication (Herreros et al., 2001). Interestingly, GPI-anchored proteins, cholesterol 
and gangliosides are all enriched in lipid rafts, which suggests that lipid microdomains 
might play a role in TeNT binding to the neuronal surface. Interestingly, TeNT and the 
closely related Botulinum toxins (BONTs) have been found associated with detergent-
resistant glycolipid-enriched microdomains (DRM) (Herreros et al., 2001). 
1.1.3 Endocytosis of Tetanus Neurotoxin 
 Synaptic activity seems to be implicated in TeNT uptake both in vivo and in 
vitro. TeNT was found to colocalise with SV markers in hippocampal neurons after 
depolarisation (Matteoli et al., 1996), and its uptake in vivo has been shown to be 
dependent on synaptic activity (Miana-Mena et al., 2002). These findings would suggest 
that TeNT internalisation is mediated via SV recycling. This mode of internalisation is 
likely to occur in hippocampal neurons, but not in MNs, where very little colocalisation 
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has been found between SV markers and the toxin (Lalli and Schiavo, 2002). In 
addition, TeNT uptake at the NMJ and its subsequent retrograde axonal transport do not 
appear to be affected by the inhibition of neurotransmitter release (Schiavo et al., 2000). 
These data were confirmed by the finding that pre-treatment with BONTs, which 
abolishes SV exocytocis and recycling, does not stop TeNT internalisation in MNs 
(Deinhardt et al., 2006a). The HC fragment of the toxin has been found in clathrin-
coated invaginations of the plasma membrane in MNs, and its internalisation was 
successfully prevented by overexpression of a dominant-negative mutant of dynamin 
and the clathrin adaptors complexes AP2 and AP180 (Deinhardt et al., 2006a). These 
data suggest that TeNT undergoes a clathrin-mediated dynamin-dependent endocytosis 
in MNs, independent of SV recycling. 
1.1.4 TeNT retrograde transport 
 As are all neurons, MNs are extremely polarised cells, which extend long axons 
to make contact with their target muscles. As a result they need a tightly controlled 
machinery to ensure the long-range axonal transport of signalling molecules back to the 
cell body, which is important for their survival (Goldstein and Yang, 2000). There are 
two main components of axonal transport, a slow one (1-50 nm/s) for microtubules, 
neurofilaments, cytoplasmic proteins and metabolic enzymes, and a fast one (0.1-5 
µm/s) used for vesicle and organelle transport and also for survival signals like 
neurotrophins and their receptors (Vallee and Bloom, 1991). 
 Since TeNT undergoes retrograde transport in neurons, it has been widely used 
to monitor this process. The compartment in which TeNT is transported has been 
visualised using labelled versions of the HC fragment. Different types of carriers were 
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identified, including tubular vesicles with a fast and continuous movement (speed up to 
3.6 µm/s) and round vesicles, which move more slowly and exhibit frequent pauses 
(Lalli and Schiavo, 2002).  
Pharmacological disruption of the microtubule and actin cytoskeleton or 
inhibition of cytoplasmic dynein (Lalli et al., 2003) affects the axonal retrograde 
transport of HC confirming that the transport of HC is dynein-dependent. Another 
molecular motor involved in HC axonal retrograde transport is myosin Va, as 
demonstrated by the fact that MNs derived from myosin Va null embryos show an 
overall slower transport of HC-positive carriers (Lalli et al., 2003). These HC-positive 
axonal retrograde carriers have been partially characterised. They have a neutral pH, 
which is crucial since an acidification of the endocytic compartment would trigger the 
translocation of the toxin into the cytoplasm (Lalli and Schiavo, 2002, Bohnert and 
Schiavo, 2005). Neurotrophins and their receptors have been found to be co-transported 
in HC-positive carriers, suggesting that they use the same long-range transport pathway 
as TeNT (Lalli and Schiavo, 2002, Deinhardt et al., 2006b). This pathway is dependent 
on two small RAB GTPases, RAB5 and RAB7. In particular RAB7 seems to be 
responsible for the long-range axonal retrograde transport of HC, which is abolished 
using a dominant-negative version of RAB7 (Deinhardt et al., 2006b) (Figure 1.1. B). 
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Figure 1.1. Structure of TeNT and its binding and endocytosis in MNs. 
Schematic representation of the structure of TeNT. The HC fragment is further subdivided into the HCN 
and HCC domains (A). The main function of these domains is indicated (adapted from the Ph.D. thesis of 
K. Deinhardt). (B) Model of internalisation of the HC fragment of TeNT. HC binds to the gangliosides on 
the neuronal plasma membrane and is internalised in a clathrin-dependent fashion. Together with 
neurotrophins and their receptors, HC enters into a RAB5-positive compartment and finally undergoes 
axonal retrograde transport in a RAB7-positive compartment. Mutants of RAB5 (RAB5N133I) and 
RAB7 (RAB7N125I) abolish the transport of HC (taken from (Deinhardt et al., 2006b)) (B). 
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1.2 Neurotrophins and their receptors 
 In addition to the HC fragment of TeNT, an antibody against the extracellular 
domain of the p75 neurotrophin receptor (p75NTR) has been used in this thesis work to 
investigate the intracellular trafficking of neurotrophins and their receptors. 
 Neurotrophins play a critical role in the development of the nervous systems and 
its maintenance during adulthood. Neurotrophins are a small family of structurally 
related growth factors with the ability to modulate cell survival and development of 
most types of neurons. They were originally identified as survival factors for neurons 
secreted from their target tissue (Cohen et al., 1954, Levi-Montalcini and Angeletti, 
1963); in particular it was proposed that during innervation neurotrophins like nerve 
growth factor (NGF) are released by the innervated tissue, promoting the survival of 
only those neurons which had made the correct connections. This would be a way of 
shaping the pattern of innervation of the tissue, negatively selecting away neurons that 
failed to make the right contacts with their target (Levi-Montalcini, 1987). 
Neurotrophins, however, have been implicated in a wide range of biological functions, 
such as the regulation of neuroblast and neural crest cell proliferation, regulation of 
neurite outgrowth, and synaptic modulation (Huang and Reichardt, 2001). 
 There are four neurotrophins, NGF, BDNF, NT-3 and NT-4/5 (Bibel and Barde, 
2000, Huang and Reichardt, 2001) and their sequences are highly conserved in 
vertebrates.  All neurotrophins are synthesised as precursors of 31-35 kDa, which are 
then cleaved by convertases to produce the mature forms of 13.2 – 15.9 kDa. Mature 
neurotrophins exist as non-covalently bound homodimers, which are released through 
the constitutive secretory pathway (NGF, NT-3) or a specialised regulated pathway 
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(BDNF) (Mowla et al., 1999, Roux and Barker, 2002). Neurons themselves can also 
synthesise neurotrophins (Roux and Barker, 2002). In addition, it has been documented 
that neurotrophin secretion in the nervous system increases after an injury (Roux and 
Barker, 2002).   
 The increasingly complex functions related to neurotrophin signalling are 
mediated by two classes of receptors, the tropomyosin-related kinase (Trk) tyrosine 
kinase receptors (TrkA, TrkB and TrKC), and p75NTR. The Trk receptors were so named 
because the first reported member of the family, TrkA, was identified as a transforming 
oncogene, in which an unknown tyrosine kinase was fused to tropomyosin (Martin-
Zanca et al., 1989). The four neurotrophins exhibit different degrees of specificity 
towards the different Trk receptors: NGF binds preferentially to TrkA, BDNF and 
NT4/5 to TrkB and NT-3 to TrkC. A certain level of crosstalk, however, has also been 
reported: NT-4/5 is also able to bind to TrkA and NT-3 also binds to TrkA and TrkB 
(Segal and Greenberg, 1996) (Figure 1.2). Pro-neurotrophins have a greater affinity for 
p75NTR, while mature neurotrophins preferentially bind Trk receptors. For this reason 
the control of neurotrophin processing determines the relative contribution of p75NTR 
versus Trk receptor signalling. In addition, the selective activation of p75NTR by pro-
neurotrophins depends on the association of the receptor with another membrane 
protein called sortilin (Schecterson and Bothwell, 2010). 
 Trk receptors are type I transmembrane proteins. Their extracellular domains 
contain two cysteine-rich regions, which flank a leucine–rich repeat, and two 
immunoglobulin (IgG)-like domains in the juxtamembrane region, which are 
responsible for the binding of the neurotrophins (Roux and Barker, 2002)(Figure 1.2.). 
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The binding of the ligand triggers the dimerization of Trk receptors, which then 
autophosphorylate, initiating their signalling cascade. In the case of TrkA, for example, 
this phosphorylation results in the creation of a docking site for adaptor proteins, which 
regulate cell growth and survival through the Ras, phosphatidylinositol 3-kinase (PI3K) 
and phospholipase Cγ (PLCγ) pathways (Segal and Greenberg, 1996) (Kaplan and 
Miller, 2000). 
 A number of truncated isoforms of the Trk receptors have been described, 
including TrkA and TrkB lacking a short amino acid region in the extracellular domain 
(Clary and Reichardt, 1994) (Strohmaier et al., 1996) and versions of TrkB and TrkC 
missing the complete intracellular kinase domain (Roux and Barker, 2002). A 
signalling-defective isoform of TrkC with amino acid insertions in its kinase domain 
has also been reported (Tsoulfas et al., 1993) (Valenzuela et al., 1993). Finally, two 
truncated forms of TrkB, T1 and T2, have been found, which have a cytoplasmic tail of 
21-23 amino acids and are highly expressed in the adult brain (Fryer et al., 1996) 
(Figure 1.2). Truncated and inactive forms of the Trk receptors display different 
affinity for neurotrophins and might, therefore, act as modulators of the signalling of 
their full-length counterparts (Roux and Barker, 2002). 
 p75NTR is as a member of the tumour necrosis factor receptor (TNFR-SF) family 
of proteins (Johnson et al., 1986) (Radeke et al., 1987) and, unlike the Trk receptors, is 
capable of binding to all four neurotrophins. Its extracellular domain is composed of 
four cysteine-repeats motifs (CRD), whilst its intracellular region contains a type II 
death domain (Figure 1.2). p75NTR stably dimerises through a disulfide bond in the 
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transmembrane region of the receptor, and this linkage seems to be important to ensure 
effective neurotrophin-dependent signalling. (Vilar et al., 2009a, Vilar et al., 2009b). 
The signalling cascades mediated by p75NTR is triggered by the specific 
interaction of its intracellular domain (ICD) and a cohort of adaptor proteins; the ICD 
does not contain a known catalytic domain (Roux and Barker, 2002). The binding to the 
neurotrophin homodimer pushes the two CRD domains of the p75NTR dimer close 
together, a movement that propagates to the intracellular domains, which are forced to 
spread apart, making them accessible to signalling adaptor proteins like NRIF and 
TRAF6 (Vilar et al., 2009a) (Vilar et al., 2009b). p75NTR is also sequentially cleaved by 
α and γ−secretases, which results in the release of its ICD into the cytoplasm, 
promoting NRIF signalling (Schecterson and Bothwell, 2010) (Figure 1.2).  
1.2.1 Neurotrophin trafficking and signalling 
 Compared to conventional growth factor signalling, neurotrophin signalling 
needs to be propagated over much longer distances. Target-derived neurotrophins bind 
their receptors at the synaptic terminals and their downstream signals have to travel the 
full length of the axon before reaching the soma, where they initiate a specific gene 
expression response (Howe and Mobley, 2005).  
 Endocytosis of ligand-receptor complexes has been considered in the past as a 
way to down-regulate the signalling cascade (Bronfman et al., 2007). However, it is 
becoming evident that growth factors continue to signal from endosomes after 
internalisation (Bronfman et al., 2007). In the case of neurotrophin signalling, Mobley 
and colleagues determined that activated TrkA receptor bound to NGF could be found 
associated with intracellular membranes, together with PLC-γ (Grimes et al., 1996, 
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Grimes et al., 1997). This finding was the basis for the formulation of the “signalling 
endosome” hypothesis for neurotrophin signalling, which is the most widely accepted in 
the literature, though other theories, such as the “wave model” and the “signal effector 
model” have been formulated (Wu et al., 2009). According to the signalling endosome 
theory, neurotrophins remain bound to their activated receptors after internalisation and 
other signalling molecules of their cascade are recruited to the internalised endosome 
and activated in situ. In this context, this organelle would, then, constitute a signalling 
platform, which, in neurons, is retrogradely transported along the axon towards the cell 
soma. 
 There are several known routes of internalisation of activated receptors from the 
plasma membrane: clathrin-mediated, caveolin-mediated, clathrin- and caveolin-
independent and macropinocytosis (Bronfman et al., 2007). All of these are believed to 
converge on one compartment, the peripheral early endosomes, also known as sorting 
endosomes, from which the receptors are recycled back to the plasma membrane, or 
targeted for lysosomal degradation via late endosomes (Di Fiore and De Camilli, 2001, 
Miaczynska et al., 2004). This endocytic network is orchestrated by a family of proteins 
called RAB GTPases, which are involved in the regulation of vesicle sorting and 
transport (Stenmark, 2009). For example, RAB5 controls early endosomal trafficking, 
RAB11 is involved in the recycling pathway and RAB7 is associated with late 
endosomes and lysosomes (Feng et al., 1995, Mukhopadhyay et al., 1997, Vitelli et al., 
1997, Bucci et al., 2000, Lebrand et al., 2002, Jordens et al., 2005, Stenmark, 2009). 
TrkA internalisation and signalling have been the most studied and best 
understood of the Trk receptors. TrkA internalisation depends on dynamin 1 and can 
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either be clathrin-mediated or occur via macropinocytosis due to the action of the 
chaperone protein Pincher (Shao et al., 2002). Clathrin-mediated TrkA endocytosis is 
connected to its signalling through ERK1/2 and the PI3-K pathway, as hinted at by the 
finding that, following the addition of NGF to PC12 cells, TrkA is recovered in 
fractions containing clathrin-coated vesicles and components of the ERK1/2 signalling 
pathway (Howe et al., 2001). Interestingly, PI3K influences the activity of RAB5, either 
acting on its effectors, such as EEA1, or on RAB5 itself, and in doing so regulates early 
endosomal endocytic trafficking (Seabra and Wasmeier, 2004). After stimulation of 
PC12 cells with NGF, TrkA internalisation is important for sustained ERK1/2 
activation, as demonstrated by the fact that endosomal accumulation of TrkA induced 
via the over-expression of a dominant negative version of RAB7 results in potentiated 
ERK1/2 phosphorylation (Saxena et al., 2005a, Saxena et al., 2005b).  
 Macropinocytosis is a form of internalisation that is regulated by actin dynamics 
in areas of spreading and ruffling of the plasma membrane (Kirkham and Parton, 2005). 
TrkA internalisation via macropinocytosis is controlled in PC12 cells by a protein 
induced by NGF, Pincher (Shao et al., 2002), and it has been connected to a preferential 
activation of ERK5 instead of ERK1/2, which is activated upon TrkA clathrin-mediated 
endocytosis (Bronfman et al., 2007). Interestingly, ERK5 was found to be the preferred 
mitogen-activated protein kinase (MAPK) for neurotrophin receptor activation in distal 
axons (Watson et al., 2001).  
 p75NTR has been reported to have an effect on TrkA trafficking and signalling. In 
one case, p75NTR was found to inhibit the poly-ubiquitination of TrkA, causing its 
retention on the plasma membrane (Makkerh et al., 2005). These results, however, are 
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controversial, since another study showed that p75NTR was required for TrkA 
ubiquitination (Geetha et al., 2005). These apparently contradictory results might be 
explained by the existence of two ubiquitination mechanisms for TrkA, one dependent 
on and one independent from p75NTR and its effector TRAF6. Interestingly, TRAF6-
induced ubiquitination of TrkA results in the activation of the TrkA signalling pathway 
mediated by ERK5, as demonstrated by the finding that the inhibition of TRAF6-
mediated ubiquitination of TrkA causes a lower ERK5 and Akt activation (Geetha et al., 
2005).  
 Regarding the trafficking of p75NTR in PC12 cells, it is known that 
pharmacological inhibition of clathrin-mediated endocytosis blocks the ligand-
dependent internalisation of this receptor. In addition, p75NTR was found to accumulate 
in transferrin-positive recycling endosomes, where it is associated with its downstream 
effectors (Bronfman et al., 2003). p75NTR does not appear to be sorted to the degradative 
pathway and studies have shown that, in NGF-stimulated PC12 cells, a certain 
population of vesicles were positive for both TrkA and p75NTR. TrkA has been found to 
follow the degradative route, even though it has also been described that a pool of the 
receptor is sorted to the recycling pathway. Such a  p75NTR/TrkA double-positive 
organelle could then either be considered as an early or a recycling endosome 
(Bronfman et al., 2007). Interestingly, TrkA has been shown to follow the recycling 
transcytotic route, dependent on RAB11 in sympathetic neurons (Ascano et al., 2009). 
The authors of that study speculate that during neurotrophin-mediated processes such as 
axon growth, guidance and neuronal survival, the demand for TrkA must be so high that 
the secretory pathway cannot cope. Therefore, as a backup mechanism, mature TrkA, 
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present on the plasma membrane of the soma is endocytosed and mobilised via RAB11-
positive recycling endosomes and transported to the axonal membrane.  
 Surprisingly, TrkA and TrkB exhibit very different behaviours in neurosecretory 
cells and cortical neurons. TrkA was found to predominantly recycle back to the plasma 
membrane in a ligand-dependent manner, while TrKB was mainly sorted to the 
degradative pathway in cortical neurons (Chen et al., 2005).  
 In summary, NGF receptors have been found on the plasma membrane, clathrin-
coated vesicles, early endosomes, late endosomes/MVBs, macropinosomes and 
recycling endosomes in PC12 cells, but the regulation of their trafficking is still largely 
unclear (Figure 1.3). 
 Studies have shown that p75NTR undergoes retrograde transport in neurons (Lalli 
and Schiavo, 2002, Chao and Lee, 2004, Deinhardt et al., 2006b), and that this receptor 
is internalised both in the axon and the somatodendritic region in hippocampal neurons. 
In addition, p75NTR was found in internalised vesicles together with NGF and the 
ganglioside GM1 and transferrin (Bronfman et al., 2003). Because of the data gathered 
in PC12 cells, which suggest that p75NTR is directed to the recycling route, it is possible 
that the receptor is transported along the axon in GM1-positive endosomes which are 
then sorted to the recycling route at the level of the cell body (Bronfman et al., 2007). 
Interestingly, GM1 has been described as a component of lipid rafts, and its 
internalisation is clathrin-dependent, as shown for the HC, which also binds to lipid rafts 
and has been reported to undergo axonal retrograde transport in the same compartment 
as p75NTR (Deinhardt et al., 2006a, Deinhardt et al., 2006b).  
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1.2.2 Neurotrophin axonal transport 
 Neurotrophin trafficking in neurons is quite different from that described for 
PC12 cells, because neurotrophins are secreted by the target tissue and therefore need to 
be retrogradely transported to the cell soma, where their signalling results in a change in 
gene expression. Many theories have been formulated on how neurotrophin signalling is 
conveyed to the neuronal cell body and the hypothesis that has gathered the most 
experimental evidence to date seems to be the “signalling endosome” model (Bronfman 
et al., 2007). The initial evidence used to propose this model was the discovery that 
activated TrkA accumulated at the distal site of ligated rat sciatic nerve. This 
accumulation would imply a retrograde axonal transport of the activated receptor 
(Bhattacharyya et al., 1997). It was then found that dynein-mediated retrograde axonal 
transport of iodinated NGF in sensory neurons was dependent on the signalling of 
different kinases including TrkA and PI3-K (Reynolds et al., 1998), and that 
internalisation and activation of Trk receptors were both required for retrogradely 
transmitted nuclear responses (Riccio et al., 1997, Watson et al., 2001, Heerssen et al., 
2004). In addition to the requirement for transport of the activated receptor, it was 
discovered that the ligand also had to be co-transported with the receptor in order to 
trigger the survival response. The need to have a functional transport of activated 
receptor together with its ligand was demonstrated with the use of NGF-coated 
microspheres, which can induce TrkA phosphorylation, but cannot be transported 
(Riccio et al., 1997). Riccio et al. found that the application of NGF microspheres to 
distal axons in a sympathetic neuron compartmentalised system was not sufficient for 
the NGF-induced survival of these neurons. Since then, more evidence supporting an 
endosome-based retrograde survival pathway in neurons has been found (Bronfman et 
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al., 2007), and some of the players regulating this process have been described. RAB5 
and RAB7, for example, have been shown to control the axonal retrograde transport of 
neurotrophins and their receptors (Saxena et al., 2005a, Saxena et al., 2005b, Deinhardt 
et al., 2006b). In addition, the stability of microtubules and the actin cytoskeleton affect 
the axonal transport of Trk receptors and p75NTR, and the retrograde motor dynein has 
been found as the main motor promoting the axonal retrograde transport of neurotrophin 
receptors (Yano et al., 2001, Heerssen et al., 2004, Lalli et al., 2003).  
 The nature of the retrogradely transported signalling organelle remains 
undefined. Mobley and co-workers have described that NGF and the Trk receptors are 
transported in RAB5-positive early endosomes (Howe et al., 2001, Delcroix et al., 
2003).  However, other evidence supports the hypothesis that MVBs might be the 
organelle involved in neurotrophin retrograde transport. For example, MVBs have been 
found to be the main endosomal population in sympathetic neuron cell bodies labelled 
with iodinated NGF (Claude et al., 1982). Other groups have found that Trk receptors 
are associated with MVBs (Valdez et al., 2005), suggesting that MVBs might be a 
stable platform for neurotrophin signalling after axonal retrograde transport. 
Interestingly, RAB7, which is a marker of late endosomes/MVBs, has been implicated 
in the control of TrkA endosomal transport and signalling through ERK1/2 in PC12 
cells (Saxena et al., 2005a, Saxena et al., 2005b). RAB7 has also been described as a 
key player in the axonal retrograde transport of TrkB/p75NTR positive endosomes in 
motor neurons, in which dominant-negative versions of this RAB GTPase completely 
abolished the transport of these neurotrophin receptors (Deinhardt et al., 2006b).  
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 If MVBs are indeed the compartment in which neurotrophins are transported, 
then Trk receptors must remain at the limiting membrane of the MVB in order for their 
tyrosine kinase domains to face the cytoplasm to remain competent for signalling. A 
mechanism preventing this receptor from being internalised to the inner membrane of 
the MVBs seems to be necessary to ensure prolonged neurotrophin signalling 
(Bronfman et al., 2007). 
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Figure 1.2. Neurotrophins and neurotrophin receptors. 
Schematic representation of the different isoforms of Trk and p75NTR receptors. The neurotrophin 
binding specificity for each receptor is specified. Different domains have different colour codes: the 
intracellular kinase domains are coloured in red, the small amino acid insertions in green, the truncated 
intracellular domains of TrkB and TrkC in purple, the cysteine repeat domains of p75NTR in grey and the 
death domain of p75NTR in orange. The cysteine clusters of the Trk receptors are coloured in blue, while 
leucine-rich motifs are in black. Adapted from Roux & Barker, 2002 and Huang & Reichardt, 2003. 
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Figure 1.3. Schematic representation of the internalisation and trafficking of TrkA and p75NTR. 
The different internalisation pathways of TrkA and p75NTR converge at the level of the early endosomes 
(EE). and from there different routes can be taken, one to the late endosomes (LE) and the lysosomes (L) 
controlled by RAB7, and the other dependent on RAB4 and RAB11, to the recycling endosomes (RE). 
From Bronfman et al., 2007. 
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1.3 High content siRNA screening 
 In the late 1990’s, automated imaging systems started to be introduced as tools 
for the screening of biological/cellular processes and following that a new term, “high-
content screen” (HCS), was coined. HCS can be defined as a “multiplexed functional 
screening based on imaging multiple targets in the physiological context of intact cells, 
by extraction of multicolour fluorescence information” (Krausz, 2007). 
 The HCS approach has several advantages over the traditional way of screening, 
such as biochemical assays or reporter genes based assays. For example, the possibility 
of designing a cell-based assay with high physiological relevance in which the response 
or “readout” is not limited to a single target, but can include the whole cell. Imaging 
single cells allows the ability to control for the biological heterogeneity of cell 
populations, and the use of multiple probes with different colours allows for the 
simultaneous determination of a series of subcellular parameters. For these reasons and 
because this data set can be integrated to produce a correlative analysis, which takes 
into account several parameters as opposed to concentrating on a single variable, HCS 
formats are generally considered to produce low false-positive and false-negative 
results. However, the strength of the HCS approach is also its main limitation: image-
based cellular assays have more variability compared to biochemical assays or reporter 
gene-based assays. This is mainly due to the relatively small number of cells analysed 
(typically between 200 – 1000 cells per condition). Image-based screens also depend on 
the even distribution of cells across the field of analysis, which is critical for the 
microscope to sample enough cells during the automated image acquisition. Therefore, 
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standardisation of the cell culture conditions and the handling of the cells are critically 
important. 
 HCS is widely used in pharmaceutical companies to perform drug-based 
screens. However, it is also well suited to the use of RNA interference (RNAi), which 
has become a powerful tool allowing researchers to identify the function of genes in the 
context of a living cell. RNAi works by promoting specific degradation of a desired 
mRNA population in a living cell via the action of interfering RNA molecules, such as 
short interfering RNA (siRNA) oligonucleotides. Commercial sources of siRNA 
directed against all predicted genes in the human, mouse and rat genome are now 
available, together with premade siRNA libraries, which target whole gene families, 
such as the kinome, phosphatome, ubiquitin ligases, ubiquitinating enzymes, molecular 
motors and membrane proteins. 
 The use of siRNA induces a transient and specific silencing effect on a 
particular gene, which usually reaches its peak after 24 hours and then recovers by 96 
hours after siRNA transfection. Although precise conditions depends on the specific 
gene that is knocked-down, a window of time between 48 hours to 96 hours after 
transfection is generally optimal to perform the screen. However, proteins with a longer 
half-life might fail to give a phenotype in this time frame, while depleting other proteins 
might significantly affect cell viability. All of these considerations have to be taken into 
account when deciding on the optimal time frame for the biological assay used in the 
screen. 
 Another concern is the risk of detecting false-positive hits due to off-target 
effects of the siRNA used. In order to tackle this issue, a set of minimal requirements 
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for siRNA studies in terms of controls and experimental settings has been established 
(Echeverri and Perrimon, 2006, Echeverri et al., 2006). There are two main approaches 
generally adopted by researchers interested in siRNA screens: the screen can be 
performed using either pools containing 3-4 siRNA duplexes (siRNA pools) or 2-4 
single siRNA duplexes in separate wells for each gene. In the case of the siRNA pools, 
each pool needs to be done in replicates (typically 2-3) to take the experimental 
variability into account, while for single siRNA duplexes, at least 2 out of 3 siRNAs 
should give the same phenotype to exclude off-target effects. In addition, the sampling 
is critical: at least 200 cells per well should be covered in order to guarantee a good 
statistical coverage of the cell population. However, depending on the robustness and 
reproducibility of the biological assay, the number of cells to sample might need to be 
increased. If siRNA pools have been used to perform the screen, once the primary hits 
have been established, single siRNA duplexes contained the pool should be individually 
tested for all of the hits. It is common practice to consider a hit validated when 3/4 or 
2/3 single siRNAs from the relevant pool produce the same phenotype. Alternatively, 
siRNA pools from a different supplier can be used, because the siRNA design algorithm 
differs among different companies and therefore the duplexes will target different parts 
of the transcript. The effective knock-down of the gene should also be tested by RT-
PCR, Western blot and immunostaining. Finally, an elegant way to demonstrate that the 
phenotype observed is really due to the knock-down of the candidate gene, is to perform 
rescue experiments either by overexpression of the cDNA and/or by the introduction of 
a siRNA-resistant mutant of the gene (Krausz, 2007). 
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1.3.1 siRNA delivery methods for HCS 
 A broad range of delivery agents designed to accommodate the needs of HCS 
are commercially available. The most common are lipid-based transfection reagents, for 
which protocols for a 96- or 384-well format have now been established. However, 
most protocols published use a final siRNA concentration of 100 nM, which is quite 
high and presents a severe risk of off target effects (Moore et al., 2007). Reverse 
transfection strategies, in which siRNA and the transfection reagent are pre-complexed 
in the well before plating the cells, have been shown to achieve higher transfection 
efficiency at lower siRNA concentrations than the classic forward transfection protocol, 
in which the cells are first seeded and the transfection mixture is added the following 
day. In addition, reverse transfection is quicker and the manipulation of the cells is also 
minimised, which can be critical in case of large scale HCS. Reverse solid phase 
throughput transfection, which consists of spotting glass slides with transfection 
complexes in an array format, has also recently been optimised. The slides have a 
reservoir in which the cells can be plated and grown. A single slide can contain several 
hundred spots which minimises the quantity of transfection reagent, siRNA and cells to 
use and also allows fast image acquisition (Erfle et al., 2004, Wheeler et al., 2005).  
 Viral libraries are also available and they provide an alternative to lipid-based 
transfection. Viral shRNA vectors normally produce high infection rates even for cells 
that are notoriously difficult to transfect such as primary cells, thus opening up the 
possibility of screening physiologically relevant cell systems. However, these shRNA 
libraries are relatively more expensive than their siRNA counterparts and their stability 
is limited, because viruses do not tolerate repeated freeze/thaw cycles very well. 
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Electroporation has also been explored for HCS applications in a 96 well plate 
as a promising way of transfecting primary cells and cells in suspension. In general, 
protocols are generally empirically developed by adjusting the different parameters such 
as voltage, pulse duration, number of pulses and duration of the intervals between the 
pulses. The cells also need to be suspended in low conductivity buffers, which can 
affect cell viability and imposes short handling times in order to avoid damage to the 
cells. Finally, the cells are generally electroporated in suspension, which means that 
adherent cells need to be resuspended, introducing additional manipulations and a 
possible source of stress for the cells (Krausz, 2007). 
1.3.2 Image acquisition systems for HCS 
 Several options are presently available for HCS image acquisition, which have 
to be considered in relation to the assay to be monitored, the costs and the speed of 
acquisition needed. One option is the use of laser scanner fluorimeters (e.g. the Acumen 
Explorer, which is present in the High Throughput Screening facility at CR-UK), which 
offer high image acquisition speed and simple reader-like handling, but have a low 
resolution. These scanners are characterised by a laser scanning excitation at various 
wavelengths combined with photomultimeter tube detection. The technology allows the 
acquisition of a whole plate in only a few minutes, and even though the resolution is 
quite low, it is still sufficient to monitor fluorescence intensity changes for assays such 
as cell proliferation, apoptosis, reporter gene expression, nuclear translocation and 
neurite outgrowth (Krausz, 2007). 
 A range of microscopes have been developed for HCS, which try to overcome 
the problems related to high-throughput image acquisition, such as the need for a robust 
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autofocus algorithm, rapid stage positioning across the plate, a stable light source, and 
high resolution imaging. One of the most widely used automated epifluorescence 
microscope of this type is the ARRAYSCAN from Cellomics, which has rapid 
automated autofocusing, a 12-bit CCD camera and a collection of dry objectives (5X, 
10X, 20X and 40X magnification). Multicolour images are acquired sequentially and 
the system comes with a proprietary image analysis software and database. The high-
throughput capability of the ARRAYSCAN is around 10,000 images per day. 
 Lately, the use of confocal microscopes for HCS has also been introduced, with 
commercial imaging systems such as IN Cell Analyser 3000 (GE Healthcare), Opera 
(Evotec Technologies) and ImageXpress Ultra (Molecular Devices). The major 
advantages offered by confocal imaging are the possibility of collecting information 
along the Z axis, a reduced background fluorescence and increased sensitivity obtained 
with the use of higher magnification and higher numerical aperture (NA) immersion 
objectives. Usually these confocal systems also come with proprietary image analysis 
software. 
1.3.3 Image analysis software for HCS and interpretation of the data 
 A vital condition for the success of an HCS approach is the existence of image 
analysis software capable of processing large amounts of data in a reliable and 
automated way. Several software packages are offered by companies together with their 
automated imaging system. Typically these software are already optimised for the 
quantification of widespread assays such as cell cycle analysis, cytoxicity, apoptosis, 
receptor internalisation, protein translocation, co-localisation, cell migration and 
cytoskeletal rearrangements, morphological analysis or neurite outgrowth. These 
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analysis modules are specifically designed for their purpose and thus generally need 
only some minor fine-tuning to be adapted to the specific assay and cell type used.  
 Third party software is also available, with the capability of analysing large 
image datasets. One of these programs is Cell Profiler image analysis software created 
by a consortium started by Anne E. Carpenter and Thouis R. Jones in the laboratory of 
David M. Sabatini and Polina Golland (www.cellprofiler.org). Cell profiler is open-
source (and thus free) and it is designed to enable researchers without training in 
computer programming and image analysis to quantitatively measure cellular 
phenotypes from large image datasets in an automated fashion. Its flexibility also allows 
the development of new analysis modules using the Matlab platform. 
 One crucial problem that needs to be considered is the storage of the data 
generated by the HCS. Terabytes of data should be stored and organised, a feat that can 
only be achieved with the creation of a laboratory information management system, 
which is able to store the data from the screen as well as to allow its rapid searching and 
evaluation. Using this informatic platform, data analysis can be run to extract metadata 
essential for the interpretation of the screen, such as the identification and correction of 
edge-effect artefacts, uneven pipetting, or the exclusion of out of focus images (Krausz, 
2007). Known players in the pathway being screened should be used in each plate as 
internal controls for the accuracy of the assay and for the estimation of the transfection 
efficiency throughout the plate. These controls are essential for the normalisation of the 
data before statistical analysis can be applied in order to identify the hits. Finally the use 
of cluster analysis algorithms can assist in finding any correlation between the hits, 
enabling the identification of protein families involved in particular pathways. 
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 The introduction of HCS strategies is generating an increasing mass of data, and 
merging functional genomics (RNAi) and the results from drug screenings has the 
potential to shed light on the function of a large number of genes. For that to happen, 
however, a systematic approach to data mining has to be undertaken. The normalisation 
of the intrinsic variability of biological assays by the use of more physiological cell 
systems, i.e. primary cultures, represents a great challenge. In particular, certain cell 
types are so unique that immortalised cell lines cannot effectively substitute for them. 
Neurons are such a cell type; the cell models commonly used to substitute for them, like 
PC12 or SHSY5Y cells, are very poor in accounting for specific neuronal functions, 
physiology and specialisation. For this reason, in order to study neurotrophin trafficking 
in the most physiologically relevant contest, this thesis work aims to develop a strategy 
to successfully apply the HCS approach to MNs. 
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and enzymes 
 Reagents were purchased from GE Healthcare, BDH, Biorad, Calbiochem, 
Clontech, Fisher Scientific, Gibco BRL, Invitrogen, Dharmacon, Qiagen, Sigma, Pierce 
and Stratagene. The fluorescent chemicals were purchased from Molecular Probes. 
Phosphate buffered saline (PBS), ethylenediaminetetraacetic acid (EDTA), Luria 
Bertani (LB) medium, 2YT medium, SOC medium, Hanks’ buffer and Dulbecco 
Modified Eagle’s Medium (DMEM) were provided by CRUK Central Services. The 
Sonic Hedgehog agonist (SAG, C28H28ClN3OS) was purchased by Axxora (Product 
number 270-426-M001). 
2.1.2 Antibodies 
 Fluorescently conjugated secondary antibodies were purchased from Invitrogen 
Molecular Probes and were used at a dilution of 1:200. HRP-conjugated secondary 
antibodies were from DAKO (dilution 1:2000). 
The following primary antibodies were used at the indicated dilutions: 
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 Table 2.1. Primary antibodies used 
 
ANTIGEN ANTIBODY NAME SUPPLIER DILUTION 
Akt 9272 Cell Signalling 1:2000 WB 
β−actin AC40 Sigma  1:1000 WB 
βIII tubulin Tuj1 Covance 
1:1000 IF 
1:2000 WB 
BICD1 2296 
Dr C. Hoogenraad, Erasmus 
University Rotterdam, The 
Netherlands 
1:2000 WB 
Dynein 
Intermediate 
chain 
74-1 Santa Cruz Biotechnology 1:2000 WB 
ERK1/2 9102 Cell Signalling 1:2000 WB 
GD1b MOG-1 
Dr. H. Willinson, 
University of Glasgow, UK 
1:1000 IF 
1:2000 WB 
GFP 4E12 CRUK monoclonal facility 1:500 IF 
MAP2 AB5622 Chemicon  1:500 IF 
pAkt (S473) D9E Cell Signalling 1:2000 WB 
pERK1/2 
(Thr202/Tyr 204) 9101 Cell Signalling 1:2000 WB 
Pan Trk C14 Santa Cruz Biotechnology 1:1000 WB 
p50 611002 BD Transduction LaboratoriesTM  1:2000 WB 
p75NTR 
intracellular 
domain 
5090 Molecular Neuropathobiology Laboratory, CRUK 1:1000 WB 
p75NTR CRD 5410 Molecular Neuropathobiology Laboratory, CRUK 
1:5000 IF 
1:1000 WB 
VAMP2 69.1 Synaptic System 
1:2000 IF 
1:1000 WB 
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2.1.3 Transfection reagents used 
 All the transfection reagents used in this thesis work are listed below: 
Table 2.2 Transfection reagents used 
 
NAME SUPPLIER 
Oligofectamine Invitrogen 
TransIT siQuest Mirus 
siPORTTM Amine Ambion 
InterferinTM Polyplus 
LipoRNAiMax Invitrogen 
CodeBreakerTM Promega 
Dharmafect 1 Dharmacon 
Dharmafect 2 Dharmacon 
Dharmafect 3 Dharmacon 
Dharmafect 4 Dharmacon 
Lullaby OZ Bioscience 
RiboJuiceTM Merck 
TransIT KO Mirus 
HiPerFect Qiagen 
Genesilencer Genlantis 
NTERnanoparticle SIGMA-Aldrich 
SiPORT NeoFX Ambion 
SimPorter Upstate 
Lipofectamine 2000 Invitrogen 
Santa Cruz Santa Cruz 
Metafectene Biontex 
Dreamfect Gold OZ Bioscience 
TransPass R1 New England Biolabs 
 
2.1.4 Q-PCR primers 
 The primers used for PCR and Q-PCR in this thesis work are listed below: 
 βIII-tubulin 
forward: 5’ GCGCATCAGCGTATACTACAA 3’ 
reverse: 5’ TTCCAAGTCCACCAGAATGG 3’ 
Chapter 2. Materials and Methods 
45 
 Bicd1 exons 1-2 
forward: 5’ GCTGGAGGCCGAGTATGAC 3’ 
reverse: 5’ AGAAGGACTGCCCAAATGC 3’ 
 Bicd1 exons 7-8 
forward: 5’AAGATCGGCAGCCCTAAAA 3’ 
reverse: 5’ TCCCAGCTAGTTGTGAGCACT 3’ 
 Bicd2 
forward: 5’ GATGGAGCAGCTCAAAGAGG 3’ 
reverse: 5’ TCCTGGATCAGGCTCTCCT 3’ 
 ChAT 
forward: 5’ TGATGGCTTCATCCAGGTC 3’ 
reverse: 5’ GGCACCAGCCTCTGGTAA 3’ 
 Dync1h1 
forward: 5’ TGCTCCACAAGTCAGTCACAA 3’ 
reverse: 5’ TCCTCAGCTCGTGAACCAC 3’ 
 HB9 
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forward: 5’ CTACTGCCCGCATGATCC 3’ 
reverse: 5’ CGTAGACCTTGTGATCCATCG 3’ 
 p50 dynamitin 
forward: 5’ GATGATGGCCAGTTCCCTTA 3’ 
reverse: 5’ TCACGCATCGTTGTCTGC 3’ 
 p75NTR 
forward: 5’ ACTGAGCGCCAGTTACGC 3’ 
reverse: 5’ CGTAGACCTTGTGATCCATCG 3’ 
 TrkA  
forward: 5’ CCGTTTCCTCCGGTCCCACG 3’ 
reverse: 5’ CCAGAAGCTGCCCAAGGCCC 3’ 
 TrkB 
forward: 5’ TGCCGAGTGCTACAACCTCT 3’ 
reverse: 5’ GCGTCCTTCAGCGTCTTC 3’ 
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 2.1.5. Sequence of the siRNA pools used 
 The individual sequences of the single siRNAs of the VAMP2 siRNA pool are 
reported below. The sequence of the non-targeting negative siRNA control is 
proprietary from Qiagen (AllStars negative control siRNA, Catalog number: 1027281). 
VAMP2 siRNA pool (Dharmacon) 
1- sense: GUAAAUAGCCAGCUGUUAUUU 
    antisense: AUAACAGCUGGUAUUUACUU 
2- sense: GCGCAUCCAGAUUGUAAAUU 
    antisense: UUUCACAAUCUGGAUGCGCUU 
3 – sense: GCGCAAAUACUGGUGGAAAUU 
     antisense: UUUCCACCAGUAUUUGCGCUU 
4 – sense: CCUCCAAACCUUACUAGUAUU 
     antisense: UACUAGUAAGGUUUGGAGGUU 
2.1.5 Design of the molecular motors and adaptors siRNA library 
(Qiagen) 
Table 2.3 reports the genes targeted by the pool of siRNA for each of the 96-
well plates`. 
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Table 2.3 Layout of the siRNA library (Qiagen) 
Position on the master plate, gene ID, symbol and description of the gene targeted are listed for each of 
the siRNA pools in the Qiagen library. 
 
PLATE 1 
row col geneId symbol description 
B 2 16560 Kif1a kinesin family member 1A 
B 3 12121 Bicd1 bicaudal D homolog 1  
B 4 229841 Cenpe centromere protein E 
B 5 13191 Dctn1 dynactin 1 
B 6 13424 Dync1h1 dynein cytoplasmic 1 heavy chain 1 
B 7 13426 Dync1i1 dynein cytoplasmic 1 intermediate chain 1 
B 8 13427 Dync1i2 dynein cytoplasmic 1 intermediate chain 2 
B 9 234663 Dync1li2 dynein, cytoplasmic 1 light intermediate chain 2 
B 10 16563 Kif2a kinesin family member 2A 
B 11 16570 Kif3c kinesin family member 3C 
C 2 16574 Kif5c kinesin family member 5C 
C 3 16573 Kif5b kinesin family member 5B 
C 4 17300 Foxc1 forkhead box C1 
C 5 16582 Kifc3 kinesin family member C3 
C 6 16593 Klc1 kinesin light chain 1 
C 7 16551 Kif11 kinesin family member 11 
C 8 16580 Kifc1 kinesin family member C1 
C 9 110033 Kif22 kinesin family member 22 
C 10 17274 Rab8a RAB8A, member RAS oncogene family 
C 11 17912 Myo1b myosin IB 
D 2 17879 Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult 
D 3 17882 Myh2 myosin, heavy polypeptide 2, skeletal muscle, adult 
D 4 17883 Myh3 myosin, heavy polypeptide 3, skeletal muscle, embryonic 
D 5 17884 Myh4 myosin, heavy polypeptide 4, skeletal muscle 
D 6 17888 Myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha 
D 7 140781 Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta 
D 8 17885 Myh8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 
D 9 17886 Myh9 myosin, heavy polypeptide 9, non-muscle 
D 10 77579 Myh10 myosin, heavy polypeptide 10, non-muscle 
D 11 546101 EG546101 predicted gene, EG546101 
E 2 107589 Mylk myosin, light polypeptide kinase 
E 3 432516 Myo1a myosin IA 
E 4 17913 Myo1c myosin IC 
E 5 338367 Myo1d myosin ID 
E 6 71602 Myo1e myosin IE 
E 7 17918 Myo5a myosin Va 
E 8 17919 Myo5b myosin Vb 
E 9 17920 Myo6 myosin VI 
E 10 17921 Myo7a myosin VIIa 
E 11 17922 Myo7b myosin VIIb 
F 2 270163 Myo9a myosin IXa 
F 3 17925 Myo9b myosin IXb 
F 4 17909 Myo10 myosin X 
F 5 19341 Rab4a RAB4A, member RAS oncogene family 
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F 6 271457 Rab5a RAB5A, member RAS oncogene family 
F 7 19344 Rab5b RAB5B, member RAS oncogene family 
F 8 19345 Rab5c RAB5C, member RAS oncogene family 
F 9 67117 Dynlt3 dynein light chain Tctex-type 3 
F 10 21648 Dynlt1 dynein light chain Tctex-type 1 
F 11 19349 Rab7 RAB7, member RAS oncogene family 
G 2 56455 Dynll1 dynein light chain LC8-type 1 
G 3 544791 Myh13 myosin, heavy polypeptide 13, skeletal muscle 
G 4 226422 Rab7l1 RAB7, member RAS oncogene family-like 1 
G 5 16569 Kif3b kinesin family member 3B 
G 6 71819 Kif23 kinesin family member 23 
G 7 381293 Kif14 kinesin family member 14 
G 8 19348 Kif20a kinesin family member 20A 
G 9 98932 Myl9 myosin, light polypeptide 9, regulatory 
G 10 69654 Dctn2 dynactin 2 
G 11 67268 2900073G15Rik RIKEN cDNA 2900073G15 gene 
     
PLATE 2 
row col geneId symbol description 
B 2 22428 Dctn6 dynactin 6 
B 3 16562 Kif1c kinesin family member 1C 
B 4 73804 Kif2c kinesin family member 2C 
B 5 16568 Kif3a kinesin family member 3A 
B 6 53598 Dctn3 dynactin 3 
B 7 667772 Myh15 myosin, heavy chain 15 
B 8 381284 E030010N08Rik RIKEN cDNA E030010N08 gene 
B 9 244281 Myo16 myosin XVI 
B 10 16565 Kif21b kinesin family member 21B 
B 11 16561 Kif1b kinesin family member 1B 
C 2 16554 Kif13b kinesin family member 13B 
C 3 16571 Kif4 kinesin family member 4 
C 4 668303 Kif26a kinesin family member 26A 
C 5 218203 Mylip myosin regulatory light chain interacting protein 
C 6 235661 Dync1li1 dynein cytoplasmic 1 light intermediate chain 1 
C 7 67665 Dctn4 dynactin 4 
C 8 17910 Myo15 myosin XV 
C 9 213575 Dync2li1 dynein cytoplasmic 2 light intermediate chain 1 
C 10 0 siControl  
C 11 667663 Myo3a myosin IIIA 
D 2 17121 Mxd3 Max dimerization protein 3 
D 3 269152 Kif26b kinesin family member 26B 
D 4 109242 Kif24 kinesin family member 24 
D 5 75050 Kif27 kinesin family member 27 
D 6 16564 Kif21a kinesin family member 21A 
D 7 208943 Myo5c myosin VC 
D 8 209737 Kif15 kinesin family member 15 
D 9 0 siControl  
D 10 16559 Kif17 kinesin family member 17 
D 11 74018 Als2 amyotrophic lateral sclerosis 2 (juvenile) homolog (human) 
E 2 17898 Myl7 myosin, light polypeptide 7, regulatory 
E 3 16553 Kif13a kinesin family member 13A 
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E 4 246177 Myo1g myosin IG 
E 5 16578 Kif9 kinesin family member 9 
E 6 16594 Klc2 kinesin light chain 2 
E 7 0   
E 8 228421 Kif18a kinesin family member 18A 
E 9 280408 Rilp Rab interacting lysosomal protein 
E 10 75465 Dynlrb2 dynein light chain roadblock-type 2 
E 11 67068 Dynlrb1 dynein light chain roadblock-type 1 
F 2 59288 Dctn5 dynactin 5 
F 3 73470 Kif2b kinesin family member 2B 
F 4 74376 Myo18b myosin XVIIIb 
F 5 228785 Mylk2 myosin, light polypeptide kinase 2, skeletal muscle 
F 6 74764 Klc4 kinesin light chain 4 
F 7 16581 Kifc2 kinesin family member C2 
F 8 59310 Mylc2pl myosin light chain 2, precursor lymphocyte-specific 
F 9 67938 Mylc2b myosin light chain, regulatory B 
F 10 16552 Kif12 kinesin family member 12 
F 11 64291 Osbpl1a oxysterol binding protein-like 1A 
G 2 231836 EG231836 predicted gene, EG231836 
G 3 216459 Myl6b myosin, light polypeptide 6B 
G 4 329421 Myo3b myosin IIIB 
G 5 68097 Dynll2 dynein light chain LC8-type 2 
G 6 77505 Dnhd1 dynein heavy chain domain 1 
G 7 327954 Dnahc2 dynein, axonemal, heavy chain 2 
G 8 232943 Klc3 kinesin light chain 3 
G 9 319991 Kif6 kinesin family member 6 
G 10 16576 Kif7 kinesin family member 7 
G 11 360013 Myo18a myosin XVIIIa 
     
PLATE 3 
row col geneId symbol description 
B 2 17897 Myl3 myosin, light polypeptide 3 
B 3 17916 Myo1f myosin IF 
B 4 18196 Nsg1 neuron specific gene family member 1 
B 5 19325 Rab10 RAB10, member RAS oncogene family 
B 6 23790 Coro1c coronin, actin binding protein 1C 
B 7 53869 Rab11a RAB11a, member RAS oncogene family 
B 8 67166 Arl8b ADP-ribosylation factor-like 8B 
B 9 67845 Zfp364 zinc finger protein 364 
B 10 72993 Appl1 
adaptor protein, phosphotyrosine interaction, PH domain and leucine 
zipper containing 1 
B 11 216190 Appl2 
adaptor protein, phosphotyrosine interaction, PH domain and leucine 
zipper containing 2 
C 2 226421 5430435G22Rik RIKEN cDNA 5430435G22 gene 
C 3 0 siControl  
C 4 668940 Myh7b myosin, heavy chain 7B, cardiac muscle, beta 
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Table 2.4 Sequences of the siRNAs contained in the Qiagen library 
Each siRNA pool (Qiagen) contains three targeting sequences. These, as well as the sequences of the 
siRNA controls, are reported below., as well as the siRNA controls.  
 
PLATE 1 
symbol siRNA 1 siRNA 2 siRNA 3 
Kif1a AAGCACCACCACTATTGTCAA ACGGATAACTGTGACACTGTT CAGATGCGGGTCTGAGTTGAA 
Bicd1 CAGGTTGAATACGAAGGCTTA TAGAGTCATGTTGGACTACTA ATGGTTTATGTTTATAAAGAT 
Cenpe CTGGGAGGAAAGAACTCTTAA CAAGGCTACAATGGTACTATA AAGCATTGGGCTCGTGAATAA 
Dctn1 CCGCATCAAGCTACCAGCTCA CACAGTCGCCTCATCTCCTAA AAGGCTGAAATCGAAGAGAAA 
Dync1h1 ATGGCTGGGTTTAGTAAATAA CGGCAAAGAATTCACCAGTAA TGGCTGGGTTTAGTAAATAAA 
Dync1i1 ATGGAACATATTTATTTGAAA CCCAGTGATGCTGGAAGCCAA CCGGACAATCCGAGTAATTGA 
Dync1i2 ATGGTAGTTATCTATAAATAA TGGGTGTATATTGTTAAGTTA CAGGTGCTAAGCTGTCATTAA 
Dync1li2 TACCATGACTTTAATGTATAA TACCATGTTGGCAATGTTCTA CTTGTTCTAAATGATCTTTAA 
Kif2a CGGGATTTACGTGGAGATCAA AAGGAGTGCATCCGAGCCTTA CTGCTGGACCATTCCATCTTA 
Kif3c CAGGGTTTCAACGGCACCGTA ATGGATCACACCAACGAGCAA AAGAAGCTCTATGCCAAGCTA 
Kif5c CACTGATTTGACTTAATTTAT CGAAGTCAGTTTCCAAGATAA CTGTACAGTAGATTTCATTAA 
Kif5b AGGGATCAAGATAATATGCAA CAGCAAGAAGTAGACCGGATA CACGAGCTCACGGTTATGCAA 
Foxc1 AAGGATAATTTCCTAAGTAGA CCCGGCACTCTTAGAGCCAAA TAGGGTGATCTGCCCTGTCAA 
Kifc3 CGGGCTCAGATTGCCATGTAT CCGCACCACCGAGTTCACCAA CAGAGGTCTGGGCTATATTTA 
Klc1 CAGGGATCAGAACAAGTATAA AGGGATCAGAACAAGTATAAA CACCGTCACAACCACCTTGAA 
Kif11 AAGGAAGAACTTGAGAATTTA AGCAAAGAACATAATGAATAA CACAGGAACTTTGCCAGTTAA 
Kifc1 CTGCGCGGAGGTTGAAATTCA GGCGAGTTACGTAGAGATCTA TGCGCGGAGGTTGAAATTCAA 
Kif22 AGCGAGAGTCCTCAAACCAAA CAGCATTGAACTTCACTGCTA AAGGGAAGGCTATGAGCTTAA 
Rab8a CGGACTCGATTGAGAAATTGA CTCGATGGCAAGAGGATTAAA CTGGCTCTAATCGGATGTTCA 
Myo1b TGGGATTATGTTAATAATAAA CAGCAGAAACTTATTTATGAA CTGGAATTAAATTGTTTCTTA 
Myh1 CACAGAGCTGTTCAAGATTAA AGGGAGAATCTGAATAAGCTA CGGAACTACTGTAACAGTAAA 
Myh2 CCGGGTCACTTTCCAGCTTAA CAGAGCAAAGATGCAGGGAAA CAGCTTGATGAAAGGCTCAAA 
Myh3 CAGCAGGACCCTGGTGGTTAA CAGCAGCTGGATACAAAGCTA CACACTTTGTACGCTGTATAA 
Myh4 CTGGATCAACTTGAGACGTTA CAGGACTTGGTGGACAAACTA CACACTAAAGTCATAAGCGAA 
Myh6 CCGGGTGATCTTCCAGCTAAA CTCGCTGTGGCCAATACACAA CAAGCTGATGACAAACCTGAA 
Myh7 AAAGAAGGACTTTGAGTTAAA TGGGAAGACTGTCAACACTAA TACCAAATCCTGTCTAATAAA 
Myh8 CCCAAGGAGTCTTATGTGAAA CTGGCATCAGCTGATATTGAA CAGGACCTGGTGGACAAATTA 
Myh9 CAGGGCTTATCTACACCTATT TCCAGCAAGAATGGCTTTGAA CTCGAGAAAGTCCACTCGGAA 
Myh10 CACAAGAATAATGCACTTAAA CAGTACTAAGACAATGTTAAA AAGACCAGAATTCCAAATTTA 
EG546101 GAGAATACAGTTCACTGTCAA AGCAGCCAAGATGTGACTTCA TAAGATGAAATTAGTAACTGA 
Mylk CGCAAAGGATTTCATCAGTAA CACACTGGTGGTGGAGAACAA CCGCGTGTCAATGTCAGAGAA 
Myo1a CAGGAGGAATACAAGAGAGAA CCGAGTGGTGAAGCAACTCAA CGCGGGCAAGGTGACCTACAA 
Myo1c ATCCAGAGAAACACTAAATAA AAGACTGAAGCAAATCCTAAA TTGGATTTGGGCAAATAAATA 
Myo1d ATGAAAGTAATTGGATTCAAA TGGGAAATACATGGATATCAA AAGAATTCTATGATTGCTTTA 
Myo1e TTGGTAGATTCTATCAATAAA AACGATATTATTGATATTATT CCCAAGCTGTACATTTATAAA 
Myo5a CCCTCGTACTGTTACCTTTAA CAGCCTTGTATCAATCTTATA AAGGAAGATGTTAACTGGAAA 
Myo5b CCCGCAGTTCTGCATAACTTA AACCTGGAGTTTCTCAATGAA TCAAACTGAGATAATATTAAA 
Myo6 CAGATAATTTCCGGTATTTAA AACCGAGATAATGAAATCTTA CAGCAGGAGATTGACATGAAA 
Myo7a CCCAGTGATGACTAAGATCTA CAGAGTCATTCTCCTCCAGAA CCAGGTGTTCTTCATGAAGAA 
Myo7b CTGCTGAATTTCATTAGTCAA CAGGTCATTCTGGCTAAGGAA CACGATGGAGCAGGAAGAGTA 
Myo9a AACTAGGTAATCAATATTAAA CCCGATGATGATGGTCATTCA CTGAATTTGAATAAAGTTAAA 
Myo9b CAGCATAACTTGAATATTGAA CACCTCCTTCCTGAAGAGTAA CAGAGTGAAATACCAGATCAA 
Myo10 CAGGACGAAGCCATCAAGATA CAGCGCTACAAGAGAAACCAA CCCAGACGAGAAGATATTTAA 
Rab4a TGGAATTTGGCTCAAAGATAA ATGCGCTTACTAATTGGTTAA CAGGTCTGTGACGAGAAGCTA 
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Rab5a TAGGAATATGAAACCGATAAA ATGAATATTGATGACATCTTA CAAGTTTCTAATTCTGAATTA 
Rab5b CAGGAGCGATACCACAGTTTA CTCGGGCAAAGACATGGGTAA TATGATATTACTAATCAGGAA 
Rab5c CCCGACTGGAATCTACTCTAA CTGGTGGTCATGGTAACCAAA CACCTGCACCTTTCTGTACAA 
Dynlt3 CAGGGAGAAATATATGAACAA CAGAAAGTAATACATCAAATA TACACTTGAGGTGGAATTAAA 
Dynlt1 CTGTGTGATCATGCAGAAGAA TTAGAATAATAAATTATTCAA ATGGGAGAACAAGACCATGTA 
Rab7 AGGCCGGAGCTTTGACCATAA TCCGTTGACCCTGCGCTTCAA TACAGAGTGTTAGAGACTCAA 
Dynll1 CTCCCTTAGGTCATTCCTTTA ACAGCTTACATTTGTATTTAT AAGGACTGCATCCAAATTCCA 
Myh13 CACGAGCCTGATAAATACCAA AAGGATGAGGAAATCGAACAA AAGAGGAGATTTCTGACTTAA 
Rab7l1 CCCGTGTACTATAGCTAGTAT TTGGGTGTCGTCTGTGACTTA TCCGTTGAGAATATTCAATAT 
Kif3b CTCAAGCATCTTATTATAGAA AACCATGACCATCCTGTTAAA CTGCAGGATGAAGATGAGATA 
Kif23 AAGGCTGAAGACTATGAAGAA TTGTTTGAATATGATCTTTAA TACGATCTATGAGGAAGATAA 
Kif14 TTCGTGAATGCTGGAAGTAAA CTGGCTGGAACTGGGAAATAA CACGATGATTCAGGAAGCCAA 
Kif20a CAGGAAGTTAAAGCTGAACTA CAGCTAGATGAAACAAGTCAA CTCCTTTGCCTTGAAGAGTAA 
Myl9 AGGGACAGTCTCTTAATACAA CAGGGTGAGGCAGGTGCTCTA CACCAAGGTAAAGCCACTGAA 
Dctn2 CAGGAATGAGCCAGACGTTTA CTGGCCGAGTCTAACACTGTA TCGGATGAAGAGGCTGGGAAA 
2900073G15Rik CACGTACGCCTTTCTCTCTAA CACAGGATTCTTTAAGCCCTA CAGAATTGTGACCCTGCATTA 
    
PLATE 2 
symbol siRNA 1 siRNA 2 siRNA 3 
Dctn6 AGCCATGCATTTATTATGTAA ACCATATACCATAACTAAATA AACGACCGCTATAATTTATAT 
Kif1c CACGGACGAGCAGAAATTGAA CAGCAGGTGTACCGAGACATA ACCTCCATCATTAATCCCAAA 
Kif2c AGCCTCGGTACCGGAACTTAA CGCCAATATAAGCACAGTGAA TAGCAGAGTCGTGGTTTCCAA 
Kif3a TGGAGAGAACTCCTTAATTAA ACGAACCTCCAAAGACATTTA GAGACCGTAATTGATTCTTTA 
Dctn3 TCCAGTGACAATAAACTTGAA AAGGGTATAACAAGACTACAA CAGGGTCAGGTTGACCTTAGA 
Myh15 AAGGAGGAACTGGAAAGTGAA AGCGGTGATGATGGACAAGTA AAGGCCTAATATATCCTAGAA 
E030010N08Rik CTGGTTGAACTTAATCCGCAA CAGGAGGTGAGTGACCTGCAA AGGAGGAATCCTGTAAATATA 
Myo16 CAGAATCAAGATGAATATAAA AACCTCTTATTTGTAATGAAA ACGGGTTATCTTCGGAAGAAA 
Kif21b CTGGTTGTAATTTGAGCACAA ACCCTTGAAGTTAGGACTAAA TAAGAGCTTGTCATAAATAAA 
Kif1b ACGAGATTTACTGAATCCCAA TACAATGACATTGGAAAGGAA CTCCATCTTCATGCTCACTTA 
Kif13b CACGAGAATGTCCATGAGGAA CAGGCTGGTCTGCATGGTTAA CAGGATGTGTCCCAAACACTA 
Kif4 CAGTACCAGGATAATATTAAA AAGAATTGGCTTGGAAATGAA TACGATGAAATACATGGTCAA 
Kif26a ACGGCAGGAATTCTTACCAAA CAGGCTTATTGACGAACGCAA CAGCGGCCTCTTTCTTTATAA 
Mylip CTGCAGTATTGTAAACTATAA CCGCCTTAAACTGAGGGTCAA ATCGGGTGCAATACTAGCTAA 
Dync1li1 TAGACTTAGTTTATAAATACA CAGCAGGGTGGGATAATGATA CCGCAAGTTCTGTTTACAGTA 
Dctn4 AAGGATAACCCTGTAATGATA CAGGATGACCCTGACATCGTA AAGCAATTACATGTCATGAAA 
Myo15 CAGAATGACTTTAAATTCAAA CACCTTCATTCTGGAACTGAA CAGAAGCATCATCAAGCAATA 
Dync2li1 CTGGTCATTATTGGAAGTAAA CTCGCTGATGTTTACCAGCAA TTGGCATTCGGTATTGATAAA 
siControl GAGGCTGAAGATATCTACAAA AGGCCAAACATTAGCAATTGA AAGTGCGTGCGTGGAGAGAAA 
Myo3a AAGAGTAGTGCTGTAATAATA CTGCACTATTATAAATGACAA CAGGAATTCGACTACAAGAAA 
Mxd3 CCCGTATATACTGCACAGTAT CCACATGTTGAAGAGACTAAA CCCAGGGAATTTCATGTAGCA 
Kif26b ACCATTCGAAATTAAAGTCTA CACCAACAAGATGACCCAGAA TTGCAGCTGAATAAATGTTAA 
Kif24 CCGGGTGAAGGAACTAAAGAA CCCAGACTGATTAGCCAACAA CAGAGAATCCTTGGACTGAAA 
Kif27 CAGGATGAAGTTTATAACACA CACAATGTGGATCACCTGAAA CCAGCTGAAGAGAGAACTTAA 
Kif21a AACAAGGTGATGGTCAATCAA CAGCGCAAGCGAGATCATCAA CCGTGTCGACATCTTATATTA 
Myo5c ATAGAACTTTATAATACTTAA CAGCTGATGCTGGATACCAAA AAGAATGTGCAGAGTAGCTTA 
Kif15 AGGCTGGATAATGATATATTA CAGGATTCCTACGATAACTTA CACAATAGAATCAATGGAGAA 
siControl TGCGCTTATATCAGCATCTAA ATCACAGAGTGTGATAAATTA ATGGGAGCTGATGTTGATCAA 
Kif17 TACCATCAACATCGAGATCTA TCCGCAGAGACTGTAACTATA CAGGAAGAGATCAAGAGGCTA 
Als2 TCCGAGCTACTTTATAATCAA ACCGATGGACTCAAAGAAGAA TGCCATTGATTTCCTAAATAA 
Myl7 CAGGGATGGGATCATCTGCAA CAGGCTGAGGTCACCTCAATA AACTCTGTGCCTGAACTAGAA 
Kif13a AAGGATCTACCTGATCGTGAA CAGGAGCAGATGAGAAGCATA CAGGAGGAGGGCTCTAACAAA 
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Myo1g CAAGGCTATGATGATCTTGTA TCCCATCTGTTTGCTGAGCAA CTCGGTGTGATGGCAAGGATA 
Kif9 CAGAAGCACAATTATATGAAA CAGGAGATTGATGAGACCAAA ATGGATATAGAAGGTAACCTA 
Klc2 AAAGACGATTTGAATCTGAAA CCGGAGAGCCCTGGAGATCTA CAGCTGGTACAAAGCCTGTAA 
siControl AAGGACCATTACCGAAAGCTA CAGGGTCGAGTGGCACAGCTA AAGCTGAGGCTCAAATATGAA 
Kif18a TTCAAAGATATTGAACATTTA TGCATTGTAAATATTGTTTAA CAGATTTATTTGCGACAACAA 
Rilp CAGGAGCGGAATGAGCTCAAA AGCCATGAAGGTGGCAGTCAA GAGGAGGAAGATCAAGGCCAA 
Dynlrb2 TAGGATCAGATCGAAGAAACA CCAGCTGACCATGAAAGCCAA ACGATGGTGGTCAATGCAGAA 
Dynlrb1 CTGTGTCATTCCTTAATTTAA CCCAAGAATAATAGTGCTAAT ATCCAGAATCCAACTGAATAA 
Dctn5 CAAGACCATTATAATGAATGA AAGCCAGAACATCGTCCTCAA TAAGACGAACCTGGAGATAAA 
Kif2b AGGGATGAAGTTATTCAGATA TTGGAGAATTTACATCTTAAA AAGGCCCAAGATTGTTCTAAA 
Myo18b CAGCAAGACGTCAATCAGCAA CACCGGGACTTTGACGTAGAA CTGGTCTTCCAGAATCGACAA 
Mylk2 ACCGGAAATGTCAACAGTGAA CGGGATCCTCTTCATGCACAA CGCGCCAGATCCAAAGAACAA 
Klc4 CACAGTGAACACTACTCTGAA TCGCTGAACTACTTAAACCAA CACACCATTGAGTGTCTGCAA 
Kifc2 CCGGATCAATTCACATCAGAA CAGGCATTTGAGAGAGGGCAA CAGTGTCTGCATCTTCACTTA 
Mylc2pl AAGGCTGACTTCATTAAGGAA CCAGATGTCTGTGGCAACTTA TCGCATAAATGTCAAGAACGA 
Mylc2b CAGCATCAGGTCAGATTTAAA AATGTTGTAAATTGTACTGAA CACTGTGAAAGCCCAGGACAA 
Kif12 AAGGGCCAGAAGGATCAGAAA AAGGCATATTAGAAAGGGAAA AAGGCCTCTCTTCTTGTTAAA 
Osbpl1a CACAATGCCAGTGATATTTAA CTGGGAGAGACTTATGAATTA CAGGTGACTGATGATGAAGAA 
EG231836 CACGGAAGTATCCACCTCAAA CAGGGAAATTGGGCACCTCAA CAGCGCCATGTGGCAGAGCAA 
Myl6b CAAAGTGGTGATCGAGTTTAA AAGGATGCTCCCGTGAAGAAA CAGCAGGGCCCTCCATCTCTA 
Myo3b CTCGGAGGAAATTGAAGCAAA AACCACCTTTCTCACAGATAA TTCCTATTTCATGACATTATA 
Dynll2 TAGGTCTGAGGTGGAAGTTAA CTGGAACAGGTCTGAAGTATA TAGTTAGGTCTTAGCAATCAA 
Dnhd1 CAGGCTCACCTTCATTATTTA CTGCAGGACCTTAATACTCAA CCGGTCCTTCATGTACAATTA 
Dnahc2 AACCGGGAGCTGAACAAGAAA ATCGAGGACATCTTTCATAAA CTCTGGAAATTTATTGACAAA 
Klc3 CCCAAATGTGGCCAAGACTAA ACGGAGGCTAGCCCAAGAGAA GACCAGAACAAATACAAGGAA 
Kif6 CAGGAGGATGATAGCCCATTA CTGATTCTTCTTAAAGACTAA AACGGCCTTTATGCACCTGAA 
Kif7 ATGGGAGAACTGGGAAAGTAA TCCCTGCATGAAGATGAACAA ACAGCTTTCAATGGTGTTATA 
Myo18a CCGGCTGATGCCAAGACGGAA GACCTGATTGATGTAAGGAAA ACCCACCATGTTTAACCTCAT 
    
PLATE 3 
symbol siRNA 1 siRNA 2 siRNA 3 
Myl3 ACCCTGTGGCCTTATGAATAA AAGATCGAGTTCACACCTGAA ACAGAAGATGAGGTAGAGAAA 
Myo1f CACGTCAAAGACATAATCCTA CAGCCGTAAGATGGACAGCAA TACCAAGGTCTTTGTTAAGAA 
Nsg1 CTGAATCTTGACATTAAAGTA AGGGACATTTCATTAAATATA TAGGTCAGAAATAAATGGCAA 
Rab10 CTGCACTTCAGTTGTATTATA CACCATCACAACCTCCTACTA CTGGATTTGACTAGTCTCCAT 
Coro1c TCCGTTGAATTAATTACGTAA CTGTGTATGTTTATAAACTAA CAGAGGGAACTCGGTGATTAT 
Rab11a AAGGCTGTGTATAGTCCATTT CAGATCTAAGACAACCTTAGA TAGGACAGAATAGAACTCTAT 
Arl8b AAGAACATTCTGGACAGATAA TGCCTGCTTTATCTAATGTAA CCGGTCAATTCAGTGAAGATA 
Zfp364 AACCCTCAACCCATAATATTA CCCAAACTACCGGAATATATA CCAGCTATCGAAGGAATAATA 
Appl1 TAGGAACAAGATAACGATATA CTGCTATATATTTGAATCAAA CAGTTAATAATTATCAATTTA 
Appl2 CCCATTCAGTTTGATATTGTA CTGGATTTACAATTTGTTAAA TGGGAGGGAGACAATAAGAAA 
5430435G22Rik CTCAATGGTATCAACATTCTA CCGAAAGAAAGTGGACTTGAA TTCGATGTACATTGCACTGAA 
siControl CTGCGGCAGTTGTTTATGATA CTGTTTCTTGAAGATGATCTA AGCAGTGTGAATATGGCTTGA 
Myh7b CTGCGACATAGCCACGAGGAA CTGGAGTACCAGCGCATGCTA TCCGATGGCTGGTTTCTCGAA 
 
Chapter 2. Materials and Methods 
54 
2.1.6 Validation rescreen 
 The siRNA pools used for the validation of the primary hits from the siRNA 
screen were purchased from Qiagen. 
Table 2.5 Layout for the plate of the validation re-screen and sequences of the single siRNAs used  
Position on the master plate, symbol, gene ID, and the accession number of the genes targeted 
are listed for each of the siRNA pool of the re-screen library. 
 
Well Gene Symbol Gene Id Accession Number 
Sequence 
 
B03 Myh13 544791 NM_001081250 GCGCAAAGUUAAAGAGAUG 
B03 Myh13 544791 NM_001081250 AAUCUGAGCUUGAUCGCAA 
B03 Myh13 544791 NM_001081250 GGAUGAGGAAAUCGAACAA 
B03 Myh13 544791 NM_001081250 GAUAAAGAAAUGUACGUGA 
B04 Rab7l1 226422 NM_144875 UGACACGACUCUACUAUAG 
B04 Rab7l1 226422 NM_144875 CAAGGGAACUACAUCAAUC 
B04 Rab7l1 226422 NM_144875 GGACAGCAAGCUCACACUA 
B04 Rab7l1 226422 NM_144875 GCCGAGAUCACCUGUUUAA 
B05 Dctn2 69654 NM_027151 GCAGAAGUACCAACGACUA 
B05 Dctn2 69654 NM_027151 GAACUGGUACAGCGACUUG 
B05 Dctn2 69654 NM_027151 GGAGGCCACUGUCCGAUGU 
B05 Dctn2 69654 NM_027151 GAGCCAGACGUUUAUGAAA 
B06 Myl3 17897 NM_010859 UUUGAUGCCUCCAAGAUUA 
B06 Myl3 17897 NM_010859 CAAGGACACUGGCACGUAC 
B06 Myl3 17897 NM_010859 GCGAGAUGAAGAUCACAUA 
B06 Myl3 17897 NM_010859 GGUGAGAGACUGACAGAAG 
B07 Dynll1 56455 NM_019682 GACAAGAAGUACAACCCUA 
B07 Dynll1 56455 NM_019682 GCAGACAUGUCGGAAGAGA 
B07 Dynll1 56455 NM_019682 UACAACAUCGAGAAGGAUA 
B07 Dynll1 56455 NM_019682 CUUCGGUAGUUAUGUGGCA 
B08 Rab7 19349 NM_009005 GUACAAAGCCACAAUAGGA 
B08 Rab7 19349 NM_009005 AAACAACAUUCCUUACUUC 
B08 Rab7 19349 NM_009005 AAACAAGAUUGACCUGGAA 
B08 Rab7 19349 NM_009005 AAGUGGAACUGUACAAUGA 
B09 Myo9b 17925 NM_015742 CAACCGGACACGGGAAUUA 
B09 Myo9b 17925 NM_015742 GAACCGAAAUCGCAAAGUU 
B09 Myo9b 17925 NM_015742 CCAAUGAGCUCAAGUUUCU 
B09 Myo9b 17925 NM_015742 CAGGAAGACUCUAGACGUA 
B10 EG231836 231836 XM_144611 GAGCGGACCUUUAUAUUUG 
B10 EG231836 231836 XM_144611 GGAUACAACACGACCAUUU 
B10 EG231836 231836 XM_144611 UGAGGGAGAUGGAACCCAA 
B10 EG231836 231836 XM_144611 GCAGGUGACCAGUGAGGAA 
B11 Myh7b 668940 NM_001085378 GGACAGAGCUCUUUCGACU 
B11 Myh7b 668940 NM_001085378 ACAAAUGGCUCCCGGUCUA 
B11 Myh7b 668940 NM_001085378 CACAAUUUCUGGCGACAAA 
B11 Myh7b 668940 NM_001085378 GCAUGGAGGUGGACGAUCU 
C03 Myo10 17909 NM_019472 ACAAUUCCCUGGACUACUA 
C03 Myo10 17909 NM_019472 GCAAUGCGAAGACAGUAUA 
C03 Myo10 17909 NM_019472 GUACAUGAAAGGUGGCUUA 
C03 Myo10 17909 NM_019472 AGACCCAACUCAUUUGUGA 
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C04 Klc2 16594 NM_008451 GCGAGGAGAGCAAGGAUAA 
C04 Klc2 16594 NM_008451 GGACGGGUCUUUCUGACAG 
C04 Klc2 16594 NM_008451 CAAUGAAGAUGAACAGAGC 
C04 Klc2 16594 NM_008451 CCACAGGAGCCUAACUCUA 
C05 Mylc2b 67938 NM_023402 GCGCGAAAGACAAAGAUGA 
C05 Mylc2b 67938 NM_023402 GCGCGCAACCUCCAAUGUG 
C05 Mylc2b 67938 NM_023402 GGGAACUUCAACUACAUUG 
C05 Mylc2b 67938 NM_023402 UCGCUUGCUUUGAUGAGGA 
C06 Rab10 19325 NM_016676 GGAAUAGACUUUAAGAUCA 
C06 Rab10 19325 NM_016676 CAAGAGAGUUGUACCGAAA 
C06 Rab10 19325 NM_016676 CACAUUAGCUGAAGACAUC 
C06 Rab10 19325 NM_016676 UAGAUGAGCAUGCCAAUGA 
C07 Bicd1 12121 NM_009753 GAUGAAAUCCGAGAAUAUA 
C07 Bicd1 12121 NM_009753 CCAAAUGUAUGAUGAACAA 
C07 Bicd1 12121 NM_009753 GAAGUGAGCCAAAUAACGA 
C07 Bicd1 12121 NM_009753 UUACAAAUGUCCAGGCAGA 
C08 Coro1c 23790 NM_011779 GAUCAAAUCCAUAAAGGAA 
C08 Coro1c 23790 NM_011779 GACCGAGCCUGUGGUGAUU 
C08 Coro1c 23790 NM_011779 CAAUUGCUCUCCAUGAAAU 
C08 Coro1c  23790 NM_011779 GAAAGUGCGAGCCCAUUAU 
C09 Dynlt3 67117 NM_025975 CCCAUAAUAUAGUCAAAGA 
C09 Dynlt3 67117 NM_025975 GGUGGUAACGAUUAUAAUG 
C09 Dynlt3 67117 NM_025975 GGGGAAAGCUUACAAGUAC 
C09 Dynlt3 67117 NM_025975 CAGAGGAGCCCGUAUGGAU 
C10 Cenpe 229841 NM_173762 GAAGAGCUCCAUAUAAUAA 
C10 Cenpe 229841 NM_173762 GAUUAUGAGUGCUUGAAUA 
C10 Cenpe 229841 NM_173762 GAUAGCAAAUUGACACGAA 
C10 Cenpe 229841 NM_173762 GAACUUAACCUUGCUCGUU 
C11 Myo16 244281 XM_356059 GGAAACAUCCCUUUAGAUU 
C11 Myo16 244281 XM_356059 CAUCACAACUCACGAAAUC 
C11 Myo16 244281 XM_356059 GAGUGUAGAUCUAUGAAUC 
C11 Myo16 244281 XM_356059 GGACUUCACCUUAAUAACU 
D03 Dync1li2 234663 NM_001013380 GAAGAUGGUUCUGGUAAGA 
D03 Dync1li2 234663 NM_001013380 UAAAGAAGCCAGAUCCAAA 
D03 Dync1li2 234663 NM_001013380 GAAAGCUGGUCCAUGACAA 
D03 Dync1li2 234663 NM_001013380 UUACAACCGUGAAGCCAGA 
D04 Kif21b 16565 NM_019962 GGGUAAAGCUGUGGAAUUA 
D04 Kif21b 16565 NM_019962 GAACCAGUCUCGCUAUGAA 
D04 Kif21b 16565 NM_019962 CAACGUGGUUUCUAUCAAA 
D04 Kif21b 16565 NM_019962 CAAACUGACUGGCCACAUU 
D05 Dync1i1 13426 NM_010063 GGAAGGGGCUGUUGAGUUA 
D05 Dync1i1 13426 NM_010063 GCAUUUGGAUCUAUGAUGU 
D05 Dync1i1 13426 NM_010063 CCACAAUGCUCGCAACCUG 
D05 Dync1i1 13426 NM_010063 GACAAUCGCAGUCAUCGAA 
D06 Kif26b 269152 NM_177757 GCGAGGAUCUGGAGUGCUA 
D06 Kif26b 269152 NM_177757 GAAAGCCUGUCGUCGGUGA 
D06 Kif26b 269152 NM_177757 GAUCGCGUCGAGAGUCUUA 
D06 Kif26b 269152 NM_177757 AAGACUAGAUUGCAUAGAU 
D07 Dynlrb2 75465 NM_029297 GAACGAUGGUGGUCAAUGC 
D07 Dynlrb2 75465 NM_029297 GGACAACUCCACAACGGUU 
D07 Dynlrb2 75465 NM_029297 GAGAAUCCAGAGUCACAAA 
D07 Dynlrb2 75465 NM_029297 AGAUCGAAGAAACAUGAAA 
D08 Kif2a 16563 NM_008442 GUAAAGGAGUUUGGAAUUA 
D08 Kif2a 16563 NM_008442 GAAAUGGUUUACAGGUUUA 
D08 Kif2a 16563 NM_008442 UGAAGAAGCCAAACUAUAA 
Chapter 2. Materials and Methods 
56 
D08 Kif2a 16563 NM_008442 GGAAUGGCAUCCUGUGAAA 
D09 Mxd3 17121 NM_016662 GGAGUUGACUGUACCCGAU 
D09 Mxd3 17121 NM_016662 GCGCUCAGACUCAGACCAA 
D09 Mxd3 17121 NM_016662 GGGCCAGGGUGCAUAUCCA 
D09 Mxd3 17121 NM_016662 AGGAAAAGCUUCGCAGCAA 
D10 Myo1b 17912 NM_010863 GAGCUUACCUGGAAAUCAA 
D10 Myo1b 17912 NM_010863 GGACUCUGCUAAAGUUAAU 
D10 Myo1b 17912 NM_010863 CAUCUAGAUUCGGCAAAUA 
D10 Myo1b 17912 NM_010863 GAUCGGUGUUGGAGAUAUG 
D11 Kif15 209737 NM_010620 GAACAACUGUCUCAAUUUA 
D11 Kif15 209737 NM_010620 GAACAGACGUGUAGCAUCA 
D11 Kif15 209737 NM_010620 GGACAACGCCAGAUUAGAA 
D11 Kif15 209737 NM_010620 GGAUUCCUACGAUAACUUA 
E03 Osbpl1a 64291 NM_020573 GGGAGAGACUUAUGAAUUA 
E03 Osbpl1a 64291 NM_020573 GCACAGGACUGGAUUUAUU 
E03 Osbpl1a 64291 NM_020573 GCAAGGAAUUACACAAAGU 
E03 Osbpl1a 64291 NM_020573 CAACGAAGCAUACACAUGG 
E04 Kif1a 16560 NM_008440 AGACAGAUUUCAUCCCUUA 
E04 Kif1a 16560 NM_008440 GGAAGCACCACCACUAUUG 
E04 Kif1a 16560 NM_008440 GAAGUGCGCGAGCUAGUUG 
E04 Kif1a 16560 NM_008440 ACACAUAUGUCAACGGCAA 
E05 Rab8a 17274 NM_023126 GAAUAAGUGUGAUGUGAAU 
E05 Rab8a 17274 NM_023126 GAAGACCUGUGUCCUGUUC 
E05 Rab8a 17274 NM_023126 GACCUACGAUUACCUGUUC 
E05 Rab8a 17274 NM_023126 GAGCAGCCAUGGAGUCAAG 
E06 Kif12 16552 NM_010616 CGUCGGAGCUCCUCACAUA 
E06 Kif12 16552 NM_010616 GAACAUGCCAUAUGGGCUA 
E06 Kif12 16552 NM_010616 GAUGUGGCGUUCCGCUUUG 
E06 Kif12 16552 NM_010616 GCUAUUAGAUCGCGUGCAG 
E07 Kif3a 16568 NM_008443 CAUGAUGUGUGCAAAUAUU 
E07 Kif3a  16568 NM_008443 AGACUUAUCAGCAUAUGUA 
E07 Kif3a 16568 NM_008443 CGACUAAUAUGAACGAGCA 
E07 Kif3a 16568 NM_008443 CCUGAGACCGUAAUUGAUU 
E08 Kif11 16551 NM_010615 GUAAAUGGCUGUUGUAAAG 
E08 Kif11 16551 NM_010615 CAGCAGAGGUCUUCCAUUU 
E08 Kif11 16551 NM_010615 GGAGAUCACUAAGAAAGUA 
E08 Kif11 16551 NM_010615 GAAACAGGAUCUGAAACUA 
E09 Arl8c 67166 NM_026011 GAUAGAAGCCUCUCGAAAU 
E09 Arl8c 67166 NM_026011 UAAAGGCAACGUCACAAUA 
E09 Arl8c 67166 NM_026011 GAUAGAUGCUGCAGAUCGA 
E09 Arl8c 67166 NM_026011 UAGAGAAAUUUGCUGCUAU 
E10 Kif13b 16554 XM_283218 GUACUUAGAUGCUGCCUUA 
E10 Kif13b 16554 XM_283218 CAGCCUACCUUCUCAGAUA 
E10 Kif13b 16554 XM_283218 GAACAUGGAUUGGUGUGGA 
E10 Kif13b 16554 XM_283218 GUGCGGACCUCAGAGCUUA 
E11 Kif7 16576 XM_133575 AAAGAGAGCAUCCAGAUUA 
E11 Kif7 16576 XM_133575 GAAUGAGGCUAUCACAUGC 
E11 Kif7 16576 XM_133575 GGUCGACACAUGUGGAUAA 
E11 Kif7 16576 XM_133575 GAUGAUCGACGUCAGGAAA 
F03 Dctn1 13191 NM_007835 GGACAGCGCUGCCAAGGAU 
F03 Dctn1 13191 NM_007835 CAAAGGUCCUCAAGAGAGA 
F03 Dctn1 13191 NM_007835 GAGCAAGCCUCCUCCGGUU 
F03 Dctn1 13191 NM_007835 CACGAGCGCUCCUUAGAUU 
F04 Dynll2 68097 NM_026556 ACAAAGCACUUCAUCUAUU 
F04 Dynll2 68097 NM_026556 GCAGCUAUGUCACACACGA 
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F04 Dynll2 68097 NM_026556 AACCCUACCUGGCAUUGUA 
F04 Dynll2 68097 NM_026556 GCCUAUAUCAAGAAGGAAU 
F05 Myh2 17882 NM_144961 CCACGAACCCAUAUGAUUA 
F05 Myh2 17882 NM_144961 GCGGAAAGAAGCUACCAUA 
F05 Myh2 17882 NM_144961 CCGGUGCUGUGAUGCAUUA 
F05 Myh2 17882 NM_144961 GCGCUGGUAUCUCAGUUAU 
F06 Dync2li1 213575 NM_172256 GGACGGAGCUGAAAUCGGA 
F06 Dync2li1 213575 NM_172256 GGCAUUCGGUAUUGAUAAA 
F06 Dync2li1 213575 NM_172256 GUAGAGAAACGGAGAAGUC 
F06 Dync2li1 213575 NM_172256 CAACCAUUAUCCUAAGGUG 
F07 Kifc3 16582 NM_010631 GGAAGUGGCUGAGAACAAA 
F07 Kifc3 16582 NM_010631 GGGCUCAGAUUGCCAUGUA 
F07 Kifc3 16582 NM_010631 CACGUGAGAUUUACAAUGA 
F07 Kifc3 16582 NM_010631 GGAAACAUCCGGGUGAUUG 
F08 Myh1 17879 XM_354615 UGAAAGAACUCACUUAUCA 
F08 Myh1 17879 XM_354615 GAAGCCGGAUCUAAUCGAA 
F08 Myh1 17879 XM_354615 GCAGAGAUAUAAGGUUUUA 
F08 Myh1 17879 XM_354615 GAACAGAAGCGCAACGUGG 
F09 Dnhd1 77505 XM_355968 CAAUAUGUCUGUCGAAUUA 
F09 Dnhd1 77505 XM_355968 GCAUGAGCGUCAAGUAUUU 
F09 Dnhd1 77505 XM_355968 GCAGAUACCUAUGAAGCUA 
F09 Dnhd1 77505 XM_355968 GGAGAAUGAUCACAGUCUA 
F10 Rab5a 271457 NM_025887 AAACAAAGCUGACUUAGCA 
F10 Rab5a 271457 NM_025887 GGUCAAGAACGGUAUCAUA 
F10 Rab5a 271457 NM_025887 GCACAAGCAGCCAUAGUUG 
F10 Rab5a 271457 NM_025887 GGCCAAAUACUGGAAAUAA 
 
Six additional wells were used for the negative siRNA controls (B2, C2, D2 and 
E2 treated with a non-targeting siRNA pool and F2 and G2 left untransfected) and six 
were treated with 1 mM EHNA together with the two probes (B12, C12, D12 and E12 
pre-treated with a non-targeting siRNA pool and F12 and G12 left untransfected before 
the treatment with EHNA).  
2.1.7 Bacterial strains 
 E. coli strain:                  Application: 
 XL-1 Blue      cloning/plasmid purification 
 TG1     protein expression 
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2.1.8 Mouse ES cell lines. 
 The HB9-GFP mouse ES cell line was a gift from Jessell and Wichterle 
(Columbia University, New York, USA) (Wichterle et al., 2002), and the homozygous 
and heterozygous Bicd1 gene trapped ES cell lines were provided by Krzysztof Wicher 
and David Ish-Horowicz (Developmental Genetics laboratory at the CRUK, London 
Research Institute). 
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2.2 Methods 
 All experiments performed on mouse primary neurons followed the guidelines 
of the UK Home Office (Animal Scientific Procedures Act 1986) and were approved by 
the CRUK London Ethical Committee.  
2.2.1 Bacterial cultures 
2.2.1.1 Preparation of electrocompetent bacteria 
 Bacteria E. coli XL1Blue were grown in 5 ml of Luria Bertani (LB) medium 
overnight at 37˚C, inoculated in an additional 800 ml of LB medium and incubated at 
37˚C until an optical density at 600 nm (OD600) of 0.6 was reached. Bacteria were 
pelleted at 4˚C at 5000 rpm for 20 min using a JA-10 rotor (Beckman), washed with 500 
ml of ice-cold water, followed by 40 ml of ice-cold water with 10% v/v glycerol. 
Finally, the pellet was re-suspended in 1 volume of ice-cold water with 10% v/v 
glycerol and stored at -80˚C.  
2.2.1.2 Bacterial transformation 
 80 µl of competent bacteria (section 2.2.1.1) were transferred to a 1 mm 
electroporation cuvette (Flowgen) and 50 – 500 pg of DNA were added. Bacteria were 
then incubated at 4˚C for 10 min and electroporated at 200 Ω, 25 µF and 1.8 kV. After 
electroporation, 400 µl of SOC medium was added to the bacteria and incubated under 
shaking at 37˚C for 30 min. Finally, the bacteria were centrifuged at 3000 rpm using a 
JA-10 rotor (Beckman) for 1 minute, re-suspended in 100 µl of LB medium and 
transferred on LB-Agar plates containing the appropriate antibiotic. 
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2.2.2 Nucleic acid techniques 
2.2.2.1 Reverse transcription polymerase chain reaction (RT-PCR) 
 The RT-PCR for TrkA (Chapter 6, Figure 6.2) was performed by Dr. M. 
Golding, Molecular NeuroPathobiology laboratory at CRUK, London Research 
Institute. Total RNA was extracted using the RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions. cDNA for the RT-PCR reactions was generated from 2 µg 
of total RNA using the SuperScript®VILOTM cDNA synthesis kit (Invitrogen) 
according to the manufacturer’s instructions. The PCR reaction was performed from 
10 ng (equivalent to RNA) of cDNA template using the MegaMix Blue Kit (Microzone) 
using the following parameters: 
 1 cycle                    denaturation                     94˚C  2 min  
 30 cycles               denaturation                      94˚C  30 s 
         annealing/extension       72˚C  40 s 
2.2.2.2 Quantitative reverse transcription polymerase chain reaction 
(Q-PCR) 
 The Q-PCR experiments were performed by Dr. M. Golding, Molecular 
NeuroPathobiology laboratory at CRUK, London Research Institute. Total RNA was 
extracted using the RNeasy mini kit (Qiagen) according to the manufacturer’s 
instructions. cDNA for the Q-PCR reactions was generated from 2 µg of total RNA 
using the SuperScript®VILOTM cDNA synthesis kit (Invitrogen) according to the 
manufacturer’s instructions. The Q-PCR was performed with a 7500 Real-Time PCR 
system (Applied Bioscience) using the SYBR® GreenERTM Reagent System 
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(Invitrogen) according to the manufacturer’s instructions. The data were normalised to 
the CT (cycle at threshold) values of the βIII tubulin control. The parameters of the Q-
PCR reaction were the following:  
Stage Repetitions Temperature Time 
Denaturation 1 95˚C 20 s 
Annealing/extension 40 95˚C 03 s 
  60˚C 30 s 
Dissociation 1 95˚C 15 s 
  60˚C 60 s 
  95˚C 15 s 
  60˚C 15 s 
 
2.2.2.3 DNA agarose gel electrophoresis 
 Agarose gels were prepared by dissolving 1-2% agarose in Tris-acetate EDTA 
(TAE) buffer (40 mM Tris-OH pH 8.0, 20 mM glacial acetic acid, 1 mM EDTA) or 
Tris-borate EDTA (TBE) buffer (90 mM Tris-OH, 90 mM boric acid, 2 mM EDTA pH 
8.0). Ethidium bromide was added to a final concentration of 0.5 µg/ml. DNA samples 
were mixed with 10X loading buffer (10% Ficoll 400, 25% glycerol, 10 mM Tris-HCl 
ph 7.6, 1 mM EDTA, 0.25% Bromophenol blue) and run at 80-150 V/cm in TAE or 
TBE buffer. 
2.2.2.4 Isolation of plasmid DNA 
 Plasmid DNA was purified using the QIAprep® Spin Mini Prep Kit, or the 
QIAfilterTM Plasmid Maxi Kit from Qiagen® according to manufacturer’s instructions. 
2.2.2.5 Nucleic acid quantification 
 DNA was diluted in water and its optical density at 260 (OD260) and 280 nm 
(OD280) was measured using a Nanodrop® spectrophotometer (Labtech International). 1 
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unit of OD260 corresponds to 50 mg/ml of double-stranded DNA. The OD280 is used for 
quality control of the purified DNA, because proteins have their maximum absorption at 
280 nm; an OD260/ OD280 ratio below 1.8 indicates a low level of purity of the DNA 
preparation. 
2.2.3 Protein techniques 
2.2.3.1 Cell lysis 
 Cells were scraped on ice in phosphate buffer (PBS; 137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.47 mM KH2HPO4, pH 7.6) and centrifuged at 1200 g for 5 
min. The cell pellet was then re-suspended in lysis buffer (10 mM Tris-HCl, pH 8.0, 
150 mM KCl, 1% NP-40, 1% glycerol, 1mM EDTA, 0.1 mM Dithiothreitol (DTT) and 
protease inhibitor cocktail (Roche), pH 7.6) and incubated at 4˚C for 30 min. The 
extract was subsequently spun at 16,000 g for 20 min and the pellet was discarded. 
2.2.3.2 Protein quantification 
 The protein concentration was determined using the BIO-RAD Protein Assay 
Reagent. One ml of the BIO-RAD Protein Assay Reagent diluted 1:4 in water was 
incubated with incremental dilutions of Bovine Serum Albumine (BSA) at room 
temperature for 5 min. The absorbance at 595 nm was measured with a 
spectrophotometer (Bio Photometer, Eppendorf) and used to create a standard curve. 
Samples containing 1 µg of protein were mixed with the BIO-RAD Protein Assay 
Reagent (1:4 in water) and incubated at room temperature for 5 min. Their absorbance 
at 595 nm was then measured and the protein concentration of the sample was inferred 
on the basis of the BSA standard curve by linear regression. 
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2.2.3.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Protein samples were diluted in sample buffer (20% glycerol, 5% β-
mercaptoethanol, a pinch of Bromophenol blue, 10% SDS, 120 mM Tris-HCl pH 6.8) 
and incubated for 10 min at 65˚C or boiled for 5 min. Samples were loaded on a pre-cast 
4-12% NuPAGE® Bis-Tris minigel (Invitrogen) and the gel run at 200 V in 2-(N-
Morpholino)ethanesulfonic acid sodium salt (MES) buffer (Invitrogen) for an hour. 
Where appropriate, gels were stained with Coomassie blue (50% methanol, 10% acetic 
acid, 0.1% Coomassie Brilliant Blue) for 15 min at room temperature and de-stained in 
water overnight.  
2.2.3.4 Western Blotting 
 Proteins were transferred from precast 4-12% NuPAGE® Bis-Tris minigel onto a 
methanol-activated Polyvinylidene fluoride (PVDF) membrane (PROTEAN®) in 
Transfer Buffer (Invitrogen) supplemented with 20% methanol at 300 mA for an hour. 
PVDF membranes were subsequently stained with Ponceau S to monitor the efficiency 
of the protein transfer. The membrane was then de-stained in water and blocked in a 
solution of 5% skimmed milk (Marvel) in PBS containing 0.05% Tween-20 for 30 min 
at room temperature. The membrane was incubated with the primary antibody diluted in 
PBS containing 0.05% Tween-20 for a period of time ranging from 1 hour (room 
temperature) to overnight (4˚C), depending on the primary antibody used. The 
membrane was then washed in PBS containing 0.05% Tween-20 and incubated with the 
appropriate HRP-conjugated secondary antibody in 5% skimmed milk (Marvel) in PBS, 
0.05% Tween-20. After extensive washing in PBS, 0.05% Tween-20, the 
immunoreactivity was detected using enhanced chemoluminescence (ECL, GE 
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Healthcare), following the manufacturer’s instructions and developed on high 
performance chemoluminescence films (GE Healthcare). 
2.2.3.5 Purification of GST-recombinant HC 
 A version of HC containing a tetracysteine tag 
(AEAAAREACCRECCAREAAAR, (Bohnert and Schiavo, 2005)) at its N-terminus 
and cloned in a pGEX-4T3 vector was electroporated into the E. coli strain TG1 
(section 2.2.1.2) and plated on ampicillin-containing LB-Agar plates. A single 
transformed colony was then picked and inoculated into 200 ml of 2YT medium 
containing 100 µg/ml ampicillin overnight at 37˚C. This preculture was then diluted to 2 
L with 2YT medium containing 100 µg/ml ampicillin and grown at 37˚C until an OD600 
of 0.8 was reached.  Protein expression was induced for 4 h at 300C by adding 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG). Bacteria were subsequently pelleted by 
centrifugation at 1000 g for 10 min, resuspended in ice cold PBS and centrifuged again 
at 1000 g for 15 min. Finally, bacteria were resuspended in ice cold PBS, transferred 
into a 50 ml Falcon tube and pelleted again at t 1000 g for 15 min, snap frozen in liquid 
nitrogen and stored at -80˚C.  
The bacterial pellet was thawed on ice and re-suspended in PBS with 0.05% 
Tween-20 supplemented with protease inhibitor cocktail (Roche). The mixture was then 
subjected to two cycles of snap-freezing and thawing and sonicated three times at 
maximum amplitude for 15 seconds. The resulting lysate was ultracentrifuged for 30 
min at 28000 rpm using a SW40 Ti rotor (Beckman). The supernatant was absorbed 
onto 2.5 ml 50% glutathione-agarose beads (Sigma) per L of bacterial culture for 2 h at 
4˚C. Beads were then incubated at 37˚C for 10 min and washed twice with DNA K 
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buffer (50 mM Tris-HCl, pH 7.4, 2 mM ATP, 10 mM MgSO4). The resin was further 
washed with PBS, 0.05% Tween-20 and with PBS, 0.05% Tween-20, 0.5 M NaCl. 
Finally, HC was cleaved from the GST by incubating the resin with 100 µl of thrombin 
(0.8 U/mg) in 2.5 ml of TCB buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% β–
mercaptoethanol) for 30 min at room temperature. Cleaved HC was eluted from the 
beads in 2.5 ml of TCB followed by 2.5 ml of TCB, 0.5 NaCl. The eluate was pooled 
together, dialysed against 20 mM HEPES-NaOH pH 7.4, 150 mM NaCl, snap-frozen in 
liquid nitrogen and stored at -800C. 
2.2.3.6 Fluorescent labelling of HC with AlexaFluor dyes 
15 nmol of purified HC (section 2.2.3.5) were first added to labelling buffer (20 
mM HEPES-NaOH pH 7.4, 250 mM NaCl) containing 10X molar excess of tris-(2-
carboxyethyl)phosphine hydrochloride (TCEP) and then the solution was mixed with 
25X molar excess of 555 AlexaFluor-maleimide (Invitrogen) in DMSO. The reaction 
mixture was subsequently incubated at 40C overnight. The cross-linking reaction was 
stopped by adding 4 mM reduced glutathione in Tris-HCl, pH 8.0 and the labelled 
protein was dialysed over three days against ice cold PBS at 4˚C. Finally AlexaFluor 
conjugated HC was aliquoted, snap-frozen in liquid nitrogen and stored at -800C. 
2.2.3.7 Fluorescent labelling of the p75NTR antibody 
 p75NTR antibody against the extracellular domain of the receptor (batch 5410, 
1.8 mg/ml) was dialysed against PBS for 48 h at 4˚C; 100 µl of the dialysed antibody 
were then mixed with 10 µl of 1M NaHCO3 and AlexaFluor488-carboxylic acid, 
tetrafluorophenyl (TFP) ester. The reaction mixture was left at room temperature for 1 
hour and subsequently dialysed against PBS at 4˚C for 24 h with frequent changes of 
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buffer. The conjugated AlexaFluor 488 p75NTR was then aliquoted and stored at 4˚C.  
2.2.3.8 Conjugation with 10 nm gold nanoparticles 
 100 µg of purified HC (section 2.2.3.5) were applied drop wise to 10 ml of a 
suspension of 10 nm gold particles at pH 6.7, which corresponds to the pI of HC. The 
solution was left stirring at 4˚C for 30 min to allow the formation of aggregates and the 
pH was subsequently raised to 9.0 with 0.2 M NaCO3. BSA was then added to a final 
concentration of 1% and the mixture was stirred for another 15 min at 4˚C. The 
suspension was finally pelleted at 45000 g for 30 min, resuspended in 1 ml of storage 
buffer (20 mM Tris-OH pH 8.2, 150 mM NaCl, 1% BSA) and stored at 4˚C. 
2.2.4 Tissue culture techniques 
2.2.4.1 Coating of the plates for motor neurons cultures 
 The plates and coverslips for primary and ES derived MNs were coated over 
night with poly-ornithine (1.5 mg/ml) diluted in milliQ water. The poly-ornithine was 
then removed and laminin diluted in Neurobasal medium was added for two h. Just 
before plating, the laminin solution was removed and MNs were plated in full medium. 
2.2.4.2 Isolation of mouse spinal cord motor neurons 
 Spinal cord MNs were purified from E11.5 – E13.5 mouse embryos (Arce et al., 
1999). Spinal cords were dissected out, removing the meninges and the dorsal horns. 
The ventral horns of the spinal cord were then minced and dissociated by incubation 
with 0.025% trypsin in PBS for 10 min at 37˚C. Following dissociation, the cells were 
triturated in Leibovitz 15 (L-15) medium containing 0.02 mg/ml of DNAse and 0.4% of 
BSA. Two ml of BSA cushion (4% embryo-tested BSA in L-15) were applied with a 
Chapter 2. Materials and Methods 
67 
glass pipette at the bottom of the cell suspension, which was then spun for 5 min at 470 
g. The resulting MN pellet was resuspended in full medium (section 2.2.4.3) and plated 
on poly-ornithine/laminin-coated dishes. 
2.2.4.3 Maintenance of primary motor neuron cultures 
 MN cultures were maintained at 37oC and 7.5% CO2 in MN complete medium, 
composed of Neurobasal (Gibco-BRL), 2% v/v of B27 supplement (Gibco-BRL), 2% 
heat-inactivated horse serum, 1% GLUTAMAXTM (Invitrogen), 25 µM β-
mercaptoethanol, 10 ng/ml rat ciliary neurotrophic factor (CNTF) and 100 pg/ml rat 
glial-derived neurotrophic factor (GNTF) (both R&D Systems). MNs were used for 
experiments from day in vitro (DIV) 5 and maintained in culture for up to two weeks. 
2.2.4.4 Culture of undifferentiated mouse ES cells. 
 ES cells are maintained in gelatinised flasks (0.1% of fish skin gelatin in 
distilled water applied to the flask for 10 min prior to seeding of the cells), without a 
feeder layer. The medium used for undifferentiated ES cell culture was composed of 
Glasgow MEM (GMEM), 5% ES cell-tested Foetal Bovine Serum (FBS), 5% Knockout 
Serum Replacement (KSR, Gicbo-BRL), 1% GLUTAMAX, 0.1 mM β-
mercaptoethanol, and 1000 units/ml of leukocyte inhibitory factor (LIF). 
 ES cells were routinely passaged every other day due to their fast growth rate, 
thus avoiding acidification of the medium, overconfluency and the resulting 
differentiation of the ES cultures. 
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2.2.4.5 In vitro differentiation of ES cells into MNs 
 Undifferentiated ES cells were trypsinized with 0.05% Trypsin/EDTA for 5 min 
at room temperature. 1.5 x 106 cells were then centrifuged at 310 g per 5 min and re-
suspended in differentiation (DNFK) medium (45% v/v Neurobasal, 22% v/v DMEM 
and F12, 1% v/v GLUTAMAX, 10% Knockout Serum Replacement, 0.1 mM β-
mercaptoethanol). Resuspended cells were plated on a 10 cm Petri dish. Non tissue-
culture treated plates allow the ES cells to grow in suspension and form Embryoid 
bodies (EBs). 
 The day after seeding the ES cells, the forming EBs were spun down and 
resuspended in 10 ml of fresh DNFK medium and plated on a new Petri dish. The 
following day, EBs were allowed to settle by gravity and re-suspended in fresh 
differentiation DFNK medium supplemented with 1 µM all-trans retinoic acid (RA) and 
333 nM Sonic Hedgehog Agonist (SAG). The EBs were then maintained in DNFK 
medium with RA and SAG for 4 days (medium changed every other day) and finally 
dissociated (section 2.2.4.6). 
2.2.4.6 Dissociation of embryoid bodies 
 EBs were allowed to settle down by gravity and then dissociated by incubation 
with 0.025% trypsin in PBS for 7 min at 37oC. Following dissociation, cells were 
triturated in Leibovitz 15 medium (L-15) containing 0.02 mg/ml of DNAse and 0.4% of 
BSA. Two ml of BSA cushion (4% embryo tested BSA in L-15), were applied with a 
glass pipette at the bottom of the cell suspension, which was then spun for 5 min at 
470g. The MN pellet was resuspended in full medium (section 2.2.4.3) supplemented 
with 1 µM all-trans retinoic acid and plated on poly-ornithine/laminin-coated dishes 
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2.2.4.7 Generation of Bicd1gt/gt ES cells. 
Mouse ES cells with a gene-trap mutation in the first intron of Bicd1 (clone 
RRP227) were obtained from the Mutant Mouse Regional Resource Centers. 
Homozygous Bicd1gt/gt cells were generated by Krzystof Wicher as previously describe 
(Lefebvre et al., 2001). Heterozygous cells were seeded at 30% confluency and grown 
in medium containing LIF and 1.5 mg/ml G418 for several days until distinct clones of 
antibiotic resistant cells appeared. Several clones were picked up into a drop of trypsin 
solution and seeded into separate wells of a 24-well plate and grown in the presence of 
500 ng/ml G418. After reaching confluency, cells were trypsinised and half of them 
used to isolate RNA (section 2.2.2.4). For detection of loss of heterozygosity RT-PCR 
reactions were performed using the One-Step RT-PCR kit (Invitrogen), primers specific 
to wild type and Bicd1gt alleles (section 2.1.4), and 35 cycles of amplification. Clones 
showing a 70% reduction of the wild type allele product were considered Bicd1gt/gt 
homozygous. 
2.2.5 Imaging techniques 
2.2.5.1 Immunocytochemistry and confocal imaging of fixed samples  
 Cells on coverslips were fixed in 4% paraformaldehyde (PFA) dissolved in PBS 
for 15-30 min at room temperature and then washed in PBS. After fixation, cells were 
permeabilised and blocked at the same time for 1 h at room temperature in a solution of 
10% goat serum, 2% BSA, 0.25% fish skin gelatin, 0.1% Triton X-100 in PBS. For 
staining with the GD1b antibody and for the experiments performed to detect p75NTR 
and TrkB on at the plasma membrane, cells were only blocked, without 
permeabilisation, in 10% goat serum, 2% BSA, 0.25% fish skin gelatin, in PBS. The 
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coverslips were subsequently incubated with the primary antibody diluted in 10% goat 
serum, 2% BSA, 0.25% fish skin gelatin, in PBS (section 2.1.2, for the dilutions) for 1 
h to overnight at room temperature or at 4˚C and then washed in PBS to remove the 
excess of primary antibody. Finally, coverslips were incubated with the appropriate 
AlexaFluor-conjugated secondary antibody diluted in 10% goat serum, 2% BSA, 0.25% 
fish skin gelatine, in PBS for 1 h at room temperature, washed in PBS and then in water, 
and mounted on Mowiol-488 prior to imaging. Cells were imaged with an upright or 
inverted Zeiss 510 confocal microscope using 40X or 63X oil immersion objective 
lenses with a numerical aperture of 1.4 and a phase contrast ring.  
2.2.5.2 Immunocytochemistry and confocal images of fixed samples 
in a 96-well format 
The plate was handled manually using a multichannel pipette. The 96-well 
plates were cooled on ice, acid-washed with isotonic solution at pH 2.0 (100 mM 
citrate-NaOH, 142 mM NaCl, pH 2.0) for 2 min and fixed with 4% PFA for 20 min, 
permeabilised and blocked at the same time for 1 h at room temperature in a solution of 
10% goat serum, 2% BSA, 0.25% fish skin gelatin, 0.1% Triton X-100 in PBS and then 
washed once with PBS. The cells were then stained with a anti-rabbit AlexaFluor 647-
conjugated secondary antibody diluted in 10% goat serum, 2% BSA, 0.25% fish skin 
gelatin, in PBS for 45 min at room temperature and then washed in PBS. Finally, each 
plate was sealed with a transparent plastic foil and images were acquired with an 
inverted 510 Zeiss Confocal microscope using the MTS macro as described in Chapter 
3 (section 3.4.1). 16 stacks were acquired for each well. 
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2.2.5.3 Time-lapse imaging of HC and p75NTR antibody 
MNs derived from ES cells seeded on poly-ornithine and laminin-coated 
MatTek dishes (MatTek Corporation) at 4 days after dissociation of the EBs were 
incubated for 30 min at 37˚C with either 20 nM  AlexaFluor 555 conjugated HC (section 
2.2.3.6) or 0.9 µg/ml  AlexaFluor 647-conjugated p75NTR 5410 antibody (section 
2.2.3.7) in the presence of 100 ng/ml of NGF diluted in full medium (section 2.2.4.3). 
Cells were subsequently washed and incubated for 15 min at 37˚C with imaging 
medium (DMEM with low bicarbonate and without phenol red, folic acid, riboflavin, 
penicillin and streptomycin). MatTek dishes were then placed in an environmental 
chamber, kept at 370C, and imaged with a Zeiss 510 inverted confocal microscope 
equipped with a 63X Plan Apochromat oil immersion objective, with a NA of 1.4. 
Images were collected every 4 seconds with a pinhole aperture of 1.5 µm. 
2.2.5.4 Transmission electron microscopy 
The handling of the samples and the acquisition of the images were performed 
by Ken Blight, Electron Microscopy Unit at CRUK, London Research Institute. MNs 
plated on coverslips were fixed in 2.5% glutaraldehyde, 4% PFA in Sorensen phosphate 
buffer at room temperature for 20 min. Samples were then post-fixed in osmium 
tetroxide, stained with tannic acid and dehydrated progressively up to 100% ethanol. 
Finally, coverslips were embedded in an EPON epoxy resin, cut in thin sections (70-75 
nm) and stained with lead citrate. Images of the stained sections were acquired using a 
Tecnai Spirit Biotwin (FEI) transmission electron microscope. 
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2.2.6 Cell-based assays 
2.2.6.1 Transfection of MNs 
2.2.6.1.1 Electroporation of primary MNs 
  The PA-4000/PA-96 WS Pulse Agile (Labtech) and the BTX ECM 
830 (Harvard Apparatus) systems were used to electroporate primary MNs. 3x105 
primary MNs per well were resuspended in siPORT (Ambion) electroporation buffer 
and plated on a 96-well plate provided by the supplier of the electroporation apparatus 
(custom built to accommodate the electrodes). SiGLO siRNA (Dharmacon) was added 
to the cell suspension at a concentration of 1.5 µM per well. Subsequently, cells were 
electroporated (Chapter 3, table 3.1 for the electroporation parameters) and left at 37˚C 
for 12 min to recover. The cell suspension was then seeded on coverslips into a 24-well 
plate in a volume of 500 µl of full medium (section 2.2.4.3). 
2.2.6.1.2 Transfection of MNs with Dharmafect 3 
  2.5 µl VAMP2 siRNA pool (Dharmacon) from a 20 µM stock (100 nM 
final concentration) were diluted in 47.5 µl of full MN medium without serum (section 
2.2.4.3) and incubated for 5 min at room temperature. At the same time 1.5 µl of 
Dharmafect 3 were diluted in 48.5 µl of full MN medium without serum (section 
2.2.4.3) and incubated for 5 min at room temperature. The two mixtures were then 
mixed together and incubated at room temperature for 20 min. The transfection mixture 
was subsequently applied drop-wise to  MNs plated on poly-D-ornithine and laminin-
coated coverslips in a 24-well plate (400 µl of full MN medium without serum plus 100 
µl of the transfection mixture per well). The medium was changed 4-5 h later to full 
medium (section 2.2.4.3). 
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2.2.6.1.3 Transfection of MNs with Dreamfect Gold in a 96-
well plate format 
  The transfection protocol described below was used with the reagents 
listed in table 2.2 for transfection reagent optimisation described in Chapter 3, (section 
3.3.2). The siRNA was diluted to a final concentration of 50 nM in 10 µl of Opti-MEM 
(Invitrogen) medium. 0.25 µl of Dreamfect Gold were diluted in 9.75 µl of Opti-MEM 
(Invitrogen) medium per well. The two mixtures were then mixed together and 
incubated at room temperature for 20 min to 1 h in the 96-well plate (20 µl of the 
transfection mixture per well). 30000 – 35000 MNs dissociated from EBs were then 
plated on the top of the transfection mixture in full medium with serum (section 
2.2.4.3). The medium was not changed for 3 days until the assay for the siRNA screen 
was performed. 
2.2.6.2 Binding of HC  
 MNs plated on poly-D-ornithine and laminin-coated coverslips were cooled on 
ice for 15 min and incubated with with 20 nM AlexaFlour 555 conjugated HC in full 
medium (section 2.2.4.3) for 15 min at 4˚C. Unbound HC was then removed by rinsing 
the cells in PBS several times. Cells were fixed in 4% PFA diluted in PBS for 20 min at 
4˚C and stained as described in section 2.2.5.1. 
2.2.6.3 Internalisation assay of HC and p75NTR antibody 
 MNs plated on poly-D-ornithine and laminin-coated coverslips were incubated 
in full medium (section 2.2.4.3) with 20 nM AlexaFlour 555 conjugated HC together 
with the p75NTR antibody (18 µg/ml) for 15-120 min at 37˚C. To remove the probes 
bound to the plasma membrane, cells were cooled on ice for 10 min and acid-washed 
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with an isotonic solution at pH 2.0 (100 mM citrate-NaOH, 142 mM NaCl, pH 2.0) for 
5 min at 4˚C. The acid-wash solution was then removed by rinsing the cells in PBS 
several times. Cells were then fixed in 4% PFA diluted in PBS for 20 min at room 
temperature and stained as described in section 2.2.5.1. 
2.2.6.4 Readout of the siRNA screen 
 First, the 96-well plates were coated with poly-D-ornithine and laminin (section 
2.2.4.1), then the siRNA from the master plates of the library was premixed with the 
Dreamfect Gold transfection reagent and added to the plates using the reverse 
transfection protocol previously optimised (section 2.2.6.1.2). EBs derived from the 
HB9-GFP ES cells were then dissociated (section 2.2.4.6) and the resulting cell 
suspension  was plated on top of the transfection mixture (35,000 cells per well). The 
plates were left in the incubator at 37˚C for 72 h and then incubated in Neurobasal 
medium with 20 nM AlexaFlour 555 conjugated HC together with the p75NTR antibody 
(18 µg/ml) for 2 h at 37˚C. In addition to HC and the p75NTR antibody, 1 mM EHNA 
was added to selected samples (plate layout, Figure 4.2) pre-treated with RISC-free 
siRNA control (Qiagen). After the incubation, cells were cooled on ice for 10 min and 
acid-washed with an isotonic solution at pH 2.0 (100 mM Citrate-NaOH, 142 mM 
NaCl, pH 2.0) for 2 min and immuno-stained with an AlexaFluor 647 conjugated 
Rabbit secondary antibody (section 2.2.5.2). 
2.2.6.5 BDNF signalling experiments 
Wild type and Bicd1gt/gt MNs were starved for 5 h in Neurobasal medium and 
then stimulated with 100 ng/ml of BDNF. Cells were lysed after 10, 20, 30, 45 and 60 
min in lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM KCl, 1% NP-40, 1% glycerol, 
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1mM EDTA, 0.1 mM Dithiothreitol (DTT) and protease and phosphatase inhibitor 
cocktail (Roche), pH 7.6) directly in the wells at 4˚C for 30 min. The extract was 
subsequently spun at 16,000 g for 20 min and the pellet was discarded. Samples were 
prepared by diluting in sample buffer (20% glycerol, 5% β-mercaptoethanol, 2.5 mg 
Bromophenol blue, 10% SDS, 120 mM Tris-HCl pH 6.8), boiled for 5 min and analysed 
by western blot (section 2.2.3.4) for their phospho ERK1/2 and phospo Akt content. 
2.2.7 Mouse Techniques 
2.2.7.1 X­Gal staining  
Embryos were fixed at room temperature for 15-30 min in 0.1 M sodium 
phosphate (NaPO4, pH 7.3), 0.4% PFA, 5mM EGTA, 2 mM magnesium chloride 
(MgCl2), at room temperature. Embryos were then washed three times in 0.1 M sodium 
phosphate (NaPO4, pH 7.3), 2 mM magnesium chloride (MgCl2), 0.1% sodium 
deoxycholate, 0.02% NP-40. Finally, embryos were transferred into glass vial and 
incubated with the developing solution (100 mM NaPO4, pH 7.3, 2 mM MgCl2, 0.01 
sodium deoxycholate, 0.02% NP-40, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 1 mg/ml X-
Gal), for 30 min to 5 h at 37˚C in the dark. Alternatively, embryos were left developing 
over-night in the fridge. The reaction was stopped by rinsing the specimen several times 
in PBS. Embryos were be post-fixed in 4% PFA and kept in 70% ethanol. 
2.2.8 Data analysis and quantification 
2.2.8.1 Quantification of the axonal retrograde transport of  HC and 
the p75NTR antibody  
 Motion Analysis software (Kinetic Imaging) was used to manually track time-
lapse videos of the axonal retrograde transport of HC and the p75NTR antibody. The 
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distance between the positions of an axonal carrier was used to determine its speed. 
Only organelles that could be followed for a minimum of three consecutive frames were 
included in the analysis (Lalli et al., 2003) (Bohnert and Schiavo, 2005).  
2.2.8.2 Quantification of immunofluorescence staining 
 The use of the ARRAYSCAN image analysis software and of Cell Profiler will 
be discussed in Chapter 3, (section 3.2.1 & 3.4.2). Image J software was used to 
quantify immunofluorescence staining in all the experiments described in this thesis 
work except the siRNA screen and the validation re-screen. Image J was used to 
threshold the fluorescence staining of interest and quantify the thresholded voxels. 
Staining with neuronal-specific antibodies, such as βΙΙΙ−tubulin or MAP2, was used to 
normalise for the neuronal population. Image J was also used to perform densitometric 
analysis of bands in western blot.  
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Chapter 3. Towards the siRNA screen 
3.1 Introduction. 
 A primary focus of the Molecular Neuropathobiology laboratory is the 
investigation of the long range trafficking of neurotrophins and neurotrophin receptors 
in MNs. Two probes have been widely used in the past to achieve this goal, the HC 
fragment of the Tetanus Neurotoxin and an antibody raised against the extracellular 
domain of p75NTR. Both probes are taken up at the synaptic terminae of MNs and are 
then transported along the axon. These probes can be conjugated to a variety of 
fluorescent dyes, making it possible to directly follow their intracellular trafficking in 
live cells. HC binds at the plasma membrane to a protein-ligand receptor complex which 
includes the polysialoganglioside GD1b (Rummel et al., 2003) and is internalised in a 
clathrin-dependent fashion (Deinhardt et al., 2006a). In contrast, the p75NTR recycles 
back to the plasma membrane at steady state, however, upon binding to its ligands NGF 
and BDNF, a pool of the receptor is internalised in a clathrin-dependent manner and 
undergoes axonal retrograde transport (Deinhardt et al., 2006b). Importantly, 
neurotrophins and neurotrophin receptors follow an axonal retrograde transport route 
shared by HC and controlled by the small GTPases Rab5 and Rab7 (Deinhardt et al., 
2006b).  
In order to discover a new cohort of players in neurotrophin trafficking an 
siRNA screen was set up using a customised library of siRNA pools specific for 155 
genes, including molecular motors and protein adaptors.  
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Aim of the work presented in this chapter 
 
• To establish a transfection method for MNs, which is efficient and suitable for a 
96 well format. 
 
• To establish a reliable method for the isolation of a large quantity of MNs from 
mouse ES cells to be used for the RNAi screen. 
 
• To design a scalable assay to monitor the trafficking of HC and p75NTR. 
 
• To optimise a high-throughput, high resolution automatic image acquisition 
protocol. 
 
• To optimise the use of software for the quantitative analysis of the acquired 
images. 
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3.2 Developing the readout for the screen. 
 The focus of my thesis work is discovering new players in the uptake and 
intracellular trafficking of HC and p75NTR, with particular attention to regulators of 
axonal retrograde transport. The physiologically relevant cell system to study the 
trafficking of HC is MNs. However, screening for axonal transport of our probes in MN 
mass cultures and with an automated imaging system was technically very challenging. 
This was due to the manipulations required to adapt the live imaging assay used in the 
laboratory to monitor axonal retrograde transport to a 96 well plate format. In addition, 
the transport is tracked manually by the operator and it was not feasible to design an 
algorithm to do it automatically, as is required to perform an siRNA screen. The use of 
compartmentalised microfluidic chambers, which separate axons from the cell bodies, 
allows to directly relate the accumulation of HC and the p75NTR antibody to their axonal 
retrograde transport. However, they cannot be adapted to the multi-well format needed 
for a high-throughput screen. I decided, therefore, to shift the focus of the assay to 
monitor the internalisation and accumulation of HC and p75NTR instead of their axonal 
retrograde transport.  
An internalisation assay was established in which a fluorescently labelled 
version of HC, together with an antibody directed against the extracellular domain of 
p75NTR, was applied to the cells at 37˚C. After a certain amount of time, MNs were 
incubated at 4˚C with an acidic isotonic buffer at pH 2.0 (acid wash) in order to remove 
the labelled HC and p75NTR antibody bound to the cell surface. Cells were then 
permeabilised and stained with an AlexaFluor dye conjugated secondary antibody, 
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which allows the detection of the internalised p75NTR antibody. The internalised probes 
were finally imaged by fluorescence microscopy. 
3.2.1 Testing the ARRAYSCAN imaging system. 
 The aim of my project was to perform an innovative high-content imaged-based 
siRNA screen on MNs. To achieve this goal, I first considered the ARRAYSCAN 
imaging system present in the High Throughput Screening Facility at the LRI. The 
ARRAYSCAN is an epi-fluorescence microscope capable of acquiring several fields 
from each well of a 96 well plate in an automated fashion.  It also operates proprietary 
software which is designed for multi-parametric analysis of the acquired images.  
In order to determine the optimal concentration of HC to use for the screen, the 
kinetics of internalisation of HC and the p75NTR antibody were assessed by incubating 
primary MNs with different concentrations of the two probes at 37oC, then performing 
an acid wash, fixing the cells and staining them for the neuronal marker βIII-tubulin. 
The 96-well plate was then scanned by the ARRAYSCAN microscope using a 20X dry 
objective and the internalised probes were quantified by the software using the neuronal 
profiling and spot count algorithms. The neuronal profiling algorithm uses the βIII-
tubulin antibody staining to draw a mask around the cell body and neurites which 
propagate from it. The software is designed to quantify the total and the average 
fluorescence intensity coming from this mask as well as counting the number, the length 
and the number of branching points of the neurites. The spot count algorithm identifies 
fluorescent spots, which represent internalised HC or p75NTR antibody (Figure 3.1). The 
software is able to quantify several different parameters, such as the number, the 
intensity and the area of each spot. A concentration of 20 nM of the HC and of 1.8 µg/ml 
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for the p75NTR antibody and an incubation time point of 45 minutes were chosen to test 
the detection limits or “range” of the assay, which enabled the ARRAYSCAN imaging 
system software to successfully discriminate between conditions in which the probes 
were internalised to conditions where their entry was prevented by incubating the cells 
on ice (negative control). The bigger the range, the greater the power of the system to 
detect subtle effects caused by knocking down candidate genes. The results of this 
internalisation experiment showed that the range of the assay was 4-5 fold for HC and 
less than 1 fold for the p75NTR antibody with the neuronal profiling algorithm and 40 
fold and 25 fold respectively using the spot count algorithm (Figure 3.2). The more 
sensitive spot count algorithm was therefore chosen for the quantification of the 
internalised HC and p75NTR antibody. 
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Figure 3.1. Use of the spot count algorithm to detect internalised HC and p75NTR antibody. 
4 images are acquired for each dataset: Hoechst, βIII tubulin, p75NTR antibody and HC. Neurons are 
identified by combining the Hoechst and the βIII tubulin staining. All the nuclei are first identified from 
the Hoechst staining (B, accepted nuclei circled in blue), then a subset of nuclei corresponding to neurons 
are identified by overlap with the βIII tubulin staining (B, recognised neuronal nuclei in turquoise). The 
neuronal nuclei are then considered for the spot counting analysis. A circle of fixed diameter is drawn 
around each nucleus and inside this defined area vesicles positive for the individual probes are identified 
as spots  (C for the p75NTR antibody, mask and identified spots in red, D for HC, mask and identified spots 
in purple). An example of a nucleus recognised as belonging to a neuron is pointed to by an arrowhead. In 
the blown up panels in C and D it is shown how a circular mask is created around that nucleus. The 
identified positive vesicles are highlighted in red for p75NTR and violet for HC. 
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Figure 3.2. Quantification of HC and p75NTR Ab internalisation with the ARRAYSCAN imaging 
system. 
Kinetics of internalisation of HC (A) and the p75NTR antibody (B) in primary MNs a 96-well plate. The 
probes were incubated together to simulate the conditions to be used for the screen; after each time-point 
the cells were acid-washed and fixed. The plate was scanned by the ARRAYSCAN imaging system and 
the spot count algorithm was used to quantify the amount of internalised probes for each time-point. As a 
negative control for internalisation MNs were incubated with HC and p75NTR on ice and then acid-washed 
(binding control) (n=3).  Two different algorithms were used to quantify the amount of internalised HC 
(C) and p75NTR antibody (D), the neuronal profiling (white columns) and the spot count (black columns). 
In order to allow a direct comparison between the two quantification methods, the data were normalised 
to the value of the binding control. For both probes the spot count algorithm was the one with the better 
range (n=3). 
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3.3 Optimisation of transfection conditions and cell culture for the 
screen. 
In order to perform an siRNA screen a protocol for performing RNA 
interference in MNs needed to be established. However, MNs are a notoriously difficult 
cell type to transfect. One of the best ways to achieve this goal in MNs has been to use 
viral transduction methodologies. Non-viral mediated transfection approaches such as 
lipid-based transfection reagents, or electroporation, however, have also proven to be 
effective in inducing RNA interference in cortical, hippocampal and sensory neurons. 
Several transfection methods for MNs have been tested previously in the 
laboratory (Katrin Deinhardt Ph.D. thesis), including the use of lipid transfection 
reagents such as Lipofectamine2000, calcium phosphate and the Gene Gun (Bio-Rad), 
but none of these proved to be reliable or reproducible. Finally a transfection method 
for plasmid DNA using nuclear microinjection was established for single cell analysis 
(Katrin Deinhardt Ph.D. thesis). This transfection method, though, is not suitable for the 
format and the scope of an siRNA screen.  
3.3.1 Electroporation and the use of the lipid-based transfection reagent 
Dharmafect 3. 
 Arnauld Jaquier and Georg Haase developed a siRNA electroporation technique 
to allow efficient knock-down of Alsin in embryonic rat spinal cord MNs. They 
electroporated E14 rat spinal MNs using an siRNA concentration of 4 mM, obtaining a 
reduction in the levels of Alsin transcript to 21% one day after transfection (Jacquier et 
al., 2006). Following this publication, I decided to try electroporation as a transfection 
method for the screen. The PA-4000/PA-96 WS Pulse Agile (Labtech) and the BTX 
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ECM 830 (Harvard Apparatus) electroporation systems were tested using a panel of 
different parameters suggested by the suppliers, including the parameters described in 
the Haase’s work (Table 3.1). Both systems are suited for a 96-well plate format and 
therefore had the potential of being successfully used for the screen. 
 To assess transfection efficiency, I monitored the internalisation of a labelled 
siRNA duplex from Dharmacon, the siGLO RISC-free control siRNA. This siRNA does 
not engage the RNA-induced silencing complex (RISC) and it is stable inside the cells 
for several days. 
 The majority of the electroporation settings tested severely affected MN 
survival, however a set of parameters which did not affect MN viability, as confirmed 
by mitochondrial staining and transferrin uptake, was finally determined (200 V/cm, 5 
ms pulse duration, 3 pulses with 1 s interval). Unfortunately, using these parameters no 
internalisation of the siGLO duplex could be observed. 
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Table 3.1 Set of parameters tested for electroporation. 
The conditions which proved to be the best for each parameter are highlighted in grey. These parameters 
correspond to the ones used by Arnauld Jaquier and Georg Haase. The other parameters were suggested 
by the supplier and proved to be toxic for MNs. 
 
Cell number (cells/ml) siRNA concentration (mM) 
1.5*105 4 
3*105 1.5 
6*105 0.1 
 
Electric field (V/cm) Duration (ms) Pulses Interval (s) 
2000 0.4 1 0.5 
2000 0.4 4 0.5 
1500 0.4 1 0.5 
1500 0.4 4 0.5 
1000 0.4 1 0.5 
1000 0.4 4 0.5 
200 5 3 1 
 
 In light of these results, I decided to switch from electroporation to lipid –based 
transfection reagents. These are the most common choice for an siRNA screen, because 
they are relatively easy to use. Although previous data obtained by the laboratory 
suggested that lipid transfection reagents were toxic to MNs and impaired the efficiency 
of axonal retrograde transport (Deinhardt and Schiavo, 2005), these reagents are 
constantly improved and new, milder formulations are designed and optimised 
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specifically for the transfection of a variety of primary cells. Six reagents were tested in 
mouse MNs: Lipofectamine 2000, Oligofectamine and Dharmafect 1, 2, 3 and 4. All of 
them affected MN viability, with the notable exception of Dharmafect 3, which 
additionally did not compromise the axonal retrograde transport of HC. MN cultures 
treated with Dharmafect 3 consistently showed internalisation of siGLO control siRNA, 
confirming the efficacy of this reagent in delivering siRNA into MNs. 
 To test the efficiency of silencing in MNs, I decided to attempt to knock-down 
the Vesicle-associated membrane protein 2 (VAMP2), a member of the synaptic 
SNARE family and an essential component of the neurotransmitter release machinery. 
This protein is several-fold more abundant in neurons than in other cell types, but its 
depletion does not affect neuronal viability (Schoch et al., 2001), making it a perfect 
candidate to assess the knock-down efficiency in MNs transfected with Dharmafect 3.  
 A mouse siRNA SMART pool (Dharmacon) was used to knock-down VAMP2 
in mouse primary MNs. The depletion of VAMP2 was confirmed by 
immunofluorescence and western blot (Figure 3.3). Several concentrations of siRNA 
and Dharmafect 3 were tested. In order to maximise the knock-down efficiency, I also 
transfected the cells twice. These experiments indicated that VAMP2 could be 
efficiently depleted within 3 days using a single transfection, a concentration of 50 nM 
of the siRNA pool and 2 µl of Dharmafect 3 per 500 µl of total volume of medium in a 
24-well plate.  
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Figure 3.3. VAMP2 knock-down in primary MNs using Dharmafect 3 transfection reagent. 
Three days after trasfection, the cells were fixed and immunostained for VAMP2 (green), NeuN (red, 
upper panel), which stains neuronal nuclei, and βIII tubulin (red, lower panel), which is a neuronal 
specific isoform of tubulin (A). Scale bar, 10 µm, n=3. The fluorescence intensity of VAMP2 was 
quantified and normalised against βIII tubulin (B) (n=3). Western blot analysis of the same experiment; 
βIII tubulin was used as loading control (C). The knockdown of VAMP2 proved to be very efficient both 
by immunofluorescence and western blot. 
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3.3.2 Optimisation of a transfection protocol for a 96-well plate format. 
The Dharmafect 3 mediated knock-down protocol for VAMP2 was then 
modified for a 96-well plate, which was the format required for the screen. 
Unfortunately, the efficient VAMP2 silencing obtained previously could not be 
repeated in this new format. Since batch variability of the transfection reagent itself was 
suggested to be a possible explanation of this lack of reproducibility, different batches 
of Dharmafect 3 were tried, as well as several ratios of the concentration of siRNA and 
transfection reagent. Knock-down of VAMP2 was observed only after transfecting the 
cells twice with 0.3 µl of Dharmafect 3 in 100 µl of medium and 100 nM of siRNA per 
well. In addition, the transfection protocol required the use of serum free medium, 
which increased MN clustering in 96 well plates. The latter effect could have been due 
to an adaptative response of the cells to stress under such conditions.  
 I decided, therefore, to widen the search for a suitable transfection reagent and 
adopt a different approach to transfection, generally referred to as reverse transfection. 
In this case the lipid-based reagent and the siRNA are premixed and incubated directly 
into the wells of a 96 well plate. The cells are then plated in the normal complete 
medium with serum on top of the transfection mixture. In collaboration with the High 
Throughput facility, a collection of 23 different transfection reagents was screened for 
their ability to induce VAMP2 knock-down in primary MNs using the reverse 
transfection protocol (Table 3.2). Two concentrations of the VAMP2 siRNA were 
utilised for each individual reagent. The ARRAYSCAN imaging system was used to 
collect the images and analyse them with the spot counting algorithm (Figure 3.4 A). 
Some of the reagents were quite toxic for MNs, the toxicity being scored manually at 
the microscope and quantified on the basis of the viable cell count for each reagent. 
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Eight transfection reagents, Transit KO, Metafectene, Dreamfect Gold and Transpass 
R1 were for a second round of validation on the basis of their low toxicity and their 
ability to induce VAMP2 silencing. Dharmafect 3 was included in the screen, but, as 
expected on the basis of the preliminary results obtained in the 96 well format, it was 
not effective. An siRNA concentration of 50 nM, compared to the 100 nM required with 
the protocol previously established with Dharmafect 3, proved to be effective in 
inducing VAMP2 knockdown. This constituted an improvement over the original 
transfection protocol, cutting down by half the quantity of siRNA from the library 
needed to complete the screen. 
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Table 3.2 Validation of suitable  transfection reagents. 
The reagents selected for the next round of validation are highlighted in grey 
Name Supplier toxicity Efficiency of silencing 
Oligofectamine Invitrogen High Low 
TransIT siQuest Mirus Low Medium 
silenAmine  Medium High 
INTERFERinTM Polyplus High Low 
LipoRNAiMax Invitrogen High Low 
CodeBreakerTM Promega Low High 
Dharmafect 1 Dharmacon Medium Low 
Dharmafect 2 Dharmacon Medium Low 
Dharmafect 3 Dharmacon Medium Low 
Dharmafect 4 Dharmacon Medium Low 
Lullaby OZ Bioscience Medium Low 
RiboJuiceTM Merck Low High 
TransIT KO Mirus Low High 
HiPerFect Qiagen High Low 
Genesilencer Genlantis Low High 
NTERnanoparticle SIGMA-Aldrich High Low 
siPORT NeoFX Ambion High Low 
SimPorter Upstate Low High 
Lipofectamine 2000 Invitrogen High Low 
Santa Cruz Santa Cruz High Low 
Metafectene Biontex Low High 
Dreamfect Gold OZ Bioscience Low High 
TransPass R1 New England Biolabs Low High 
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Figure 3.4. Screen for the optimal transfection reagent. 
VAMP2 knockdown in primary MNs using 23 different transfection reagents in a 96 well format. The 
spot count for VAMP2-positive vesicles for the reagents that proved non-toxic are represented in the 
chart (A). The best eight reagents were re-screened using the same protocol, but using three different 
concentrations of each reagent. Images were taken with a 510 Zeiss confocal microscope and quantified 
with Image J. The quantity of each reagent used is indicated. S stands for the sample treated with the 
siRNA control pool, while V stands for the samples treated with the VAMP2 siRNA pool (B). The best 
four reagents from this re-screen were tested for their ability to induce knockdown of VAMP2 in a 96 
well plate format. All four reagents proved to be effective in knocking down VAMP2 by Western blot 
(n=3) (C). 
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 The 8 reagents selected from the pilot screen performed with the ARRAYSCAN 
imaging system were then re-screened using a glass bottom 96-well plate, which made 
it possible to acquire images with a Zeiss 510 confocal microscope. The advantages of 
using the confocal are several, including the possibility to utilise a 63X oil objective and 
to use phase contrast images (the ARRAYSCAN doesn’t have high NA oil immersion 
phase contrast objectives) to assess whether the transfection reagents affected cell 
morphology. Primary MNs were transfected with a fixed concentration of 50 nM 
siRNA against VAMP2, while three different concentrations (0.15, 0.3, 0.5 µl in 100 µl 
of medium per well) of the reagents were tested, in order to establish the minimum 
effective concentration for each of them. The images were then analysed using the 
Image J software.  
Only TransIT KO, Metafectene, Dreamfect Gold and TransPass R1 were found 
to be efficient in knocking down VAMP2 without affecting MN morphology. A 
minimum effective concentration of 0.3 µl per well for Metafectene, Dreamfect Gold 
and TransPass R1, and 0.5 µl per well for TransIT KO was established (Figure 3.4 B). 
 A final test was performed to detect the knock-down of VAMP2 in western blot. 
Again a 96-well plate was used and primary MNs were transfected with 50 nM of the 
VAMP2 siRNA pool using either Metafectene, Dreamfect Gold, TransPass R1 (0.3 µl 
per 100 µl of medium) or TransIT KO (0.5 µl per 100 µl of medium) with the reverse 
transfection protocol described above. MNs were scraped from the wells and lysed in 
the presence of NP-40, and eight wells for each condition were pooled together. All four 
reagents proved to be effective in inducing knock-down of VAMP2 in primary MNs. 
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 In summary, starting with a library of 23 different transfection reagents, a new 
reverse transfection protocol for primary MNs in a 96-well plate was established. Four 
transfection reagents, Metafectene, Dreamfect Gold, TransPass R1 and TransIT KO, 
were identified as capable of inducing efficient silencing of VAMP2 in primary MNs 
under conditions suitable for performing the siRNA screen.  
3.3.3 Establishment of a differentiation protocol for the derivation of MNs 
from mouse ES cells. 
 Having determined the feasibility of RNA interference in MNs, I then focused 
my attention on the determination of the optimal source of cells to use for the screen. 
Several factors had been taken into account, such as reproducibility and yield. Primary 
mouse embryonic MNs require a labour intensive dissection from E11.5 – E13.5 
embryos and are affected by a certain degree of variability amongst preparations, due to 
differences in the health and the genetic background of the dissected embryos. The 
opportunity of finding an easier way to obtain a large quantity of MNs in a highly 
reproducible manner was therefore investigated.  
Developmentally relevant signals can be used to induce mouse embryonic stem 
cells (ES cells) to differentiate into spinal progenitor cells and then into MNs in vitro. 
Wichterle and collaborators generated a transgenic ES cell line (Hb9-GFP), which 
expresses the enhanced green fluorescent protein (eGFP) under the control of the mouse 
Hb9 promoter. Hb9 is a transcription factor whose expression is restricted to MNs in the 
ventral horns of the spinal cord (Wichterle et al., 2002). The generation of MNs from 
embryoid bodies (EBs) depends on both the caudalizing action of retinoic acid (RA) 
and the ventralizing action of Sonic Hedgehog (Shh). One day after the addition of RA 
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and Shh into the growth medium, the EBs contain many neural stem cells, and after 2 – 
3 days under these differentiating conditions the cells start to express MN markers. 
Finally, around day 5, there is a peak of expression of pan neuronal and MN specific 
markers like Hb9. 
 I decided to test the potential for using the mouse Hb9-GFP ES cells to derive 
MNs for the RNAi screen. Matthew Golding in the laboratory had already developed a 
protocol to derive MNs from monolayer cultures of mouse ES cells. This protocol was 
not suited for the siRNA screen because of its inherent high variability of MN yield. 
The original protocol for the differentiation of this mouse ES cell line into MNs 
established by Wichterle and colleagues (Wichterle et al., 2002) was, therefore, used as 
a guideline to derive MNs from ES cells. I adopted a different method of dissociation of 
the EBs using trypsin instead of papain and I used a synthetic agonist (SAG) of the Shh 
signalling pathway instead of recombinant Shh (Materials and Methods, section 2.2.4.4 
– 2.2.4.6). This agonist was proven to be very effective in inducing MN differentiation, 
considerably increasing the yield of MNs obtained after 4 days (Figure 3.5). 
 It was also established that the addition of RA, to the normal growth medium 
after plating the dissociated EBs greatly enhanced the survival of GFP-positive MNs in 
culture. This is not surprising considering the known pro-survival effect of RA on MNs 
(Maden, 2007) . 
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Figure 3.5. Derivation of MNs from mouse embryonic stem cells. 
Flow diagram describing the protocol used for the differentiation of MNs from mouse ES cells. After 
growth in suspension in differentiating medium for 3 days, the ES cells form EBs. These EBs are then 
committed to a MN fate by the addition of RA and SAG. At the end of the 4th day in the presence of the 
differentiating agents, the EBs were dissociated and plated (A). Scale bar, 10 µm. An Hb9-GFP ES cell 
derived MN at 4 days after plating. GFP in green, GFP antibody staining in red, βIII tubulin staining in 
blue (B). The characteristic long axon of the MN is pointed at by an arrow head, while the soma is 
indicated with an asterix. Scale bar 50 µm. 
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3.3.4 Choice of a transfection reagent for MNs derived from mouse ES 
cells. 
 In order to use MNs derived from mouse ES cells as a cell system for the RNAi 
screen, it was important to determine whether they would be transfectable using the 
same protocol optimised for primary cultures. Metafectene, Dreamfect Gold, TransPass 
R1 and TransIT KO were, therefore, re-screened for their ability to transfect MNs 
derived from mouse ES cells. 
 MNs derived from mouse ES cells were transfected with 50 nM of the VAMP2 
siRNA pool using the reverse transfection protocol optimised for primary MNs, and the 
cells were then either analysed by western blot and immunostained in parallel with the 
VAMP2 antibody. VAMP2 protein levels were then quantified using Image J. 
Dreamfect Gold was the best transfection reagent for inducing knock-down of VAMP2 
in this system and this reagent was chosen to perform the RNAi screen (Figure 3.6). 
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Figure 3.6. VAMP2 knock-down in MNs derived from Hb9-GFP ES cells. 
Knock-down of VAMP2 (red) revealed by immunofluorescence in MNs differentiated from mouse ES 
cells (green) transfected with Dreamfect Gold in a 96 well plate format (A). Scale bar, 20 µm, n=3. 
Dreamfect Gold proven to be very effective in knocking-down VAMP2. Western blot analysis of the 
VAMP2 knock-down in MNs derived from ES cells transfected in a 96 well format. Dreamfect Gold 
induced a very effective silencing of VAMP2 (B) (n=3). These results prove that efficient knock-down 
can be obtained in a cell type notoriously difficult to transfect such as MNs with the reverse transfection 
protocol optimised for the siRNA screen. 
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3.4 Exploring the use of confocal microscopy for high-throughput 
imaging. 
 The ARRAYSCAN imaging system is limited to the use of dry objectives, 
which means that 0.75 is the maximum numerical aperture (NA) that can be achieved. 
The biggest problem, though, is the fact that this microscope uses an autofocus function 
based on the intensity levels of the nuclear staining. This is problematic when imaging 
cultures of MNs, as they consist of a mixture of cell populations, including an 
underlying layer of fibroblasts and glial cells, which provide trophic support to the 
neurons. There are then at least two layers of nuclei, which makes it difficult, if not 
impossible, for the microscope to focus on the most relevant cell population. In 
addition, neurons tend to aggregate in clumps, which results in an intrinsic lack of 
homogeneity in the density of the cultures. Several areas of the wells are, therefore, 
devoid of cells, making it even more difficult for the ARRAYSCAN to focus. Even 
though the first attempts to use the ARRAYSCAN imaging system were successful (as 
shown in section 3.2.1), it became clear that using this system for the screen was 
impractical because of the problems associated with the autofocus function. 
 I therefore decided to attempt to image the 96-well plates from the screen using 
a Zeiss 510 inverted confocal microscope. The use of glass bottom plates made it 
possible to utilise a 40X oil objective with an NA of 1.4, and the MTS macro (see next 
section) could be used to acquire images in an automated fashion. In summary, the 
major advantages of using a confocal microscope for screening purposes are: 1) its 
ability to autofocus on the neurons, 2) the high resolution and 3) the possibility of 
taking confocal Z stacks, which enables the acquisition of 3D information. 
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3.4.1 The Multi Field Acquisition macro. 
 The inverted Zeiss 510 confocal microscope has an automated stage, a feature 
that makes it possible to perform automated acquisition of several fields from a 96-well 
plate, when used in combination with the Multi Field acquisition macro (MTS) 
designed for the Zeiss software. The MTS macro instructs the microscope to move in a 
sequential manner to a series of coordinates, each one corresponding to a single well 
from a 96 well plate, and then to acquire a tile of 16 images or Z stacks for each 
coordinate. The final data output of the macro is a database where all the images from 
each tile are grouped together. 
 The MTS macro also enables the microscope to autofocus before acquiring 
every image or Z stacks. The autofocus function can be performed on any staining 
(DAPI, Hoechst, GFP or antibody staining) and it works by determining the focal plane 
with the maximum fluorescence intensity. The autofocus algorithm of the MTS macro 
proved to be more efficient in finding the optimum optical plane compared to the one 
from the ARRAYSCAN imaging system. In addition, even if the best optical plane was 
not found, the acquisition of a Z stack guaranteed that there would be at least one image 
in focus for each field. This was a major improvement compared with the imaging 
provided by the ARRAYSCAN and solved the problem associated with imaging clumps 
of neurons. Using the Hb9-GFP ES MNs had the major advantage of being able to 
instruct the MTS macro to use the GFP channel (i.e. MNs) for the autofocus function.  
3.4.2 Use of the Cell Profiler software for image quantification. 
  Cell Profiler is a free program developed by Anne Carpenter and Thouis John in 
the laboratories of David M. Sabatini and Polina Golland (http://www.cellprofiler.org/). 
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This software was developed to analyse large image datasets and is based on a 
collection of modules, which can be composed into a pipeline and then executed. Basic 
modules allow many functions, including loading, creating, subtracting images, splitting 
or merging different imaging channels, identifying primary objects, creating an object 
mask and calculating the pixel intensity.  
 I decided to use the Cell Profiler software to attempt an analysis similar to the 
one performed with the ARRAYSCAN software. First, the best in focus image for the 
confocal Z stacks was chosen and loaded into the Cell Profiler software. The images 
were then split into the three separate RGB channels, with the GFP one used to identify 
the “primary objects” (i.e. MNs). With this set of information Cell Profiler could 
already calculate the total and mean intensity of HC and p75NTR inside each MN, giving 
a fluorescent intensity per cell of each probe as a final output. In order to obtain 
something similar to the ARRAYSCAN spot count, the GFP channel was used to create 
a cell mask, which was then saved as an image and subtracted from the HC and p75NTR 
channels. Finally individual HC and p75NTR-positive vesicles were identified and 
counted in the subtracted image for each channel, the final output being the average 
number of HC or p75NTR-positive vesicles per MN (Figure 3.7). 
 Using this quantification method, I tested the ability of Cell Profiler to detect a 
difference between control internalisation conditions and upon inhibition of the uptake 
of HC and the p75NTR antibody. Hb9-GFP ES cell derived MNs were incubated with HC 
together with the p75NTR antibody for 45 minutes at 37˚C or at 4˚C for 15 minutes. The 
cells were then acid-washed to remove the probes bound to the cell surface. Confocal 
images were acquired using a 40X oil objective and the images were then quantified 
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using the Cell Profiler software to score the total intensity of the two probes per cell and 
the number of HC and p75NTR-positive vesicles per MN (Figure 3.8 for quantification). 
For both probes, the vesicles count algorithm is the one with the largest data point 
spread, allowing to detect a difference of 40-fold between the sample internalised at 
37˚C and the one incubated on ice and then acid-washed (Figure 3.8 for a direct 
comparison of the two quantification algorithms).  
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Figure 3.7 Cell Profiler quantification pipeline. 
The best RGB images from each Z stack acquired with the MTS macro are split into three different 
channels, namely GFP (A), HC (D) and p75NTR (E). Primary objects (i.e. MNs) are identified on the basis 
of the GFP intensity (B) and a cell mask image is created (C). At this stage the fluorescence intensity for 
the HC and p75NTR inside each mask can be measured and quantified and expressed as mean HC and 
p75NTR fluorescence intensity per MN (Figure 3.8 for the quantification). Alternatively all vesicles 
positive for HC and p75NTR inside the MN mask can be identified (F & G) and counted. The final output 
of the pipeline is the number of HC and p75NTR vesicles per MN (Figure 3.8 for the quantification). A 
single MN is indicated by an asterix; after a mask is created on the basis of the GFP staining (C), single 
vesicles positive for HC (F, D) and p75NTR (E,G) can be identified (the identified vesicles are coloured in 
green, F & G) inside that mask.  
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Figure 3.8. Cell profiler quantification of the internalisation of HC and the p75NTR antibody. 
MNs were incubated with HC and the p75NTR antibody for 45 minutes at 37˚C or just on ice for 15 
minutes on a 96 well plate. The cells were then acid-washed to remove the probes bound to the cell 
surface. The “binding control” is a control for the efficiency of the acid wash, where the internalisation is 
prevented and the signal corresponds to the residual background. The amount of internalised HC (A) and 
p75NTR antibody (B) compared to the binding control was quantified with Cell Profiler in two ways, as 
mean fluorescence intensity of the two probes per MN (white columns) or as total number of Hc and 
p75NTR positive vesicles per MN (black columns). In order to allow for a direct comparison between the 
two quantification methods, the data were normalised to the value of the binding control. The 
quantification method which gives the greatest fold difference (around 40-fold for both probes) is the 
positive vesicles count (black columns) (n=3). This method was therefore chosen for the quantification of 
the siRNA screen. 
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Summary of the achievements presented in this chapter. 
 
• A protocol for the differentiation of MNs from mouse ES cells has been 
established, which enabled the generation of a sufficient quantity of MNs for the 
planned siRNA screen. In addition, the GFP expression driven by the Hb9 
promoter makes it easier to identify MNs and create a specific mask during 
image analysis. 
 
• A library of 23 different lipid-based transfection reagents was screened for their 
ability to induce knock-down of VAMP2 in primary and ES-derived MNs in a 
96-well format. Dreamfect Gold was selected as the most effective transfection 
reagent. 
 
• The MTS macro was optimised to enable high-resolution automated image 
acquisition from a 96-well plate format using a Zeiss 510 inverted confocal 
microscope. 
 
• Using the Cell Profiler image analysis software, an algorithm was established to 
enable the reliable quantification of internalised HC and p75NTR antibody. This 
quantification was then used as the readout for the siRNA screen. 
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Chapter 4. The siRNA screen 
4.1  Introduction 
 Performing an siRNA screen has become an increasingly used approach for 
finding new components of biological pathways. There are several siRNA libraries 
available that target a variety of metabolic pathways and protein families, and 
established protocols for transfection of several cell lines. I planned to use this approach 
to gather new insights into the trafficking of neurotrophins and their receptors by using 
an antibody against p75NTR and the HC fragment of Tetanus toxin, which has been 
shown to traffic in the same compartment as the neurotrophins and their receptors 
during axonal retrograde transport (Lalli and Schiavo, 2002, Deinhardt et al., 2006b). I 
intended to perform a novel siRNA screen on a cell system that has not be used so far 
and that is believed to be physiologically relevant for the trafficking of neurotrophins. 
To achieve this I used MNs derived from mouse ES cells, because they resemble 
primary MNs as closely as possible. The screen was also made possible by developing a 
system for the acquisition of high resolution images and high content software image 
analysis. 
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Aims of the work presented in this Chapter 
 
• To establish a positive control for the HC and the p75NTR antibody 
internalisation assay developed in Chapter 3. 
 
• To perform the screen with a customised library of siRNA pools targeting 155 
genes, including molecular motors and their adaptors. 
 
• To analyse the data and rank the individual siRNA pools for their ability to 
affect the internalisation of HC and the p75NTR antibody. 
 
• To select the best hits from the screen for further characterisation. 
 
• To validate the selected hits using siRNA pools from a different supplier. 
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4.2 Developing a positive control for the readout of the screen 
 An siRNA screen requires a series of important internal controls. The first 
control is one for detecting off-target effects of the siRNA pools themselves and 
normally consists of a non-targeting siRNA pool (siControl) provided in the library 
itself. Other controls are also required: a positive one for the assay, to show that the 
assay has worked, and another control to show that the knockdown has worked. 
Normally, these last two controls are combined with the use of a previously identified 
“positive control” gene that when silenced is able to influence the readout of the screen. 
These controls make it possible to know that the assay has worked and also that the 
knockdown in the plate was efficient.  
 A first attempt was made by trying to knockdown genes that have been 
previously demonstrated to be involved in the internalisation of HC, e.g. clathrin heavy 
chain, dynamin 1 and the AP2 clathrin adaptor complex. None of these genes, however, 
could be efficiently knocked-down in MNs. I decided therefore to use a different 
approach by blocking the internalisation of HC and the p75NTR antibody using a small 
organic inhibitor. The inhibitor chosen was EHNA ((erythro-9-(2-Hydroxy-3-
nonyl)adenine), a cell-permeable inhibitor of phosphodiesterase II (PDE II) (IC50 800 
nM) (Podzuweit et al., 1995), which is also known to block the retrograde motor dynein 
by inhibiting its ATPase activity. EHNA had already been successfully used in the 
laboratory by Giovanna Lalli to show that inhibition of cytoplasmic dynein abolishes 
the fast component of the axonal retrograde transport of HC in primary MNs (Lalli et al., 
2003).  
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 ES cell-derived MNs were incubated at 37˚C with HC and the p75NTR antibody in 
presence of 1 mM EHNA to assess whether the drug had any effect on the 
internalisation and/or accumulation of these two probes. The kinetics of accumulation 
of HC and the p75NTR antibody in the cell soma were established by detecting the extent 
of probe internalisation every 15 minutes up to two hours after binding at 37˚C. At each 
time-point the cells were acid-washed to remove probes bound to the cell surface. HC 
exhibited linear accumulation kinetics, which was significantly inhibited by EHNA 
(Figure 4.1 A). In contrast, the accumulation of the p75NTR antibody in the presence of 
HC was not linear and it did not seem to differ in the presence of EHNA until 75 
minutes, when the curve of the EHNA treated samples started to progressively diverge 
from the controls (Figure 4.1 B). The conclusion that can be drawn from these kinetic 
profiles is that EHNA inhibits the accumulation of both HC and the p75NTR antibody in a 
progressive manner. 
 The maximum difference in accumulation of the two probes in the presence or 
absence of EHNA, was observed after two hours, which was the last time-point taken. 
This time point was sufficient to allow the axonal retrograde transport of the two probes 
to reach steady state, which according to previous data from the laboratory starts 45 
minutes after binding. It is also interesting that the difference between the two 
accumulation curves for the p75NTR antibody started to be significant only after 75 
minutes (Figure 4.1 B), contrary to what was seen for HC (Figure 4.1 A). The 
difference in the two accumulation curves of the p75NTR antibody after 75 minutes 
indicates that the effects of EHNA are only apparent approximately 30 minutes after the 
onset of p75NTR retrograde transport. Because EHNA is a well-characterised dynein 
inhibitor, it is possible to speculate that in the first 75 minutes from the binding of the 
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p75NTR antibody, the intracellular accumulation of the probe is a dynein-independent 
process, whereas after that time point it becomes dynein-dependent (Discussion, section 
7.1.4). Interestingly, this time point is compatible with the 45 minutes delay in the onset 
of axonal retrograde transport. Considering the data obtained previously(Lalli et al., 
2003), it is tempting to speculate that the difference in the accumulation observed might 
be the result of an inhibition of the axonal retrograde transport of p75NTR. It was 
therefore decided to use two hours as the end point for the assay during the screen. This 
would give us a chance to find genes that are effectors of both the internalisation and/or 
the retrograde axonal transport of the these probes. 
 The kinetics of internalisation of the p75NTR antibody alone was also tested. The 
intracellular accumulation of the probe overlapped with the curve obtained co-
incubating the cells with the antibody and HC in the presence of EHNA (Figure 4.1, 
Discussion, section 7.1.4). 
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Figure 4.1 Kinetics of HC and the p75NTR antibody internalisation. 
Kinetics of accumulation of HC (A) and the p75NTR antibody (B) in MNs derived from HB9-GFP ES cells 
in the absence (black curve) or presence (red curve) of the EHNA inhibitor (n=3). The accumulation of 
HC is significantly in presence of EHNA (p<0.0001, two ways ANOVA). In the case of p75NTR the two 
curves of accumulation are identical until 75 minutes when they diverge (p<0.0001, two ways ANOVA). 
The kinetics of internalisation of the p75NTR antibody alone was also established (blue curve) and was 
found to overlap with the curve of internalisation of the p75NTR antibody in presence of HC and EHNA 
(B). 
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4.3 The siRNA screen 
4.3.1 Plate design 
I decided to run the siRNA screen in a 96-well plate format. The library came 
already aliquoted on 3 master plates (Material and Methods, table 2.3) and contained 
four internal siControls in random positions in the centre of the plate. Each gene was 
targeted by a pool of three siRNAs (Material and Methods, table 2.4).  
The edges of the library plates were left empty and I decided to take advantage 
of them to place the controls. The EHNA inhibitor was used as a control for the 
accumulation of both the p75NTR antibody and HC. The transfection efficiency control 
for VAMP2 knockdown was added in the last row of plate 1 and 2 and in the fifth row 
of plate 3 (Figure 4.2). The VAMP2 knockdown samples were analysed by Western 
blot compared with non-targeting siControls (Figure 4.5 for the Western blot analysis 
of the plates from the screen). Four wells from each plate were used for this purpose to 
ensure that enough protein was harvested (the plate layouts are described in detail in 
Figure 4.2).  
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Figure 4.2 Plate design. 
Layout of the three plates of the siRNA screen. The empty wells are coloured in black, those containing 
siRNA controls in grey, and those treated with the EHNA inhibitor in red. Finally the wells treated with 
the VAMP2 siRNA pool are coloured in blue. 
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4.4 The primary screen and its analysis with Cell Profiler 
 The entire library was not screened at the same time, but divided into three 
sessions, one for each plate of the library done in triplicate. This decision was justified 
by the fact that all the handling, treatment and image acquisition had to be done 
manually by the operator.  
 The screen was performed as described in section 2.2.6.4 of Materials and 
Methods. Each plate was sealed with a transparent plastic foil and images were acquired 
with a 510 Zeiss Confocal microscope using the MTS macro as explained in Chapter 3 
(section 3.4.1). 16 stacks were acquired for each well and the best focused image for 
each stack was selected. The images were analysed using the Cell Profiler imaging 
software as described in Chapter 3 (section 3.4.3). 
 The output of the image analysis performed with Cell Profiler was the number 
of intracellular vesicles positive for HC and the p75NTR antibody. This raw data set was 
then fed to the Cell HTS software (available via the High-throughput Facility at CRUK, 
http://hts.cancerresearchuk.org/cellHTS/), which calculated a Z score for each well 
(Table 4.1 - 4.2 for the list of the Z-scores and Figure 4.3 - 4.4 for their visual 
representation). A Z-score, also called “standard” or “normal” score, is a statistical 
method to “normalise” or standardise a data set, where the normalisation is a way to 
correct for unwanted and unavoidable technical variations (for example pipetting errors 
and the so called edge-effects, due to the evaporation of the medium in the wells 
situated at the edge of the plates, which causes artefacts in cell behaviour). 
Mathematically, the Z-score is defined as a dimensionless quantity obtained by 
subtracting the population mean from an individual raw score and then dividing the 
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difference by the standard deviation of the population. The resulting score is a measure 
of how many units of standard deviation a data point is above or below the mean of the 
population. In the case of the readout of our screen, a positive or negative Z-score 
indicates that a particular siRNA pool caused an increase or decrease in the 
accumulation of the probe under investigation compared to the mean value of 
accumulation for the whole population of siRNAs present in the library. Importantly, 
data sets can only be allocated Z-scores when they have a Gaussian distribution.  
Table 4.1 TeNT HC Z-scores. 
The Z-scores from the three replicates of each well are indicated. The “well annotation” column indicates 
whether the well was treated with a targeting siRNA (sample), a non-targeting siRNA control (siControls) 
or a positive control for the assay (EHNA treated samples). siControls are highlighted in grey, EHNA 
treated samples in red. 
 Plate Well Z-score Well annotation 
1 B03 2.05 sample 
3 B02 2.05 sample 
3 B06 1.87 sample 
1 F09 1.71 sample 
2 G02 1.62 sample 
1 B04 1.56 sample 
2 B09 1.56 sample 
3 B05 1.54 sample 
1 B09 1.52 sample 
2 C03 1.38 sample 
1 F07 1.3 sample 
2 E02 1.29 sample 
2 B10 1.28 sample 
1 G08 1.24 sample 
1 G11 1.21 sample 
2 B02 1.14 sample 
1 E03 1.06 sample 
1 B02 1.02 sample 
3 B07 0.93 sample 
1 F10 0.93 sample 
3 C04 0.91 sample 
1 B08 0.88 sample 
2 E09 0.87 sample 
1 C10 0.87 sample 
1 E10 0.86 sample 
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2 D04 0.86 sample 
2 C06 0.81 sample 
1 B06 0.74 sample 
1 B07 0.72 sample 
2 C05 0.72 sample 
1 G04 0.68 sample 
2 B03 0.68 sample 
2 E05 0.66 sample 
2 C01 0.64 siControl 
2 C04 0.63 sample 
2 D10 0.61 sample 
1 C06 0.57 sample 
2 F02 0.56 sample 
2 E04 0.51 sample 
1 G05 0.5 sample 
1 G03 0.49 sample 
1 G09 0.48 sample 
2 F03 0.48 sample 
2 E03 0.45 sample 
2 D11 0.42 sample 
1 F05 0.39 sample 
2 E08 0.36 sample 
1 E04 0.34 sample 
3 B03 0.32 sample 
2 E10 0.31 sample 
2 B08 0.29 sample 
1 E09 0.28 sample 
1 D06 0.27 sample 
1 C01 0.23 siControl 
2 D09 0.22 negative 
1 G07 0.22 sample 
2 B04 0.15 sample 
2 G07 0.14 sample 
1 F04 0.13 sample 
1 E07 0.1 sample 
3 C03 0.07 siControl 
2 F05 0.07 sample 
2 B06 0.07 sample 
2 B07 0.07 sample 
1 E06 0.03 sample 
1 D10 0.02 sample 
1 F02 0.01 sample 
2 F09 0.01 sample 
2 G08 0 sample 
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1 D04 -0.03 sample 
2 D06 -0.03 sample 
2 G03 -0.05 sample 
2 D05 -0.07 sample 
2 F04 -0.07 sample 
1 C11 -0.07 sample 
1 D07 -0.09 sample 
1 C09 -0.1 sample 
1 G02 -0.1 sample 
1 C02 -0.13 sample 
2 C08 -0.15 sample 
2 E11 -0.18 sample 
2 B05 -0.2 sample 
2 B11 -0.23 sample 
1 B10 -0.26 sample 
1 E11 -0.29 sample 
2 C07 -0.3 sample 
1 E08 -0.31 sample 
3 B09 -0.32 sample 
2 F07 -0.33 sample 
1 E05 -0.34 sample 
2 D07 -0.35 sample 
2 D02 -0.39 sample 
2 G04 -0.46 sample 
1 C04 -0.46 sample 
1 C08 -0.46 sample 
3 C02 -0.48 sample 
3 B11 -0.48 sample 
2 E06 -0.53 sample 
2 F06 -0.53 sample 
1 F11 -0.54 sample 
1 D09 -0.55 sample 
2 C11 -0.55 sample 
1 C07 -0.56 sample 
1 F08 -0.57 sample 
2 D03 -0.57 sample 
1 D05 -0.58 sample 
1 E02 -0.59 sample 
1 G10 -0.6 sample 
3 B10 -0.65 sample 
2 G09 -0.67 sample 
1 B11 -0.68 sample 
3 B08 -0.7 sample 
1 D08 -0.71 sample 
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3 B04 -0.71 sample 
2 G11 -0.71 sample 
2 C10 -0.77 siControl 
1 D11 -0.79 sample 
1 G06 -0.82 sample 
1 C03 -0.86 sample 
2 F08 -0.87 sample 
1 F03 -0.91 sample 
1 F06 -0.95 sample 
2 G06 -0.96 sample 
2 D08 -0.99 sample 
1 D02 -1.04 sample 
1 C05 -1.06 sample 
2 C09 -1.09 sample 
1 D03 -1.09 sample 
2 F11 -1.18 sample 
2 F10 -1.19 sample 
2 G05 -1.23 sample 
3 C07 -1.34 siControl 
2 E07 -1.37 siControl 
1 B05 -1.45 sample 
2 F12 -1.53 positive 
2 G10 -1.64 sample 
2 C02 -1.72 sample 
2 C12 -1.76 positive 
3 D03 -1.91 positive 
1 F12 -2.14 positive 
1 C12 -2.71 positive 
3 D06 -2.74 positive 
Table 4.2 p75NTR Z-scores. 
The Z-scores from the three replicates of each well are indicated. The “well annotation” column indicates 
whether the well was treated with a targeting siRNA (sample), a non-targeting siRNA control (siControls) 
or a positive control for the assay (EHNA treated samples). siControls are highlighted in grey, EHNA 
treated samples in red. 
Plate Well Z-score Well annotation 
1 G03 4.06 sample 
1 G04 4.06 sample 
1 G10 3.66 sample 
3 B02 3.17 sample 
1 G02 3.15 sample 
1 F11 2.92 sample 
1 F03 2.61 sample 
2 G02 2.43 sample 
3 C04 2.18 sample 
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1 F04 2.12 sample 
2 E06 2.09 sample 
2 F09 1.93 sample 
2 C06 1.84 sample 
2 D09 1.74 sample 
2 B06 1.71 sample 
2 E02 1.71 sample 
3 B05 1.54 sample 
1 G05 1.44 sample 
2 C09 1.38 sample 
2 F02 1.15 sample 
1 B06 1.1 sample 
2 G03 0.86 sample 
1 E02 0.86 sample 
1 B08 0.74 sample 
1 C03 0.74 sample 
2 F05 0.74 sample 
1 D02 0.71 sample 
1 E03 0.71 sample 
1 G07 0.68 sample 
2 F04 0.67 sample 
2 G07 0.65 sample 
1 D06 0.61 sample 
1 D03 0.58 sample 
1 G08 0.58 sample 
1 F08 0.57 sample 
1 B03 0.57 sample 
2 C01 0.52 siControl 
2 E04 0.5 sample 
1 E10 0.49 sample 
2 F08 0.45 sample 
2 C05 0.44 sample 
2 B03 0.43 sample 
2 B09 0.43 sample 
2 C02 0.42 sample 
3 B07 0.42 sample 
2 C07 0.41 sample 
2 F06 0.4 sample 
2 D05 0.39 sample 
2 E08 0.38 sample 
1 D05 0.37 sample 
1 E05 0.34 sample 
1 F02 0.31 sample 
1 G09 0.27 sample 
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2 B04 0.25 sample 
1 F10 0.19 sample 
1 B09 0.19 sample 
2 D04 0.14 sample 
1 E11 0.14 sample 
3 B09 0.13 sample 
2 B07 0.13 sample 
1 B04 0.12 sample 
2 E11 0.12 sample 
1 F09 0.11 sample 
1 E09 0.09 sample 
2 G04 0.09 sample 
1 B05 0.06 sample 
2 E03 0.06 sample 
3 B11 0.06 sample 
2 C10 0.04 siControl 
1 E08 0 sample 
2 G10 0 sample 
2 B08 -0.03 sample 
2 F03 -0.04 sample 
1 D04 -0.1 sample 
1 C04 -0.11 sample 
1 G06 -0.11 sample 
3 B04 -0.13 sample 
3 C07 -0.17 siControl 
2 E05 -0.17 sample 
2 B02 -0.19 sample 
2 D07 -0.2 siControl 
2 C11 -0.23 sample 
1 F05 -0.25 sample 
2 C04 -0.25 sample 
2 E07 -0.25 siControl 
1 F07 -0.26 sample 
3 B03 -0.27 sample 
2 G05 -0.28 sample 
2 C08 -0.28 sample 
2 D06 -0.29 sample 
2 E09 -0.3 sample 
3 B10 -0.31 sample 
1 C02 -0.32 sample 
1 C01 -0.33 siControl 
1 F06 -0.36 sample 
1 D09 -0.38 sample 
1 D10 -0.4 sample 
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1 E06 -0.41 sample 
2 C03 -0.42 sample 
2 G11 -0.42 sample 
3 B06 -0.45 sample 
1 D08 -0.49 sample 
1 C08 -0.53 sample 
2 G08 -0.54 sample 
1 G11 -0.57 sample 
1 C06 -0.58 sample 
1 D07 -0.58 sample 
2 G06 -0.59 sample 
1 B11 -0.6 sample 
2 B11 -0.67 sample 
1 E07 -0.71 sample 
3 C02 -0.74 sample 
1 E04 -0.76 sample 
2 D10 -0.78 sample 
1 D11 -0.78 sample 
2 D11 -0.79 sample 
3 B08 -0.8 sample 
2 F07 -0.86 sample 
1 C09 -0.87 sample 
3 C03 -0.89 siControl 
1 C05 -0.9 sample 
2 G09 -0.9 sample 
1 C07 -0.97 sample 
2 B05 -0.97 sample 
2 F10 -0.98 sample 
1 C10 -1.02 sample 
1 B02 -1.11 sample 
2 F11 -1.15 sample 
2 D08 -1.18 sample 
1 C11 -1.22 sample 
2 D02 -1.23 sample 
1 B10 -1.26 sample 
2 E10 -1.36 sample 
2 D03 -1.36 sample 
1 B07 -1.47 sample 
2 B10 -1.87 sample 
2 F12 -2.27 positive 
2 C12 -2.36 positive 
1 F12 -2.5 positive 
3 D02 -2.58 positive 
1 C12 -2.77 positive 
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Figure 4.3 Summary of Z-scores for HC. 
The Z-scores for all the genes screened for HC accumulation are plotted from the highest value to the 
lowest (A). The EHNA treated samples are highlighted in red, the siRNA controls in blue throughout the 
figure. The Z-scores from the first replicate of the screen are plotted against the Z-scores of the second 
replicate (B) and the third replicate(C). Finally the Z-scores from the second replica of the screen are 
plotted against the Z-scores of the third replicate (D). This representation gives an idea of how consistent 
the data are across the replicates. Ideally, if the data points are highly reproducible, the dot points should 
distribute as a diagonal line; the more the data are scattered, the less reproducible the data points were 
between the different replicas. 
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Figure 4.4 Summary of the siRNA screen for the p75NTR antibody. 
The Z-scores for all the genes screened for the p75NTR antibody accumulation are plotted from the highest 
value to the lowest (A). The EHNA treated samples are highlighted in red, the siRNA controls in blue 
throughout the figure. The Z-scores from the first replicate are plotted against the Z-scores of the second 
(B) and the third (C) replicate. Finally, the Z-scores from the second replicate are plotted against the Z-
scores of the third replicate (E). 
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Figure 4.5 Internal control for knockdown efficiency of the siRNA screen. 
Five wells from each plate were treated with siRNA control (see plate layout in Figure 4.2) and five with 
the VAMP2 siRNA pool. The protein lysates from each set of samples for each plate were pooled and 
analysed in Western blot to asses for knockdown efficiency. βIII tubulin was used as loading control.  
 
4.4.1 Selecting the primary hits. 
 For the selection of the hits from the primary screen a threshold Z score had to 
be chosen. An upper limit of 1.5 standard deviations from the mean and lower limit of 
0.7 for HC and 1.5 – 0.8 for the p75NTR antibody was chosen (Table 4.3, Table 4.4, and 
Discussion, section 7.1.5).  
 In general, more putative negative regulators of the system have been identified, 
as shown by the fact that knockingdown most of the candidates resulted in an increased 
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rather than a decreased intracellular accumulation of the two probes. There were few 
hits in common for both probes. Down-regulation of the predicted gene EG231836 and 
Rab10 caused the increased accumulation of HC and p75NTR, whereas knockdown of 
Osbpl1a, Kif12 and Arl8b decreased the intracellular accumulation of the two probes. In 
addition, there seemed to be a prevalence of myosin motors amongst the genes that 
caused an increased accumulation of the two probes, and a prevalence of kinesin motors 
amongst the ones that caused a decreased accumulation (Table 4.3 & 4.4).  
Table 4.3 TeNT HC primary hits 
All the genes that were considered hits from the primary screen are listed below together with their Z-
score. The hits are divided by their ability to increase or decrease HC accumulation. The hits common for 
HC and the p75NTR antibody are highlighted in grey. 
 
INCREASED INTRACELLULAR ACCUMULATION 
Z-score Symbol Name Gene ID Accession number 
2.05 BICD1 bicaudal D homolog 1 12121 NM_009753 
2.05 MYL3 
myosin, light 
polypeptide 3 17897 NM_010859 XM_979450 
1.87 CORO1C 
coronin, actin binding 
protein 1C 23790 NM_011779 
1.71 DYNLT3 
dynein light chain 
Tctex-type3 67117 NM_025975 
1.62 EG231836 
predicted gene, 
EG231836 231836 XM_144611 XM_917042 XM_980715 
1.56 CENPE centromere protein E 229841 NM_173762 
1.54 MYO16 myosin XVI 244281 
NM_001081397 XM_356059 XM_906282 
XM_975950 XM_976346 XM_977585 
1.54 RAB10 
RAB10, member RAS 
oncogene famiy 19325 NM_016676 
1.52 DYNC1LI2 
dynein, cytoplasmic 1 
light intermediate 
chain2 234663 NM_001013380 XM_134573 
DECREASED INTRACELLULAR ACCUMULATION 
Z-score Symbol Name Gene ID Accession number 
-1.72 KIF13B 
kinesin family member 
13b 16554 
XM_001001128 XM_001001137 XM_283218 
XM_894888 XM_915018 XM_923518 
-1.64 KIF7 
kinesin family member 
7 16576 XM_133575 
-1.45 DCTN1 dynactin1 13191 NM_007835 XM_977604 
-1.21 DYNLL2 
dybein light chain LC8-
type 2 68097 NM_026556 
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-1.17 KIF12 
kinesin family member 
12 16552 NM_010616 
-1.16 OSBPL1A 
oxysterol binding 
protein-like 1A 64291 NM_207530 
-1.09 MYH2 
myosin, heavy 
polypeptide 2 17882 NM_001039545 NM_144961 
-1.09 DYNC2LI1 
dynein cytomplasmic 2 
light intermediate chain 
1 213575 NM_172256 XM_984615 XM_985116 
-1.06 KIFC3 
kinesin family member 
C3 16582 NM_010631 
-1.04 MYH1 
myosin 
heavypolypeptide 1 17879 NM_030679 XM_354615 
-0.99 KIF15 
kinesin family member 
15 209737 NM_010620 
-0.96 DNHD1 
dynein heavy chain 
domain 1 77505 
XM_001000131 XM_355968 XM_908793 
XM_983220 
-0.95 RAB5A 
RAB5a, member RAS 
oncogene family 271457 NM_025887 
-0.7 ARL8B Arl8b 67166 NM_026011 
 
Table 4.4p75NTR primary hits 
All the genes considered hits from the primary screen are listed below together with their Z-score. The 
hits are divided by their ability to increase or decrease the p75NTR antibody accumulation. The hits 
common for HC and the p75NTR antibody are highlighted in grey. 
INCREASED INTRACELLULAR ACCUMULATION 
Z-score Symbol Name Gene ID Accession number 
4.06 MYH13 
myosin, heavy polypeptide 
13, skeleta; muscle 544791 
NM_001081250 XM_618893 
XM_908247 XM_991668 
4.06 RAB7L1 RAB7 family-like 1 226422 NM_144875 
3.66 DCTN2 dynactin 2 69654 NM_027151 
3.17 MYL3 myosin, light polypeptide 3 17897 NM_010859 XM_979450 
3.15 DYNLL1 
dynein light chain LC-type 
1 56455 NM_019682 
2.92 RAB7 RAB7 19349 NM_009005 
2.61 MYO9B myosin Ixb 17925 NM_015742 
2.43 EG231836 predicted gene, EG231836 231836 XM_144611 XM_917042 XM_980715 
2.18 MYH7B myosin, heavy chain 7B 668940 XR_002269 XR_002637 XR_005103 
2.12 MYO10 myosin X 17909 NM_019472 
2.09 KLC1 kinesin light chain 2 16594 NM_008451 
1.93 MYHLC2B 
myosin light chain, 
regulatory B 67938 NM_023402 
1.54 RAB10 RAB10 19325 NM_016676 
DECREASED INTRACELLULAR ACCUMULATION 
Z-score Symbol Name Gene ID Accession number 
-1.86 KIF21B kinesin family member 21B 16565 NM_001039472 NM_019962 
-1.47 DYNC1I1 
dynein cytoplasimc 1 
intermadiate chain 1 13426 NM_010063 
-1.36 KIF26B kinesin family member 21B 269152 NM_177757 
-1.36 DYNNLB2 dynein light chain road- 75465 NM_029297 
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block-type 2 
-1.26 KIF2A kinesin family member 2A 16563 NM_008442 
-1.22 MXD3 max dimerisation protein 3] 17121 NM_016662 
-1.22 MYO1B myosin 1B 17912 NM_010863 
-1.2 KIF15 Kinesin family member 15 209737 NM_010620 
-1.14 OSBPL1A 
oxysterol binding protein-
like 1A 64291 NM_207530 
-1.11 KIF1A kinesin family member 1A 16560 NM_008440 
-1.02 RAB8A RAB8a 17274 NM_023126 XM_981797 
-0.98 KIF12 kinesin family member 12 16552 NM_010616 
-0.98 KIF3A kinesin family meber 3A 16568 NM_008443 
-0.97 KIF11 kinesin family member 11 16551 NM_010615 
-0.8 ARL8B 
ADP-rybosilation factor-
like 8B 67166 NM_026011 
4.5 Hit validation 
4.5.1 Validation using Dharmacon smart pools 
 There are several strategies commonly used to validate the hits from an siRNA 
screen. The idea behind the validation is to assess whether or not a particular phenotype 
registered in the primary screen is due to the knockdown of the gene or is instead a 
consequence of off-target effects. A commonly used way to assess such off-target 
effects is to “deconvolute” the siRNA pool for each one of the hits, i.e. to test each oligo 
from the pool separately. A hit will be validated as a genuine candidate if at least two 
out of three of the single duplexes reproduce the phenotype observed. Another way of 
validating the hits is to order siRNA pools from a different supplier and to test whether 
they result in the same phenotype as those used in the primary screen. This is because 
each company has its own algorithm to design siRNA duplexes, which means that 
siRNA pools from different suppliers tend to target different parts of the transcript. 
 I decided to use the second approach for the validation of the primary screen, 
because it allowed me to contain the size of the rescreen library to one plate and it was 
considerably cheaper to buy the Dharmacon SMART pools than the single Qiagen 
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siRNA duplexes. SMART pools from Dharmacon were, therefore, tested for each one 
of the primary hits. The siRNA pools came in a 96-well plate format (Materials and 
Methods section, table 2.5), and they were screened as described for the primary screen 
(section 4.3.2 of this Chapter).  
4.5.2 Selecting the hits from the validation re-screen 
 The validation re-screen with the Dharmacon siRNA pools was performed five 
times and the data for the replicates were pooled together for each of the individual 
genes and controls. As for the primary screen, the number of positive vesicles for HC 
and the p75NTR antibody per cell body was quantified using the Cell profiler software. 
In the case of the primary screen, these data were fed to the Cell HTS software to 
calculate the Z-scores. However in the case of the validation screen, the siRNA pools 
are selected for their ability to affect the readout, which means that the population is not 
normally distributed, which is a pre-requisite for calculating the Z-scores (section 4.3.2 
of this Chapter). For this reason the data from each siRNA pool were compared to the 
median of the siRNA controls, instead of to the median of the whole validation siRNA 
library (Figure 4.6). 
 From the primary hits, only the knockdown of BICD1 was confirmed to increase 
the accumulation of HC, while the knockdown of DCNT1, DYNC2LI1, KIF3C and 
KIF15 seemed to reduce the accumulation of this probe, in accordance with what was 
observed in the primary screen (see Table 4.5 and Figure 4.6). 
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Table 4.5 HC scores from the validation of hits obtained from the primary screen.  
The score for each candidate is indicated together with the value obtained by subtracting the median of 
the siRNA controls from the individual score for each gene. The candidates that were considered to be 
genuine as “validated” are highlighted in yellow. The scores of the siControls and the EHNA-treated 
samples are reported and highlighted in grey. The scores are obtained by calculating the mean of the 
values of the five replicates for each candidate gene. A candidate is considered “validated” if its 
knockdown consistently showed the same effect as previously observed in the primary screen.  
Mean of the siControls Mean of EHNA treated samples  
1.1911315 0.11340095  
INCREASED INTRACELLULAR ACCUMULATION 
Candidate name Score 
Score minus the median of the 
siControls 
 
BICD1 1.831421 0.6402895 
MYL3 1.2197258 0.0285943 
CORO1C 1.26823372 0.07710222 
DYNLT3 0.66562036 -0.52551114 
EG231836 1.24756302 0.05643152 
MYO16 1.42768216 0.23655066 
CENPE 0.8220231 -0.3691084 
RAB10 0.95982068 -0.23131082 
DYNC1LI2 1.1063869 -0.0847446 
DECREASED IINTRACELLULAR ACCUMULATION 
Candidate name Score Score minus the median of the 
siControls 
 
KIF13B 0.86119454 -0.32993696 
KIF7 0.87835562 -0.31277588 
DCTN1 0.75369896 -0.43743254 
DYNLL2 1.0708651 -0.1202664 
KIF12 1.1888181 -0.0023134 
OSBPL1A 0.87861126 -0.31252024 
MYH2 1.05655968 -0.13457182 
DYNC2LI1 0.78353784 -0.40759366 
KIF3C 0.70126436 -0.48986714 
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MYH1 1.01950226 -0.17162924 
KIF15 0.71261168 -0.47851982 
DNHD1 1.16207428 -0.02905722 
RAB5A 1.2500167 0.0588852 
ARL8C 1.31220688 0.12107538 
 
Only the knockdown of RAB7 was confirmed to increase the intracellular 
accumulation of the p75NTR antibody, whilst the knockdown of KIF21B, MXD3 and 
KIF11 seemed to reduce its accumulation, consistent with the results of the primary 
screen (Table 4.6). 
 
Table 4.6 p75NTR antibody scores from the validation of hits obtained from the primary screen. 
The score for each candidate is indicated together with the value obtained by subtracting the median of 
the siRNA controls from the individual score for each gene. The candidates that were considered 
“validated” are highlighted in yellow. The scores of the siControls and the EHNA-treated samples are 
reported and highlighted in grey. The scores are obtained by calculating the mean of the values of the five 
replicates for each candidate gene. A candidate is considered “validated” if its knockdown consistently 
showed the same effect as previously observed in the primary screen regarding the p75NTR antibody 
accumulation compared to the controls.  
Median of the siControls Median of EHNA treated samples  
1.313071 0.1074658  
INCREASED INTRACELLULAR ACCUMULATION 
Candidate name Score Score minus the median of the 
siControls 
MYH13 1.48087468 0.16780368 
RAB7L1 0.85880744 -0.45426356 
DCTN2 0.9419114 -0.3711596 
MYL3 1.23503192 -0.07803908 
DYNLL1 1.22249072 -0.09058028 
RAB7 1.5793482 0.2662772 
MYO9B 0.88561824 -0.42745276 
EG231836 0.80367186 -0.50939914 
MYH7B 0.50435852 -0.80871248 
MYO10 0.85313542 -0.45993558 
MYLC2B 1.27796624 -0.03510476 
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RAB10 1.15070274 -0.16236826 
DECREASED INTRACELLULAR ACCUMULATION 
Candidate name Score Score minus the median of the 
siControls 
KIF21B 0.73966624 -0.57340476 
DYNC1I1 1.16264346 -0.15042754 
KIF26B 0.90418152 -0.40888948 
DYNLRB2 0.95027282 -0.36279818 
KIF2A 1.13100118 -0.18206982 
MXD3 0.73556886 -0.57750214 
MYO1B 1.09169806 -0.22137294 
KIF15 1.0111803 -0.3018907 
OSBPL1A 1.12998484 -0.18308616 
KIF1A 1.05208572 -0.26098528 
RAB8A 1.3917102 0.0786392 
KIF12 1.32336156 0.01029056 
KIF3A 1.5711236 0.2580526 
KIF11 0.84326322 -0.46980778 
ARL8C 1.09350966 -0.21956134 
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Figure 4.6. Charts of the scores of the validation screen. 
The relative scores of the accumulation of Hc (A) and p75NTR (B) for each candidate gene are plotted 
(section 4.4.1 of this Chapter). The columns corresponding to the genes that resulted in an increased 
intracellular accumulation of each probe in the original screen are coloured in black, while the ones 
corresponding to the genes that resulted in a decreased intracellular accumulation of the probes are 
coloured in white. They were subtracted from the median of the siRNA controls, in order to clearly 
visualise whether their knockdown increased or decreased the internalisation of the two probes compared 
to the controls. In summary, the knockdown of BICD1 increased HC accumulation, whilst knocking-down 
DCNT1, DYNC2LI1, KIF3C and KIF15 caused decreased HC accumulation consistent with what was 
observed in the primary screen (A). Knockdown of RAB7 was confirmed to increase p75NTR 
accumulation, and KIF21B, MXD3 and KIF11 to decrease it (B). 
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Summary of the achievements presented in this Chapter 
 
• EHNA was selected as a positive control for the internalisation assay of the two 
probes, because of its ability to decrease the accumulation of HC and p75NTR in 
MNs derived from HB9-GFP ES cells.  
 
• The siRNA screen was performed in triplicates with an siRNA library of 
molecular motors and adaptors covering 155 genes. 
 
• Images were analysed using the Cell Profiler software and the resulting values 
were transformed into Z-scores using the Cell HTS software. 
  
• A list of primary hits were chosen on the basis of the Z-score ranking and 
corresponding Dharmacon siRNA smart pools were used to re-screen the 
primary hits. 
 
• The results suggested that the knockdown of BICD1 increased HC accumulation, 
whilst knocking-down DCNT1, DYNC2LI1, KIF3C and KIF15 inhibited HC 
accumulation in agreement with the results obtained in the primary screen. The 
data also suggested that the knockdown of RAB7 was confirmed to increase 
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p75NTR accumulation, whilst KIF21B, MXD3 and KIF11 down-regulation 
decreased it. 
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Chapter 5. BICD family of proteins 
 
 The Bicaudal-D family of proteins was originally identified in Drosophila, 
where two dominant maternal-effect mutants were characterised, in which a large 
proportion of the embryos presented an anterior to posterior mutation, hence the name 
“bicaudal”, which in Latin means “two tails” (Mohler and Wieschaus, 1986). In 
metazoan animals the BICD protein is highly conserved, with only one isoform present 
in invertebrates and two (BICD1 and BICD2) in mammals, which also have two BICD-
related proteins (BICD-R1 and BICD-R2) (Figure 5.1 A).  
 Mammalian BICD1 and BICD2 proteins share a good degree of homology; they 
both have 3 coiled-coil regions, with the C-terminal one being the most conserved 
between the two proteins with 93% identity. BICD-Rs, instead, have only two coiled-
coil domains and their similarity to BICDs is lower than 30% (Figure 5.1 A). 
5.1.1 Drosophila BICD 
 In Drosophila the BICD protein is essential for the correct specification of the 
oocyte, a process which requires a microtubule-dependent accumulation of specific 
mRNAs. BICD plays a role in determining the correct subcellular localisation of a 
certain number of mRNAs during oogenesis and embryogenesis. In order to execute this 
function, BICD, which has no RNA binding motifs, needs to form a complex with the 
Egalitarian protein (Egl) (Bullock and Ish-Horowicz, 2001). BICD has also been 
implicated in dynein-driven nuclear migration along microtubules in partnership with 
the protein Lissencephaly 1 (Lis1), and in bidirectional transport of lipid droplets in the 
Chapter 5. BICD family of proteins 
136 
Drosophila blastoderm embryo (for a more comprehensive description of the roles of 
BICD in Drosophila see (Dienstbier and Li, 2009)). 
 Interestingly, a very recent paper pointed to a role for BICD in Drosophila 
neurons, reporting that zygotic BICD function is obligatory only in the nervous system 
(Li et al., 2010). BICD directly associates with clathrin heavy chain (CHC) and this 
association has been shown to be instrumental for the correct localisation of CHC in 
synaptic boutons, suggesting that BICD plays a role in dynein-mediated recycling of 
CHC at the synaptic plasma membrane. This function is required to maintain normal 
levels of neurotransmission during prolonged high-frequency electrical stimulation (Li 
et al., 2010) (Figure 5.1 A). 
5.1.2 Mammalian BICDs 
 The first protein of the BICD family to be cloned in mammals was BICD1, 
whose human and murine cDNA was cloned in 1997 (Baens and Marynen, 1997). This 
paper established by Northern blot that BICD1 mRNA is expressed in brain, heart and 
skeletal muscle in both humans and mice (Baens and Marynen, 1997). 
 BICD2 was isolated in a yeast two-hybrid screen for interactors of the 
microtubule binding protein CLIP-115 (Hoogenraad et al., 2001). It was then found that 
BICD2 was involved in microtubule-dependent transport via its direct interaction with 
dynamitin (p50), a subunit of dynactin, which is part of the cytoplasmic dynein/dynactin 
motor complex. During interphase BICD2 localises to the Golgi and to the minus ends 
of microtubules together with dynactin (Hoogenraad et al., 2001). 
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5.1.3 BICD regulates COPI-independent Golgi to ER transport 
 An additional function of mammalian BICD proteins was discovered in 2002, 
when BICD1 was found in a yeast two-hybrid screen for interactors of Rab6 (Matanis et 
al., 2002). BICD1 and BICD2 are both able to bind the C-terminal domain of the GTP 
bound form of Rab6A through their C-terminal regions. Furthermore, BICD1 and 2 
interact with the dynein complex through their N-terminal domains (Matanis et al., 
2002).  BICD1 and 2 were also found to colocalise with Rab6A on the trans-Golgi 
network (TGN) and on cytoplasmic vesicles associated with the Golgi apparatus. This 
cellular localisation is dependent upon Rab6A and the recruitment of cytoplasmic 
dynein by Rab6A-containing vesicles is enhanced by overexpression of BICD1 
(Matanis et al., 2002).  Overexpression of the C-terminal domain of BICD1 and BICD2, 
which does interact with Rab6A but not  with dynein, inhibits the movement of Rab6A-
positive vesicles towards the minus end of microtubules, causing their accumulation in 
the cell periphery. These Rab6A-positive structures contain COPI-independent ER 
cargoes such as β1,4-galactosyltransferase (GalTase), which suggests that the concerted 
action of the dynein complex, Rab6A and BICD plays a role in the regulation of the 
COPI-independent Golgi to ER transport (Matanis et al., 2002) (Figure 5.1 B). 
5.1.4 BICD2 regulates the transport of Rab6 positive exocytotic carriers 
 In all eukaryotic cells, there is a route of transport, mediated by Golgi-derived 
vesicles, that leads to constitutive exocytosis of newly synthesized lipids, membrane 
proteins and components of the extracellular matrix. These exocytotic carriers bud off 
the TGN and move along microtubules towards the periphery of the cell, where they 
finally fuse with the plasma membrane. The knock-down of Rab6A, which was found 
on their surface, does not prevent their exocytosis, but affects their movement and 
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processivity (Grigoriev et al., 2007). Kinesin-1 (KIF5B), a plus-end microtubule motor, 
is also involved in the motility of Rab6A exocytotic carriers and interestingly, BICD2 
was also found to interact with KIF5B. Together these observations suggest that the 
interaction between kinesin-1, BICD2 and Rab6A is likely to play a role in the 
trafficking of Rab6A exocytotic carriers from the TGN to the plasma membrane 
(Figure 5.1 B). 
5.1.5 BICDs and axonal retrograde transport in neurons  
 BICD1 has also been found to interact with the active form of Rab6B, which is 
predominantly expressed in the brain (Wanschers et al., 2007). These two proteins 
colocalise on the Golgi apparatus and on vesicles aligned along microtubules. 
Furthermore, BICD1 co-localises with dynein in the neurites of differentiated SK-N-SH 
cells, where BICD1-associated vesicles undergo bi-directional movements. These 
observations suggested that BICD1 together with Rab6B might control retrograde 
transport of cargoes in neurons (Wanschers et al., 2007). 
 Interestingly BICD2 has been used as a tool to influence axonal retrograde 
transport (Teuling et al., 2008). There is genetic evidence, that correlates mutations of 
the dynein/dynactin complex with the pathogenesis of motor neuron deseases (LaMonte 
et al., 2002, Hafezparast et al., 2003). A transgenic mouse expressing the N-terminus of 
BICD2 under the control of the neuronal specific Thy 1 promoter was generated to 
investigate the effect of chronic impairment of the dynein/dynactin complex in neurons 
in vivo. The expression of the N-terminus of BICD2 causes an over-accumulation of 
dynein/dynactin complexes in the cell body of MNs and Golgi fragmentation, indicating 
an impairment of retrograde trafficking. Unexpectedly these transgenic mice did not 
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develop any sign of motor neuron degeneration or motor abnormalities (Teuling et al., 
2008). These mice were also crossbred with a mouse model of amyotrophic lateral 
sclerosis (ALS), the SOD1-G93A strain, to determine whether impairing axonal 
transport would worsen the phenotype. However, these mutant mice surprisingly had an 
increased lifespan (Teuling et al., 2008). 
5.1.6 BICDs and the centrosome 
 Another important function of BICD1 is associated with its localisation to the 
centrosome. It is known that during mitosis GSK-3β interacts with microtubules and 
accumulates at the centrosomes and spindle poles (Wakefield et al., 2003).  GSK-
3β phosphorylates BICD1, thus stabilising its interaction with the dynein complex 
which is required for the anchoring of the microtubules to the centrosome (Fumoto et 
al., 2006). The role of BICD1 in this context is likely to be the regulation of the dynein 
mediated transport of proteins necessary for the tethering of microtubules to the 
centrosome. One such protein is ninein, a minus-end capping protein essential for this 
process (Bornens, 2002) (Delgehyr et al., 2005). BICD1 directly interacts with ninein 
and its knockdown affects its centrosomal localisation, suggesting that BICD1 is an 
adaptor for ninein recruitment to cytoplasmic dynein (Fumoto et al., 2006) (Figure 5.1 
B).  
 Recently it was shown that BICD2 influences the relative positioning of the 
nucleus and the centrosomes in dividing cells (Splinter et al., 2010). BICD2 was found 
to bind a component of the nuclear pore complex (NPC), the RAN binding protein 2 
(RanBP2), during the G2 phase of the cell cycle. In this context BICD2 would be able 
to recruit the dynein/dynactin complex to NPCs, playing a role in the tethering of the 
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centrosomes to the nucleus before mitotic entry. Kinesin-1 was found to counteract the 
dynein complex, pushing apart the duplicated centrosomes from the nuclei in late G2. 
Depletion of BICD2, but not BICD1, affected not only the dynein-mediated tethering of 
the centrosome to the nucleus, but also prevented the kinesin-1 function. These data 
reveal that BICD2 is a key molecular motor adaptor, capable of regulating the action of 
dynein and kinesin-1 in positioning the nucleus and the centrosomes prior to mitosis. 
(Figure 5.1 B) 
5.1.7 BICD1 and receptor endocytosis 
 Using a yeast two-hybrid screen approach, BICD1 was found to interact with the 
C-terminal domain of the protease-activated receptor 1 (PAR1) (Swift et al., 2010), a G 
protein-coupled receptor, which has been shown to be important in cancer, 
angiogenesis, inflammation and thrombosis (Ossovskaya and Bunnett, 2004). The 
internalisation of PAR1 is dynamin- and clathrin-dependent (Trejo et al., 2000). BICD1 
colocalises with PAR1 and tubulin, and its silencing caused an impairment of activated 
PAR1 endocytosis, which suggests that BICD1 has a role in regulating the transport of 
the activated receptor from the plasma membrane to the endosomal compartment 
(Figure 5.1 B). Moreover, BICD1 knockdown affected PAR1 signalling, inhibiting the 
PAR1-driven proliferation of breast carcinoma cells. These observations link for the 
first time a BICD protein to the internalisation of a receptor. In addition, this effect on 
endocytosis also has repercussions for the signalling of the receptor itself, which 
highlights the fact that molecular motor adaptors might be key players in signalling as 
well as intracellular trafficking. 
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5.1.8 The trafficking of pp150 is dependent on BICD1 
 The tegument protein pp150 is an abundant constituent of the human 
cytomegalovirus (HCMV) virion, for which both nuclear and cytoplasmic localisations 
have been reported. Its function is still unknown: however, it is essential for the 
production of a fully infectious virus. BICD1 was found to interact with pp150 in a 
yeast two-hybrid screen (Indran et al., 2010). BICD1 knockdown caused a decreased 
viral yield, which could be explained by a defect in the localisation of pp150, which 
failed to traffic to the cytoplasmic viral assembly compartment (AC). Moreover, the 
overexpression of dynamitin (p50), a subunit of dynactin, which is able to disrupt the 
dynein complex, and the N-terminus of BICD1, which acts as a dominant-negative, 
caused a disruption of the AC, which resulted in a decreased viral yield. These data 
provide evidence that the assembly of HCMV is dynein-dependent and that the 
molecular motor adaptor BICD1 is instrumental in this process, determining the correct 
localisation and function of the tegument protein pp150. 
5.1.9 BICDR-1 regulates neuritogenesis 
 The latest addition to the BICD family of proteins in mammals are BICD-related 
protein 1 (BICDR-1) and 2 (BICDR-2) (Schlager et al., 2010)(Figure 5.1). Murine 
BICDR-1 is predominantly expressed in kidney and brain, while BICDR-2 could not be 
detected by Northern blot or tissue dot blot. The C-terminal region of BICDR-1 
interacts with Rab6A and B and BICDR-1 is also able to bind the dynein/dynactin and 
KIF1C motor complexes. Through its interaction with the dynein and kinesin molecular 
motors, BICDR-1 determines the pericentrosomal localisation of Rab6-positive 
secretory vesicles, preventing their secretion and also inhibiting neuritogenesis. 
Interestingly, the expression of BICDR-1 in mouse development is high at early stages 
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of embryonic development (embryonic day 10) and then drops off rapidly. A similar 
pattern is replicated in vitro in hipppocampal cultures, where BICDR-1 expression 
levels drop at 3 days in vitro (DIV 3). These results suggest that BICDR-1 plays a role 
in the temporal regulation of the secretory trafficking in neurons, sequestering Rab6 
positive secretory vesicles around the centrosome (Figure 5.1 B). This functional block 
is then released when neuritogenesis has to occur by dropping the level of expression of 
BICDR-1. 
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Table 5.1 Mammalian BICDs, BICD-related proteins and their interaction partners.  
Summary of the known interactors of mammalian BICD and BICD-R proteins. The interacting partner is 
specified together with the region of the BICD protein it interacts with (if known). Modified from 
(Dienstbier and Li, 2009). 
 
BICD interacting proteins 
Interacting partner BICD protein BICD interacting 
fragment 
Reference(s) 
Kinesin 1 heavy chain BICD2 336-595 (Grigoriev et al., 2007) 
GSK-3β BICD1 437-617 (Fumoto et al., 2006) 
RAB6A BICD2  (Matanis et al., 2002) 
RAB6A, RAB6B BICD1 673-803 (Matanis et al., 2002) 
Ninein BICD1 Full length (Fumoto et al., 2006) 
pp150 BICD1 343-835 (Indran et al., 2010) 
PAR1 BICD1 Full-length (Swift et al., 2010) 
RAB6A, RAB6B BICDR-1 382-577 (Schlager et al., 2010) 
KIF1C BICDR-1 Full-length (Schlager et al., 2010) 
Dynein-dynactin 
complex 
BICDR-1 Full-length (Schlager et al., 2010) 
p50 dynamitin BICD2 706-810 (Hoogenraad et al., 2001) 
Dynein intermediate 
chain 
BICD2 1-271 (Hoogenraad et al., 2001) 
Dynein-dynactin 
complex 
BICD2 1-575 (Hoogenraad et al., 2001) 
RANBP2 BICD2 487-820 (Splinter et al., 2010) 
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Figure 5.1 Structure and function of mammalian BICDs and their possible roles in neurons 
The secondary structure of the four known members of the BICD family in mammals are reported and 
related to one another in terms of percentage of identity (A). BICD1 and BICD2 have three coiled-coil 
domains (CC, in black), which share a high percentage of identity, expecially in the C-terminal region 
(CC3), which is 93% identical. BICD-R1 and BICD-R2 have only two CC domains. BICDs and BICD-R 
share less than 30% identity (Probir Chakravarty, Cancer Research UK London Research Institute). The 
possibile roles of BICD family members in neurons (B). The only known role of dBICD in Drosophila 
neurons is also indicated (see section 1.4.1.). Both schematics are adapted from (Terenzio and Schiavo, 
2010). 
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Chapter 6. Characterisation of the role of BICD1 in 
motor neurons 
6.1 Introduction 
 BICD1 is one of the four members of the mammalian BICD family of proteins 
(Chapter 5, section 5.4), and is an adaptor for the dynein/dynactin motor complex. It 
also has a plethora of interactors and it has been associated with several cellular 
functions, such as COPI-independent Golgi to ER retrograde transport, the anchorage of 
dynein to the centrosome, the endocytosis of PAR1 receptor and the trafficking of the 
cytomegalovirus protein pp150. All of these roles have been described in cancer cell 
lines; however, nothing is known of the function of mammalian BICD1 in primary 
cells, especially in neurons. In this Chapter, a mouse ES cell line lacking the BICD1 
protein was used to explore the function of BICD1 in MNs, with particular focus on the 
possible relationship between this protein and the trafficking of neurotrophins and their 
receptors. 
Note: Previously when using an acronym the reference was always to the corresponding 
protein, however in this chapter it is necessary to refer to the gene as well. Acronyms in 
uppercase (i.e. BICD1) will, therefore, been used throughout this chapter to indicate the 
corresponding protein, whilst lowercase and italics (i.e. Bicd1) will refer to the gene 
(http://www.informatics.jax.org/mgihome/nomen/gene.shtml).  
Chapter 6. Characterisation of the role of BICD1 in motor neurons 
146 
Aim of the work presented in this chapter: 
 
• Justification for the decision to choose the BICD1 protein as a candidate 
from the screen for further characterisation; 
 
• To characterise MNs derived from an ES cell line gene-trapped for Bicd1 
and to confirm the BICD1 knockdown phenotype observed in the screen;  
 
• To further investigate the molecular basis of the phenotype observed. 
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6.2 The choice of BICD1 as the candidate to characterise 
 I had to decide on a candidate gene from the screen to characterise further. Some 
of the candidates from the siRNA screen were expected, such as RAB7, for example, 
which we already knew was involved in the axonal retrograde transport of p75NTR, or 
DCNT1, which is a component of the dynein/dynactin motor complex and is known to 
play a role in axonal retrograde transport and intracellular trafficking of HC (Lalli et al., 
2003).  
 BICD1 was a very interesting candidate, because of its well-described role as a 
microtubule-associated protein and more importantly as a dynein adaptor. BICD1 was 
also described to interact with the neuronal isoform of RAB6, RAB6B, and was 
proposed to play a role in axonal retrograde transport in neurons (Wanschers et al., 
2007). We were intrigued by the possibility of BICD1 being an important player in the 
trafficking of HC and possibly of neurotrophins and their receptors. I decided, therefore, 
to concentrate my efforts on this candidate. 
6.3 Derivation of MNs from Bicd1 gene-trapped mouse ES cells 
6.3.1 Use of Bicd1 gene-trapped mouse ES cells to generate MNs 
 The knockdown protocol perfected for Hb9-GFP ES cell derived MNs was 
designed to be effective in a 96-well plate format. However, it would have to be 
modified and adapted to other formats and to a more traditional forward transfection 
protocol in order to suit the needs of the molecular characterisation of BICD1. In 
addition, to check for off-target effects due to the siRNA technology, I wanted to verify 
the BICD1 phenotype observed in the screen by taking a different knockdown approach 
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(Discussion, section 7.3). I decided, then, to take advantage of the possibility of 
deriving MNs from mouse ES cells. Three mouse ES cell lines where used: a 
heterozygous gene trap ES cell line for the Bicd1 gene (Bicd1gt/+, clone RRP27) 
generated by the International Gene Trap Consortium (IGTC, 
http://www.genetrap.org/), a homozygous cell line generated from the RRP27 clone by 
Krzyzstof  Wicher (Developmental Genetics laboratory at CRUK) (Materials and 
Methods, section 2.2.4.7), and a wild type Sv 129 mouse ES cell line kindly provided 
by Ian Rosewell (Transgenic Facility at CR-UK). The Sv 129 ES cell line, derived from 
an outbred mouse strain, was the same one used by the IGTC to generate the RRP27 ES 
cell clone.  
 The same protocol established for MN differentiation from the HB9-GFP ES 
cells was successfully used to generate MNs from all the three Bicd1 genotypes 
(Material and Method, section 2.2.4.5 and Chapter 3, section 3.3.3). 
6.3.2 Gene trap technology  
 Gene trap technology allows the generation of transgenic ES cells through the 
use of a vector designed to randomly insert into a genomic sequence, intronic or a 
protein coding region, and interrupt the transcription of a trapped gene. In the basic 
version of a gene trap vector, corresponding to the one used to generate the Bicd1 gene 
trapped ES cell line used for this study, the insertion cassette contains a splice acceptor 
site (SA), which interrupts downstream splicing of the trapped gene and instead causes 
transcription of the vector sequence. With this strategy the endogenous promoter of the 
mutated gene is used to express the gene trap vector, which usually contains a 
combination of a reporter and selection gene (in this case the β−galactosidase + 
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neomycin R genes) (Figure 6.1 A and B). The end result is the production of a 
truncated fusion protein containing the exons upstream of the point of insertion of the 
vector, followed by the vector cassette. If the insertion of the vector occurs after the first 
exon, it results in a functional deletion of the trapped gene. The trapped gene is 
identified using a PCR primer designed in the 5’ region of the vector cassette to 
sequence the cDNA upstream of the vector (Figure 6.1 B).  
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Figure 6.1. Gene trap vector and strategy. 
Schematic of a standard gene trap vector, composed of a splicing acceptor site (SA), a reporter and 
selection gene (Trap cassette), and a poly A tail (pA), (A). Flowchart of a conventional gene trap strategy 
(B). Because the vector is inserted randomly in the genome, a primer located in the 5’ region of the 
cassette is used to sequence (5’ RACE sequencing) upstream of the integration site and therefore identify 
the gene that has been trapped. The figure is adapted from 
http://www.genetrap.org/tutorials/overview.html#limitations. 
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6.4 Characterisation of Bicd1gt/+ and Bicd1gt/gt MNs 
6.4.1 Bicd1gt/+ and Bicd1gt/gt MNs die earlier in culture compared to wild 
type MNs 
 Morphologically, the cultures of differentiated MNs looked similar in the three 
genotypes. However, fewer non neuronal cells seemed to be present in Bicd1gt/gt MNs 
cultures. Cell survival seemed also different. Preliminary data showed that Bicd1gt/gt 
MNs die two weeks after dissociation from the EBs if cultured in full medium and after 
9 – 10 days if cultured in the presence of arabinofuranosyl cytidine (Ara-C), a drug that 
selectively kills proliferating cells. Ara-C was used in order to stop the proliferation of 
glia, thus enriching the culture for neurons. However MNs appeared to be more fragile, 
possibly because they did not receive the trophic support normally provided by the glial 
cells. This was more evident for Bicd1gt/gt MNs, which seems to be more susceptible to 
cell death than wt cells. Bicd1gt/+ MNs showed an intermediate life span in vitro 
compared to Bicd1gt/gt MNs and wild type MNs. 
6.4.2 MN commitment and differentiation are not impaired in Bicd1gt/gt 
ES cells  
Two sets of primers for quantitative polymerase chain reaction (Q-PCR) were 
designed, one spanning between exons 1 and 2 of the Bicd1 gene, which is where the 
gene trap cassette is inserted, and the second one spanning between exons 7 and 8. Both 
of these Q-PCRs showed a 70% reduction of the Bicd1 transcript in Bicd1gt/gt MNs 
(Figure 6.2 C). Bicd1gt/gt MNs should, therefore, be considered as hypomorph mutants 
(Discussion, section 7.3.). 
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I needed to make sure that the lack of the BICD1 protein was not affecting the 
differentiation potential of the gene-trapped ES cells, which might have resulted in a 
different neuronal population, invalidating the use of these cells for further experiments. 
Thus expression of well-established MN markers, like the homeobox transcriptional 
factor Hb9 and choline acetyltransferase (ChAT), was tested by Q-PCR by Dr. M. 
Golding 4 days after the dissociation of the EBs. No significant difference in expression 
of Hb9 and ChAT was found between Bicd1gt/gt and wild type MNs, indicating that the 
percentage of MNs in these cultures was very similar (Figure 6.2 C and Discussion, 
section 7.3).  
Bicd2 expression levels were also tested by Q-PCR. Approximately 80% 
increased expression of Bicd2 was shown in Bicd1gt/gt MNs compared to wild type cells 
(Figure 6.2 C). This behaviour was the inverse of Bicd1 expression and it could be 
explained as an attempt by Bicd1gt/gt MNs to compensate for the lack of the BICD1 
protein (Discussion, section 7.3.). 
It was important to characterise Bicd1gt/gt MNs cultures for the expression levels 
of the genes whose behaviour I wanted to investigate, namely the neurotrophin 
receptors p75NTR and TrkB (Introduction, section 1.1.2). Dr. M. Golding in the MNP 
laboratory performed a set of reverse transcription polymerase chain reactions (RT-
PCR) from cDNA obtained from wild type and Bicd1gt/gt MNs. The expression of TrkA, 
TrkB, TrkC was tested. As expected, TrkB and TrkC were expressed in both wild type 
and Bicd1gt/gt MNs, whilst TrkA transcript was not detectable (Figure 6.2 A), 
confirming the data previously obtained by the laboratory for wild type primary mouse 
MN cultures. In addition, no significant difference was shown by Q-PCR in the levels 
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of P75NTR transcript in the two genotypes (Figure 6.3), while TrkB seemed to be 25% 
less expressed in Bicd1gt/gt MNs. The levels of expression of the enzyme responsible for 
the synthesis of the GD1b polysialogangliosides, which determines the binding of HC to 
the neuronal PM, the N-acetylgalactosaminyltransferase (GalNAcT), were also tested 
and no difference was found between wild type and Bicd1gt/gt MNs (Figure 6.2 C). 
I then decided to test the protein levels of p75NTR in western blot, and I found 
that there was a 40% increase in Bicd1gt/gt MNs compared to wild type MNs (Figure 6.2 
B and C for the quantification). Consistent with the data on the mRNA levels of TrkB, 
there was a 30% reduction of the protein levels of Trk receptors using a Pan Trk 
antibody (Figure 6.2 B and C for the quantification). Finally, the Q-PCR data were 
supported by western blot analysis as there was a 70% reduction of the BICD1 protein 
in Bicd1gt/gt MNs (Figure 6.2 B and C for the quantification). The residual Bicd1 
protein was supposedly due the inherent leakiness of the gene trapping technology used 
to generate the ES cells. For a discussion about these data please refer to section 7.3 and 
7.3.3 of the Discussion Chapter. 
 
Chapter 6. Characterisation of the role of BICD1 in motor neurons 
154 
 
Figure 6.2 Characterisation of gene expression in Bicd1gt/gt MNs.  
The presence of the neurothrophin receptors, TrkA, TrkB and TrkC  was tested by PCR in Bicd1gt/gt MNs 
(A). As expected TrkA was not present. cDNA from adult mouse brain was used as a positive control (A). 
The protein levels of  BICD1, Trk receptors (Pan Trk antibody) and p75NTR are shown in western blot 
(B). The levels of transcript for each of the gene in Bicd1gt/gt MNs (C) were normalised by the value of 
the corresponding  transcript in wt MNs. The expression levels of the indicated genes are reported as fold 
change over the wild type, which is set to 0 (C, black columns). The Q-PCR data are obtained from 3 
independent experiments. The protein levels of BICD1, TrkB and TrkC (pan Trk antibody), and p75NTR 
are also shown (C, white columns). The protein levels were calculated using Image J from western blots 
from 3 independent experiments. 
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6.5 Depletion of BICD1 does not affect axonal retrograde transport 
A possible role for BICD1 in axonal transport was proposed by Wanschers et al. 
on the basis of the interaction of this protein with the neuronal isoform of Rab6, Rab6B, 
and its bidirectional transport in neurites of a differentiated human neuroblastoma cell 
line (SK-N-SH cells, Chapter 5, section 5.4.5.). Since the main aim of the siRNA screen 
was to find players involved in trafficking of neurotrophins and their receptors, 
including axonal retrograde transport, the possibility that the depletion of BICD1 might 
affect axonal retrograde transport was therefore tested. 
MNs generated from wt, Bicd1gt/+ and Bicd1gt/gt ES cells were incubated for 30 
minutes either with 20 nM AlexaFluor 555-conjugated HC or with 0.9 µg/ml AlexaFluor 
647-conjugated p75NTR antibody in the presence of 100 ng/ml of NGF. NGF is a 
physiological ligand for p75NTR and specifically stimulates the internalisation of this 
receptor alone since TrkA is not present in this type of neurons. After incubation with 
either probe, the cells were washed in DMEM and imaged. HC and p75NTR-positive 
carriers were tracked and their instantaneous speed was determined. Speed distribution 
profiles of axonal retrograde transport of the two probes for MNs of the three genotypes 
were calculated (Figure 6.3 A & B). No statistically significant difference between the 
three different genotypes was observed in axonal transport of HC (Figure 6.3 A) or the 
p75NTR antibody (see Figure 6.3 B). 
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Figure 6.3 .Kinetics of axonal retrograde transport of HC and p75NTR antibody in wild type, 
Bicd1gt/+ and Bicd1gt/gt MNs. 
The frequency distribution of instantaneous speeds for HC- (A) and p75NTR- (B) positive carriers are 
plotted. Four independent experiments were performed for each probe and each genotype. No statistically 
significant difference in the axonal transport of HC and p75NTR in wt MNs compared to Bicd1gt/+ and 
Bicd1gt/gt cells has been identified. 
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6.6 Internalisation of HC and the p75NTR antibody in Bicd1gt/gt MNs. 
6.6.1 Confirmation of the BICD1 knockdown phenotype observed in the 
screen using Bicd1gt/gt MNs 
 I sought to confirm that the depletion of BICD1 in Bicd1gt/gt MNs would induce 
the same phenotype that was observed in the screen, i.e. increased accumulation of HC 
in MN cell bodies. MNs derived from wt, Bicd1gt/+ and Bicd1gt/gt mouse ES cells were, 
therefore, used to assay the kinetics of internalisation of AlexaFluor 546-labelled HC 
and the p75NTR antibody incubated together at 37˚C to mimic the conditions of the 
siRNA screen. The extent of internalisation of both probes was assessed at fifteen, thirty 
and sixty minutes. The cells were acid-washed for 3 minutes at 4˚C, fixed in 4% PFA, 
and then immunostained for p75NTR. The internalised pool of the two probes was 
visualised with a confocal microscope and the intensity of fluorescence of HC and 
p75NTR antibody quantified using the Image J software and divided by the intensity of 
the βIII tubulin staining for data normalisation. In the case of HC, a statistically 
significant difference between wild type and Bicd1gt/gt MNs could be observed after 1h 
of incubation at 37˚C (p < 0.05, pair-wise ANOVA, followed by Bonferroni post test, n 
= 3) (Figure 6.4 A), while for the p75NTR antibody there was a statistically significant 
difference between all three genotypes at this time-point (p < 0.05, pair-wise ANOVA, 
followed by Bonferroni post test, n = 3) (Figure 6.4 B).  
 These data confirmed the results obtained in the siRNA screen, where BICD1 
was selected as a candidate for the accumulation of HC. Surprisingly, an accumulation of 
the p75NTR antibody was also observed, in contrast with the results of the primary 
screen. 
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Figure 6.4 Kinetics of internalisation of HC and p75NTR antibody in wild type, Bicd1gt/+ and Bicd1gt/gt 
MNs. 
MNs derived from wild type, Bicd1gt/+ and Bicd1gt/gt ES cells were used to assay the kinetics of 
internalisation of Hc (A) and the p75NTR antibody (B). A statistically significant difference between wild 
type and Bicd1gt/gt MNs was observed after 1h of incubation for both probes. In the case of the p75NTR 
antibody a statistically significant difference between the three genotypes was observed after 1h. 
Statistical significance calculated using a one-way ANOVA test, followed by Bonferroni post test, n=3. 
Results are shown +/- s.e.m. 
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6.6.2 p75NTR accumulation in Bicd1gt/gt MNs is enhanced by BDNF 
stimulation. 
 I wanted to test whether the results obtained when co-incubating the p75NTR 
antibody with HC could be repeated using a physiological ligand for this receptor. In 
MNs derived from mouse ES cells TrkA is not present, but TrkB is. I therefore decided 
to use BDNF, which binds to both TrkB and p75NTR, to stimulate the internalisation of 
the p75NTR antibody. The p75NTR antibody was co-incubated with 100 ng/ml of BDNF 
at 37˚C for one hour; cells were then acid-washed for 3 minutes at 4˚C and fixed in 4% 
PFA. The intensity of fluorescence of the p75NTR antibody was quantified using the 
Image J software and divided by the intensity of the βIII tubulin staining, to normalise 
the data to the number of neurons (Figure 6.5).  
  A statistically significant increase in the accumulation of the p75NTR antibody in 
Bicd1gt/gt MNs compared to wild type cells was observed (p < 0.001). Bicd1gt/+ MNs 
behaved like wild type cells, whist there was also a significant difference between 
Bicd1gt/gt and Bicd1gt/+ MNs (p < 0.001, Figure 6.5 B). 
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Figure 6.5 p75NTR antibody internalisation upon BDNF stimulation. 
MNs derived from wild type, Bicd1gt/+ and Bicd1gt/gt ES cells were incubated for 1 hour with the p75NTR 
antibody and 100 ng/ml BDNF. MNs were then acid-washed for 3 minutes and fixed in 4% PFA. βIII 
tubulin (in green) was used to stain the neurons; the p75NTR antibody is in red (A). Scale bar, 20 µm. 
Quantification of three independent experiments on internalisation of the p75NTR antibody for an hour 
upon BDNF stimulation (B). There is a statistically significant increase in the accumulation of the p75NTR 
antibody in Bicd1gt/gt cells compared to wild type and Bicd1gt/+ MNs. *** p<0.001 by one-way ANOVA 
followed by Bonferroni test, n=3. Results are shown +/- s.e.m. 
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6.6.3 Nature of the organelle in which HC accumulates in Bicd1gt/gt MNs. 
 In order to gain a better understanding of the nature of the organelles in which 
HC accumulates after one hour incubation and obtain some clues as to whether there 
was a block or a diversion of the normal trafficking of this protein in Bicd1gt/gt MNs, a 
version of this probe conjugated with 10 nM gold by Guillermo Menendez in the 
laboratory was used to perform transmission electro-microscopy (TEM) studies. MNs 
derived from wild type, Bicd1gt/+ and Bicd1gt/gt ES cells were incubated with 50 nM 
gold-labelled HC for an 1 hour at 370C and then fixed, processed, sectioned and imaged 
by Ken Blight from the Electron Microscopy unit at CRUK, London Research Institute. 
 HC was found bound to the plasma membrane (PM), and upon internalisation 
accumulated predominantly in immature multi-vesicular bodies (MVBs) with low 
internal vesicle content; occasionally some gold could also be found in lysosomes. 
Compared with mutant cells, wild type MNs internalised less probe, which appeared to 
be dispersed within the lumen of MVBs (Figure 6.6), with a small amount localised to 
one side of the organelle. In Bicd1gt/gt MNs there seemed to be more HC bound to the 
PM and a higher intracellular accumulation of the probe. As a result, more MVBs were 
labelled. In addition, Bicd1gt/gt MVBs contained more HC than their wild type 
counterparts and the probe tended to mostly cluster in close apposition to the delimiting 
membrane of the organelle (Figure 6.6). Bicd1gt/+ MNs presented an intermediate 
phenotype, with an increased accumulation of HC compared to wild type cells. 
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Figure 6.6 HC accumulates in MVBs in Bicd1gt/gt MNs. 
Using a gold-conjugated HC it was determined that this probes accumulates predominantly in MVBs with 
a low internal vesicle content. Representative images of MVBs are shown from wild type (A, blown up 
panel 1) and Bicd1gt/gt MNs (B, blown up panels 2 & 3).  White arrows point to the gold labelled probe. 
Gold labelled HC was generally found dispersed within wild type MVBs (A, blown up panel 1). Bicd1gt/gt 
MVBs contained more HC than their wild type counterparts and the probe tended to cluster in close 
apposition to the delimiting membrane of the organelle (B, blown up panels 2 & 3). 
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6.7 GD1b and neurotrophin receptor homeostasis at the plasma 
membrane. 
6.7.1 HC binding at the plasma membrane of Bicd1gt/gt MNs. 
 In light of the results discussed above (section 6.6.1), I sought to test whether 
the increased accumulation of the probe in mutant MNs was due to a block in 
trafficking and/or degradation, and/or to an increased binding at the PM. This was all 
the more important because of the EM data shown in section 6.7, which clearly 
demonstrated an increased binding of HC to the PM, in addition to its increased 
intracellular accumulation.  
 20 nM of AlexaFluor 555-conjugated HC was incubated at 4˚C for 15 minutes 
with wild type, Bicd1gt/+ and Bicd1gt/gt MNs. Cells were then fixed with 4% PFA and 
imaged with a confocal microscope (Figure 6.7 A). The intensity of fluorescence of 
bound HC per MN was quantified from three independent experiments, and the data 
were normalised to the average fluorescence intensity of the probe per MN of wild type 
cells and plotted (Figure 6.7 B). The increase of HC binding to the neuronal plasma 
membrane was found to be statistically significant (p < 0.05) in Bicd1gt/+ compared to 
wild type MNs. The same difference was also found between Bicd1gt/+ and Bicd1gt/gt 
MNs (Figure 6.7 B). 
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6.7.2 GD1b levels at the plasma membrane are increased in Bicd1gt/gt 
MNs. 
 Having found that HC binding is increased in Bicd1gt/gt MNs compared to wild 
type cells, I sought to determine if the plasma membrane levels of GD1b, a main lipid 
receptor of HC (Introduction, section 1.1.2), were increased in Bicd1gt/gt MNs.  
 MNs derived from wild type, Bicd1gt/+ and Bicd1gt/gt ES cells were fixed in 4% 
PFA, and immuno-stained for GD1b. Images from three independent experiments were 
then acquired using a confocal microscope (Figure 6.8 A) and the fluorescence 
intensity of GD1b at the PM was quantified using Image J. Finally, these data were 
normalised to the average fluorescence intensity of GD1b per MN of wt cells and 
plotted (Figure 6.8 B). In accordance with the HC binding data shown in Figure 6.7, 
Bicd1gt/gt MNs were found to have a statistically significant higher content of GD1b at 
the PM (p < 0.001) compared to wild type MNs. In addition, the levels of GD1b 
exposed at the PM in Bicd1gt/+ MNs were also significantly (p < 0.01) increased 
compared to wild type cells (Figure 6.8 B). 
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Figure 6.7 Enhanced binding of HC to the PM of Bicd1gt/gt MNs. 
Wild type, Bicd1gt/+ and Bicd1gt/gt MNs were incubated with 20 nM AlexaFluor 555-conjugated HC for 15 
minutes at 40˚C. Cells were then imaged with a confocal microscope (A) and the fluorescence intensity of 
HC (in red) was quantified. βIII tubulin was used to identify the neurons. The HC staining was also 
visualised using a rainbow palette (false colours) to better highlight the differences of intensity in the 
three genotypes. The lowest intensity is in blue and the highest in red as indicated by the gradient bar (A).  
Scale bar 20 µm. The data from three independent experiments were pooled together and the values 
obtained for Bicd1gt/+ and Bicd1gt/gt MNs were normalised to wild type cells. Finally, the normalised 
fluorescence intensity of HC bound to the PM between the three genotypes was plotted. A statistically 
significant difference was found between the in wild type vs Bicd1gt/+ MNs and wild type vs Bicd1gt/gt 
MNs (B). *p<0.05 by one-way ANOVA followed by Bonferroni test, n=3. Results are shown +/- s.e.m. 
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Figure 6.8 Enhanced levels of GD1b on the plasma membrane of Bicd1gt/gt MNs. 
Representative pictures of wild type, Bicd1gt/+ and Bicd1gt/gt MNs fixed in 4% PFA and stained for Gd1b 
(in green), without permeabilisation (A). The GD1b staining has also been visualised using a rainbow 
palette to better appreciate the difference of intensity in the three genotypes. Scale bar, 20 µm. 
Quantification of three independent experiments of GD1b staining in unpermeabilised MNs (B). A 
statistically significant increase of GD1b exposed at the plasma membrane was found in Bicd1gt/+ and 
Bicd1gt/gt MNs compared to wild type cells. **p<0.01 and ***p<0.001 by one-way ANOVA followed by 
Bonferroni test, n=3. Results are shown +/- s.e.m. 
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6.7.3  Increased cell surface localisation of Trk receptors in Bicd1gt/gt MNs. 
 I then decided to also investigate the levels of p75NTR on the neuronal surface. 
MNs derived from wild type, Bicd1gt/+ and Bicd1gt/gt ES cells were fixed in 4% PFA and 
stained for p75NTR without permeabilisation,. Images of three independent experiments 
were taken and the intensity of fluorescence per MN was quantified using Image J. 
These raw data were then normalised to the average fluorescence intensity of p75NTR 
per MN of wt cells and plotted (Figure 6.9 A). Bicd1gt/gt MNs were found to have a 
statistically significant (p < 0.05) difference in cell surface p75NTR compared to wild 
type MNs. 
 The data regarding the accumulation of the p75NTR antibody were obtained in 
presence of BDNF, which meant that the internalised p75NTR could have been in a 
complex with the TrkB receptor. It was therefore important to test whether TrkB would 
exhibit a similar behaviour under steady state levels of p75NTR in Bicd1gt/gt MNs. MNs 
derived from wild type, Bicd1gt/+ and Bicd1gt/gt were stained for TrkB. Images were 
acquired from three independent experiments and quantified in the same way described 
for p75NTR. The intensity of fluorescence of TrkB was normalised as before and plotted 
(Figure 6.10 B). Bicd1gt/gt MNs were found to have a statistically significant (p < 0.05) 
difference in levels of TrkB at the PM compared to wild type MNs. The same difference 
was found between Bicd1gt/+ and Bicd1gt/gt MNs (Figure 6.10 B).  
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Figure 6.9 Enhanced levels of p75NTR on the plasma membrane of Bicd1gt/gt MNs. 
Wild type, Bicd1gt/+ and Bicd1gt/gt MNs were fixed in 4% PFA and stained for p75NTR. p75NTR has been 
visualised using a rainbow palette to better appreciate the difference in intensity of this staining (A). Scale 
bar 20 µm. The fluorescence intensity of the two antibodies per MN was quantified and the data from 
three independent experiments were pooled and the values were normalised to wild type cells. Finally, the 
fold difference of the PM staining of p75NTR between the three genotypes was plotted (B). A statistically 
significant difference between the level of p75NTR at the PM in wild type vs Bicd1gt/gt MNs was found 
(B). *p<0.05 by one-way ANOVA followed by Bonferroni test, n=3. The results are shown +/- s.e.m. 
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Figure 6.10 Levels of TrkB exposed at the plasma membrane in Bicd1gt/gt MNs. 
Wild type, Bicd1gt/+ and Bicd1gt/gt MNs were fixed in 4% PFA and stained for TrkB (in red). TrkB has 
also been visualised using a rainbow palette to better appreciate the difference amongst the three 
genotypes (A). Scale bar 20 µm. The amount of fluorescence intensity of the two antibodies per MN was 
quantified and the data from three independent experiments were normalised to wild type cells. Finally, 
the fold difference of TrkB localised to the PM amongst the three genotypes was plotted (B). A 
statistically significant difference was observed in the levels of TrkB at the PM between wild type and 
Bicd1gt/gt MNs and between Bicd1gt/+ and Bicd1gt/gt (B). *p<0.05 by one-way ANOVA followed by 
Bonferroni test, n=3. Results are shown +/- s.e.m. 
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6.8 BDNF signalling in Bicd1gt/gt MNs 
 The finding that the levels of p75NTR and TrkB at the PM are altered at steady 
state in Bicd1gt/gt MNs, resulting in an increased exposure of these receptors on the 
neuronal surface, suggests that p75NTR and TrkB signalling in Bicd1gt/gt cells might also 
be affected. For this reason I decided to stimulate MNs derived from wild type, and 
Bicd1gt/gt ES cells with 100 ng/ml of BDNF and assay for the activation of ERK1/2 and 
Akt by western blotting. 
 In collaboration with Dr. M. Golding in the laboratory, the kinetic of activation 
of ERK1/2 and Akt upon BDNF stimulation after 5 hours of starvation were 
established. The levels of phosphorylation of ERK1/2 and Akt were determined (Figure 
6.11 A & 6.12 A) and normalised to the total levels of the corresponding protein 
(Figure 6.11 B & 6.12 B) from three independent experiments. 
Akt seemed to have a peak of phosphorylation 10 minutes after stimulation with 
BDNF in wild type MNs; after that time point the phosphorylation decreases 
progressively (Figure 6.11 B). The same overall trend was observed in Bicd1gt/gt MNs, 
but the intensity of the peak at 10 minutes was less than half compared to wild type 
cells, and the decrease of phosphorylation was less pronounced compared to their wild 
type counterpart (Figure 6.11 B). An initial peak of ERK1/2 phosphorylation was 
observed at 10 minutes and then, the levels of phosphorylation decreased progressively 
in wild type MNs (Figure 6.12 B). The same overall behaviour was observed in 
Bicd1gt/gt MNs, however the intensity of the peak was much lower (p < 0.05, one-way 
ANOVA, followed by Bonferroni test, n=3) (Figure 6.12 B). 
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Figure 6.11. Kinetics of Akt phosphorylation in Bicd1gt/gt MNs in response to BDNF stimulation. 
Wild type, Bicd1gt/+ and Bicd1gt/gt MNs were starved for 5 hours and stimulated with 100 ng/ml. The cells 
were then lysed at several time points and analysed by western blot for the levels of pAkt (S473) and total 
Akt (A). Densitometric analysis of pAkt bands was performed using Image J. The levels of pAkt (S473) 
normalised to the levels of total Akt from three independent experiments are plotted (B). The activation 
of pAkt (S473) in Bicd1gt/gt MNs is statistically significantly reduced compared to wild type MNs (two 
ways ANOVA, p<0.0001). Results are shown +/- s.e.m.  
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Figure 6.12 Kinetics of ERK1/2 phosphorylation in Bicd1gt/gt MNs in response to BDNF stimulation. 
Wild type, Bicd1gt/+ and Bicd1gt/gt MNs were starved for 5 hours and stimulated with 100 ng/ml of BDNF. 
The cells were then lysed at several time points and analysed by western blot for the levels of pERK1/2 
and total ERK1/2 (A). Densitometric analysis of pERK1/2 bands was performed using Image J. The 
levels of pERK1/2 normalised to the levels of total ERK1/2 from three independent experiments are 
plotted (B). The activation of pERK1/2 in Bicd1gt/gt MNs is reduced compared to wild type MNs (two 
ways ANOVA, p<0.0001). Results are shown +/- s.e.m. 
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6.9  Bicd1 expression pattern in mouse development 
 I decided to try to use the Bicd1 gene trapped mouse ES cells to derive a mouse 
since no mutant Bicd1 mice have been described in the literature. The transgenic 
department at CR-UK performed a series of 8-cell injections using 2 lines of Bicd1gt/+ 
mouse ES cells (the RRP27 and the C4 ES cell clones, also purchased from the 
International Gene Trap Consortium). Unfortunately, no viable pup was obtained with 
any of the ES cell clones. The 8-cell injection technique differs from a conventional ES 
cell transfer, because the ES cells are not injected into the blastocyst but when the 
embryo reaches the 8-cell stage. The result of this new approach is the generation of 
embryos that are entirely derived from the injected ES cells (Poueymirou et al., 2007). 
This feature allowed me to obtain E12.5 and E13.5 Bicd1gt/+ embryos to use to test the 
expression pattern of Bicd1. X-Gal staining (Materials and Methods, section 2.2.7.1) 
was performed on 12.5 and E13.5 Bicd1gt/+ embryos in collaboration with Bradley 
Spencer-Dene in the Histopathology unit at the CR-UK and Bicd1 was found expressed 
almost exclusively in the nervous system (Figure 6.13). No staining could be detected 
earlier than E11.5, when it started to be visible, though weak. After E13.5 Bicd1 
expression was no longer detectable in the nervous system and became more diffuse. 
 At E11.5 and E12.5 Bicd1 was expressed primarily in the spinal cord and in 
brain (Figure 6.13 A-C), while at E13.5, Bicd1 expression was detected mainly in 
dorsal root ganglia neurons (DRG) (Figure 6.13 D, E, F).  
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Figure 6.13 Expression pattern of Bicd1 in mouse development. 
β-gal histochemistry of mouse embryos at different embryonic days from E12.5 (A-C) to E13.5 (D-F). 
Bicd1 expression seems generally to be resticted to the nervous system. Side (A), back (B) and front (C) 
view of an E12.5 mouse embryos generated from Bicd1gt/+ ES cells . Bicd1 is expressed in the CNS, in 
the spinal cord (SC, black arrow) and in the brain. At E13.5 the expression of Bicd1 is predominant in 
DRG (black arrows), as it is appearent from the side (D), back (E) and front (F) view. 
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Summary of the achievements presented in this Chapter 
 
• BICD1 was selected for further investigation and MNs generated using a 
Bicd1 gene-trapped ES cell line were characterised; 
 
• 70% reduction in BICD1 protein levels did not affect the differentiation 
of Bicd1gt/gt ES cells into MNs; 
 
• Bicd1gt/gt MNs displayed a higher intracellular accumulation of HC and 
the p75NTR antibody compared to wt MNs; 
 
• The reduction in BICD1 protein caused an increased localisation of 
p75NTR, TrkB and GD1b to the neuronal plasma membrane; 
 
• In Bicd1gt/gt MNs, BDNF signalling via TrkB was altered, resulting in an 
decreased activation of ERK1/2 and Akt compared to wild type cells; 
 
 
• Bicd1 was found to be expressed primarily on the nervous system 
between embryonic day 11.5 and 13.5.
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Chapter 7. Discussion 
7.1 Set up for an RNAi screen in MNs. 
RNAi screens have become increasingly popular because of the unique 
opportunity they offer to discover new players in a particular pathway of interest. With 
the introduction of complex algorithms for image analysis, it is now possible to extract 
more high content data from image-based screens, allowing for more refined answers. 
As such, an siRNA screen can be set up to look at the behaviour of several fluorescently 
labelled probes at the same time in accordance with several parameters, like cellular 
localisation, fluorescence intensity and colocalisation with different interacting partners 
(Krausz, 2007). A recent work constitutes an extreme example of the complexity of the 
image analysis available nowadays (Collinet et al., 2010). In this case, the whole 
genome was screened to find players involved in the endocytosis of transferrin and 
epidermal growth factor. The readout was provided by a complex algorithm of 
multiparametric image analysis, which allowed the authors to build up a map of genetic 
interactions on the basis of the phenotypes observed in the screen.  
The goal of my thesis was to apply concept and technology of high content 
screening (HCS, Introduction, section 1.3) to investigate neurotrophin trafficking in a 
relevant physiological cellular system, i.e. MNs, in order to find new players in this 
biological process. I will discuss here some of the decisions taken when designing the 
siRNA screen. 
7.1.1 Choice of the cell system. 
Historically, the Molecular Neuropathobiology (MNP) laboratory has been 
interested in characterising the process of axonal retrograde transport of neurotrophins 
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and their receptors. They also made use of a probe, the binding fragment of TeNT (HC), 
which has been shown to share the same route of axonal retrograde transport (Deinhardt 
et al., 2006b). The field of axonal retrograde transport has gained further importance 
after the formulation of the “signalling endosome” theory, whereby endosomes 
transported retrogradely along the axon constitute a platform for neurotrophin signalling 
(Grimes et al., 1997, Grimes et al., 1996). This theory provided a concept to explain the 
association with certain neurodegenerative diseases, such as Amyotrophic Lateral 
Sclerosis ALS (Strom et al., 2008) and Alzheimer’s disease (Schindowski et al., 2008), 
with feature defects in axonal retrograde transport. A physiologically relevant cell type 
to investigate HC and neurotrophin trafficking are MNs, because survival of these cells 
is ensured in vivo by the neurotrophins secreted by their target muscles, with the 
neurotrophins being retrogradely transported to the cell soma (Bronfman et al., 2007). 
In addition MNs constitute the only physiological route of infection for TeNT, which is 
taken up by the NMJ and transported to the spinal cord, where it enters the inhibitory 
interneurons and prevents neurotransmitter release (Lalli et al., 2003, Salinas et al., 
2010). Consequently, I aimed to use MNs as a cellular platform to perform the siRNA 
screen, despite the difficulties in adapting primary cells to the format required for HCS.  
The first problem to solve was to be able to generate enough cells to perform the 
screen and to minimise the cell heterogeneity inherent in the dissection and culture of 
ventral horn preparations of the spinal cord. Primary MN cultures are also 
“contaminated” with other neuronal populations, which makes it difficult to identify 
MNs, especially in the context of a high-throughput screen, where cell identification is 
performed by the software. Working with a mixed population of neurons is therefore far 
from optimal and will affect the reproducibility of the assay and ultimately diminish the 
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chances of generating reproducible data. To solve this problem, transgenic mouse ES 
cells were chosen to generate MNs for the siRNA screen. These cells were engineered 
by Wichterle and colleagues to express GFP under the control of the MN specific Hb9 
promoter, which allows the visualisation of MNs after differentiation (Wichterle et al., 
2002). Using this ES cell line it was possible to easily scale up the production of MNs 
with the major advantage of being able to identify a homogeneous population of 
fluorescent MNs for the analysis. To differentiate the Hb9-GFP ES cells into MNs, I 
adapted the original protocol developed by Wichterle and co-workers. In the paper the 
yield of MNs was around 50%, whilst using this new improved protocol, I found that 
more than 80% of all cells in the embryoid bodies (EBs) were expressing GFP, as 
quantified by cytofluorimetric (FACS) analysis. Additionally, I found that the peak of 
MN specification in the EBs was at 4 days after addition of SAG and retinoic acid 
(RA), while in the original protocol the peak was at 5 days. This acceleration in MN 
specification was maybe due to an increased potency of the Sonic Hedgehog agonist 
that we used.  
7.1.2 Transfection method 
 In parallel with establishing a reliable protocol of differentiation of ES cells into 
MNs, I also optimised an efficient protocol for siRNA downregulation in MN cultures. 
Previous attempts in the laboratory to transfect MNs using lipid-based transfection 
reagents such as Lipofectamine 2000 were largely unsuccessful, resulting in a low yield 
of transfection, an overall high toxicity and impairment of axonal transport (Deinhardt 
and Schiavo, 2005). It was then decided to adopt an alternative approach, such as 
electroporation, which had been successfully applied to primary cells and in particular 
has been used for MNs by Arnauld Jacquier and colleagues (Jacquier et al., 2006). I 
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tried two different electroporation systems, the PA-4000/PA-96 WS Pulse AgileR and 
the BTX ECM 830, which were designed to electoporate cells in a 96 well format. As 
discussed in Chapter 3 (section 3.3.1), efficient transfection could never be obtained 
using these systems with the parameters suggested by the supplier or those used by 
Jacquier and colleagues (Chapter 3, Table 3.1). The major problem with this 
transfection method, especially considering its application for HCS, was the complex 
handling procedure, which resulted in high cell mortality. Following these results, 
electroporation was abandoned, because it was ineffective and impractical for the 
purpose of the siRNA screen. I therefore decided to test a few lipid–based transfection 
reagents in primary MN cultures for their ability to transfect siRNA targeting VAMP2. 
This protein was chosen because of its abundance in neurons and the fact that its 
depletion does not affect neuronal viability (Schoch et al., 2001). As discussed in 
Chapter 3 (section 3.3.1), Dharmafect 3 initially proved to be effective in knocking-
down VAMP2 in primary MNs (Figure 3.3) with a traditional forward transfection 
protocol in a 24 well plate format, and showed no toxicity. The transfection efficiency, 
though, dropped once the batch of reagent was changed and, when the VAMP2 
knockdown was attempted in a 96 well format, Dharmafect 3 proved completely 
ineffective. At this point, I decided to abandon the standard forward transfection in 
favour of a reverse transfection protocol, which considerably reduced the handling time 
and better suited the needs of an siRNA screen. Together with the high throughput 
screening facility at CRUK, I screened 23 different lipid-based transfection reagents in 
primary MNs for their ability to induce knockdown of VAMP2 directly on a 96 well 
plate and with a reverse transfection protocol (Chapter 3, Table 3.2), and finally 
narrowed down the best transfection reagent to Dreamfect Gold (Figure 3.6). Wary of 
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past experiences, a batch of the reagent was tested and a large quantity of the same 
batch was ordered to cover the needs of the screen and the subsequent validation. 
7.1.3 Imaging and software analysis 
 I wanted an image-based readout for the siRNA screen, as a way to directly 
visualise the intracellular trafficking of the fluorescently labelled HC and the antibody 
directed against the extracellular domain of p75NTR. In order to achieve this goal, I 
needed means to acquire images with high enough resolution to allow the visualisation 
of the probes and to develop an algorithm of image analysis to quantify the data 
(Chapter 3, section 3.4.2). I described the initial attempts I made with the 
ARRAYSCAN imaging system, which is a microscope expressly designed for HCS 
(Krausz, 2007), and discussed the reasons why the use of this system was finally 
abandoned in favour of a confocal microscope (Chapter 3, section 3.4.1). 
 Confocal microscopy offered very high image resolution, but acquisition times 
were longer than for the ARRAYSCAN imaging system. However, the size of the 
siRNA library I intended to use for the screen was small (155 genes), so the automated 
acquisition capability of the Zeiss 510 confocal was more than adequate for the task. In 
order to be able to utilise the 40X oil objective lens I had to resort to the using glass 
bottom 96 well plates and to brush the immersion oil all over the bottom of the plates. 
This was the only way to obtain images with an high enough resolution to enable the 
identification of single HC and p75NTR positive endosomes with the Cell Profiler 
software. The confocal automatic acquisition was made possible by the use of the MTS 
macro, designed for this purpose (discussed in Chapter 3, section 3.4.2), and the GFP 
fluorescence of MNs derived from Hb9-GFP ES cells (Wichterle et al., 2002). The 
autofocus function could not rely on nuclear staining, as is usually the case in image-
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based HCS, because MN cultures contain several other cell types, such as glia and 
fibroblasts, which grow underneath the neurons and would cause the microscope to 
focus on a completely irrelevant plane. In addition, MNs tended to converge in clumps, 
which extended in the Z axis for several planes of focus. This problem could only be 
solved by acquiring many series of Z-stacks, which would not have been possible with 
any of the standard epifluorescence image acquisition systems designed for HCS. For 
unknown reasons, the tendency of MNs to clump represented a serious problem in a 96 
well format. Standard forward transfection seemed to stress MNs probably because of 
the repeated changing of the medium and the handling required, whereas the reverse 
transfection protocol proved to be beneficial in alleviating the clumping of MNs and 
had no obvious adverse effects on cell viability or morphology.  
 Cell Profiler was chosen as the software for image-quantification, because it 
proved to be excellent for the recognition of cell morphology and spot identification, 
and also versatile, enabling me to easily extract features from the images such as the 
number of endosomes positive for HC or p75NTR for individual MN (for a discussion of 
the image-analysis pipeline see Chapter 3, section 3.4.2).  
7.1.4 Read-out 
 I required an assay which would be relevant to the investigation of neurotrophin 
trafficking, but which would also not involve many manipulations and be easy to scale 
up. I therefore opted to incubate the cells with HC and the p75NTR antibody for two 
hours at 370C, followed by an acid wash, in order to be able to visualise exclusively the 
internalised pool of the two proteins (Chapter 4, section 4.2). The reason for choosing 
an end-point of 2 hours is related to the use of the EHNA inhibitor as an internal control 
for the assay. EHNA is a well-established dynein inhibitor (Penningroth et al., 1982, 
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Reynolds et al., 1998, Lalli et al., 2003), and it served as a proof of principle that the 
inhibition of a retrograde molecular motor affects the readout of the screen, which was 
an important point, since the siRNA library I intended to use was a molecular motor and 
adaptor library. EHNA inhibits the accumulation of both HC and the p75NTR antibody 
(Chapter 4, Figure 4.1), but while EHNA affected the accumulation of HC from the 
very beginning in a progressive fashion, it did not seem to affect the accumulation of 
the p75NTR antibody until 75 minutes. The different effects on the accumulation of the 
two probes suggests a different mechanism of endocytosis and trafficking: in the case of 
HC, dynein seemed to be involved from the very beginning, however in the case of 
p75NTR there seemed to be a dynein-independent pool that was predominant up until 75 
minutes. After that time point the dynein-dependent component gave a significant 
enough contribution to the total accumulation of the probe to reveal a difference in 
EHNA-treated MNs. Interestingly, a previous study showed that the onset of axonal 
retrograde transport of HC is around 45 minutes and p75NTR colocalizes with HC 
predominantly in endosomes, which are transported along the axons, while very little 
localisation was seen in the somatodendritic compartment (Lalli and Schiavo, 2002). 
Finally, as reported in Figure 4.1, HC induced a higher accumulation of the p75NTR 
antibody and the curve of accumulation of this probe in the absence of HC overlapped 
with the curve of the p75NTR antibody incubated together with HC and in the presence of 
EHNA. It is tempting to speculate that in the absence of HC, the accumulation of the 
p75NTR antibody is indicative of the internalisation and recycling of the receptor at 
steady state, which is dynein-independent, while the addition of HC triggers a dynein-
mediated internalisation and transport of a different pool of p75NTR. Previous findings 
from the laboratory showed that HC is capable of eliciting the axonal retrograde 
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transport of the p75NTR antibody (Deinhardt et al., 2007); it is therefore likely that 
EHNA inhibits the axonal retrograde transport of the p75NTR and its consequent 
accumulation in the neuronal cell bodies.  
 It has been shown that HC binds to GT1b (Rummel et al., 2003) and that p75NTR 
forms a complex with this ganglioside (Fujitani et al., 2005, Williams et al., 2008). In 
this light it is possible that HC induces the clustering of GT1b, causing the accumulation 
of GT1b-bound p75NTR in HC and GT1b-enriched clathrin-coated pits feeding to the 
axonal transport route. In support of this hypothesis, p75NTR in the absence of ligand 
undergoes clathrin-independent recycling at the PM (Deinhardt et al., 2007). In such 
conditions no axonal retrograde transport of p75NTR was observed (Deinhardt et al., 
2007). Addition of neurotrophins, such as NGF, or HC redirects a pool of the receptor to 
a dynamin and clathrin-dependent route of internalisation coupled to axonal retrograde 
transport (Deinhardt et al., 2007). It is plausible that the route of internalisation of HC 
connected to its axonal retrograde transport and the one used by ligand stimulated 
p75NTR, which are both dynamin and clathrin-dependent (Deinhardt et al., 2006a) 
(Deinhardt et al., 2007), are the same. TeNT would in-fact benefit from taking 
advantage of a pre-existent axonal retrograde transport route. In this respect the axonal 
retrograde transport of the p75NTR antibody induced by HC would mimic the 
physiological process that the receptor normally undergoes when it is stimulated by its 
physiological ligand NGF. 
7.1.5 The screen 
The molecular motor and adaptor siRNA library was chosen because the 
laboratory is interested in molecular motors, for which the expertise and a set of 
reagents and constructs are already available. In addition, Qiagen offered us the 
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possibility to customise the library, so that many genes of interest for the laboratory 
could be added, including many adaptors such as some of the Rab GTPases.  
 The layout of the plates and the procedure of the screen have already been 
described in Chapter 4, Figure 4.2. Importantly, I set up a series of additional controls, 
i.e. a few wells treated with a non targeting siRNA negative control and a few treated 
with the EHNA inhibitor. The calculation of the Z-scores, described in section 4.3.2, 
takes into account the distribution of the whole population. The scattering of the 
negative controls gives an indication of the variability of the assay. Ideally, negative 
controls should cluster in the middle of the population curve, were the siRNAs which 
do not affect the read out should be located. There are no precise rules about where to 
set the threshold to decide which samples should be considered as hits. Generally, 
setting the value of the threshold Z-score depends on the range of the assay used, i.e. 
how many standard deviations a true hit is expected to differ from the mean of the 
population. Certain types of screens, i.e. those based on luciferase activity, have a range 
of 40-50 standard deviations from the mean, while imaged-based screens generally have 
a much smaller range. Ultimately, the threshold I chose for both probes was not very 
stringent (Chapter, section 4.3.3.). However, this was not problematic because of the 
small size of the library, which yielded only very few primary hits to validate compared 
to the hundreds normally expected in a HCS. Not surprisingly, therefore, only 9 
candidates out of the 44 primary hits were confirmed in the validation re-screen 
(Chapter 4, section 4.4.2).  
7.1.6 Validated candidates  
 Among the validated candidates, the only protein that seemed to increase the 
accumulation of HC when knocked-down was BICD1, while the only one to have a 
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similar effect in the trafficking of p75NTR was RAB7. RAB7 is a marker of late 
endosomes, MVBs and lysosomes (Stenmark, 2009) and a key regulator of the 
trafficking to late endosomes and lysosomes (Feng et al., 1995, Mukhopadhyay et al., 
1997, Vitelli et al., 1997, Bucci et al., 2000, Lebrand et al., 2002). It was also found to 
be crucial in the axonal retrograde transport of HC and p75NTR (Deinhardt et al., 2006b), 
since overexpression of a dominant negative version (RAB7N125I) inhibited the axonal 
retrograde transport of the two probes.  In addition, RAB7 has been found to be 
involved in the regulation of EGF receptor (EGFR) trafficking to late endosomes and its 
degradation (Ceresa and Bahr, 2006). The effects caused by RAB7 knockdown 
observed in the screen do not seem to be due to the an interference with the axonal 
retrograde transport of the p75NTR, in which case the prediction would have been a 
reduced accumulation in the cell soma of the probe rather than an increased one. At the 
same time, HC and the p75NTR have been described to share the same route of axonal 
retrograde transport (Lalli and Schiavo, 2002) (Deinhardt et al., 2006b), therefore 
interfering with this process would affect the two probes equally, which is not the case, 
since RAB7 was found as a candidate only for the p75NTR antibody. It might therefore 
be possible that the lack of RAB7 affected the trafficking of the p75NTR antibody 
internalised in the soma and dendrites, maybe preventing the probe from being directed 
to lysosomal degradation, thus determining its intracellular accumulation. Similar 
considerations are also relevant for BICD1, which only affected HC, and will be 
discussed extensively in the next sections. Interestingly, mutations of RAB7 has been 
involved in the pathogenesis of Charcot–Marie–Tooth type 2B (CMT2B) (Verhoeven et al., 2003, Houlden et al., 2004, Meggouh et al., 2006), an  inherited neuropathy that affects peripheral nerves (Jaradeh, 2003). The molecular mechanism by which 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RAB7 mutations  cause  the  disease  is  still  unclear.  Several  hypothesis,  including disruption of axonal transport, however, have been formulated (Cogli et al., 2009). Intriguingly, RAB7 is ubiquitously expressed, suggesting that this protein has a set of functions specific for few neuronal subtypes, since only the peripheral nervous system is affected by the CMT2B mutants. 
  The knockdown of Dcnt1, the p150 subunit of Dynactin, caused a decrease in 
the accumulation of HC, which could be linked to a role of cytoplasmic dynein as a 
facilitator of HC endocytosis. This would be consistent with the inhibition of the 
intracellular accumulation of HC obtained in the presence of EHNA (Figure 4.1). The 
inhibition of endocytosis after treatment with EHNA is not exclusive to HC, but it also 
extends to the internalisation of the p75NTR antibody (Figure 4.1). Again, Dcnt1 was not 
picked up as a candidate affecting the trafficking of p75NTR, suggesting that its action 
might be connected to the interaction with a specific component of the dynein complex, 
rather than interfering with the complex as a whole. Interestingly, BICD1 has been 
described to interact with cytoplasmic dynein (Hoogenraad et al., 2001). As described 
for RAB7, mutations of p150 were shown to cause neurodegenerative conditions in 
humans and mice, such as amyotrophic lateral sclerosis (ALS) (Munch et al., 2004) and lower motor neuron disease (Puls et al., 2003) (Levy et al., 2006, Olkkonen and Ikonen, 2006). 
 A few kinesin motors were found in the screen to inhibit the accumulation of HC 
and the p75NTR antibody when knocked down. This might be due to the fact that this 
family of motors transports cargoes towards the cell periphery and might therefore be 
involved in the transport of neurotrophin receptors to the PM. Notably, a kinesin-1-
dependent mechanism of anterograde transport of Trk receptors and p75NTR complexed 
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with the scaffolding protein Kidins220, has been hypothesised (Bracale et al., 2007). A 
decreased level of p75NTR exposed at the neuronal surface, caused by the impairment of 
a possible kinesin-dependent transport of the receptor to the PM, might explain the 
decreased accumulation of the p75NTR antibody phenotypes found in the siRNA screen. 
Interestingly, as for RAB7 and p150, some kinesin motors have also been implicated in 
the pathogenesis of neurodegenerative conditions, such as KIF1B in the case of 
CMT2A disease (Zhao et al., 2001) and KIF5A for hereditary spastic paraplegia (Reid 
et al., 2002, Olkkonen and Ikonen, 2006). 
 One of the strongest and most interesting candidates resulting from the screen 
was BICD1. Upon its down-regulation, HC was found to accumulate in MN cell bodies 
in a perinuclear region. BICD1 was initially described as a microtubule-associated 
dynein adaptor, and was also hypothesised to play a role in axonal transport in neurons 
(Wanschers et al., 2007). Given its role in regulating dynein-dependent traffic, which is 
essential for neurotrophin axonal transport (Lalli et al., 2003) (Hafezparast et al., 2003) 
(LaMonte et al., 2002), I decided to concentrate my efforts on this candidate.  
7.2 Characterisation of Bicd1 gene trapped ES cells. 
I had the opportunity to take advantage of a genetic model generated by Krzysztof 
Wicher in David Ish-Horowicz laboratory at CRUK. Krzysztof purchased the RRP27 
Bicd1 gene trapped ES clone from The Gene Trap International consortium and kept it 
under high G418 concentration to bring it to homozygosity (Materials and Methods, 
section 2.2.4.7). As reported in Chapter 6 (section 6.4.2), Bicd1gt/gt MNs expressed less 
than 30% of the Bicd1 transcript compared to wild type cells (Figure 6.2 C). The 
reason why a complete ablation was not obtained is due to inherent ‘leakiness’ of the 
gene trapping strategy (Stanford et al., 2001). Confirming the Q-PCR data, 
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approximately 30% of the BICD1 protein was still present in Bicd1gt/gt MNs (Figure 6.2 
C). The reduction of BICD1 protein levels using this genetic model was equivalent to a 
robust knockdown. A caveat of this approach is that the depletion of BICD1 might 
compromise and/or alter the differentiation potential of the ES cells. As presented in 
Chapter 6 (section 6.4.1), culture of MNs differentiated from Bicd1gt/gt ES cells 
appeared morphologically normal. However fewer glial cells were found in the mutant 
culture. Furthermore, Bicd1gt/gt MNs were found to have a reduced lifespan. It was 
essential to determine that the expression of MN specific markers such as HB9 and 
ChAT was unaltered in Bicd1gt/gt MNs. The Q-PCR data confirmed that this was indeed 
the case (Figure 6.2 C). Remarkably, the level of expression of Bicd2 was substantially 
increased in Bicd1gt/gt MNs (Figure 6.2 C), suggesting these cells tried to compensate 
for the depletion of BICD1 up-regulating the related Bicd2 gene. However, upregulation 
of Bicd2 expression is not able to fully compensate for the reduction in BICD1 levels, 
suggesting that the functions of BICD1 and BICD2 are not redundant in MNs.  
7.2.1 BICD1 is expressed in the nervous system during mouse 
development 
Little is known about the expression pattern of the Bicd family during mouse 
development, with the exception of Bicdr1, a Bicd-related protein, which is highly 
expressed at E10. At this embryonic day its distribution seems to be restricted to the 
nervous system, particularly to DRG, mesencephalon and romboenchephalon (Schlager 
et al., 2010). Given the absence of a mouse model to study the function of BICD1 in 
vivo, I decided to take advantage of the Bicd1 gene-trapped mouse ES cells to generate 
one.  
The results of t
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context of intracellular trafficking and signalling of neurotrophin receptors in neurons. 
Reassuringly, between E12.5 and E13.5 the expression of Bicd1 was indeed restricted to 
the nervous system  (Figure 6.13). At E12.5, Bicd1 was found in the spinal cord and in 
the forebrain, while at E13.5 it started to disappear from those regions and the β−gal 
staining labelled prevalently DRGs and the hindbrain (Figure 6.13). This pattern of 
expression suggests that BICD1 plays an important role in neurons. Importantly, what is 
known so far for mammalian BICD1 and BICD2 derives primarily from studies 
conducted on cancer cell lines, which might not be the most physiologically relevant 
cell type to investigate the role of BICD1. Simon Bullock’s group recently published a 
paper on the function of Drosophila BICD in neurons (Li et al., 2010). Interestingly, 
they showed that zygotic BICD function is only obligatory in the nervous system and 
that BICD is involved in transporting clathrin heavy chain back to the plasma 
membrane at synaptic sites in order to sustain synaptic vesicle recycling under 
prolonged electrical stimulation. This function of BICD might be conserved in 
mammalian cells, however it is probably not related to the phenotype I observed in the 
screen, because neither of the probes I used, HC and p75NTR, has been described to enter 
MNs via synaptic vesicle recycling. Also the study of Li and colleagues showed that 
BICD function becomes essential under conditions of sustained stimulation  (Li et al., 
2010), while the MN cultures I used were maintained in resting conditions. In addition, 
Li and colleagues showed that depletion of BICD determined an inhibition of 
endocytosis, which contrasts with my study where down-regulation of BICD1 during 
the screen and in Bicd1gt/gt MNs caused an accumulation of HC and the p75NTR antibody 
(Figure 6.4 & 6.5), indicating that the endocytosis of the probes was not impaired. 
Finally, there is also the possibility that the function described by Li and colleagues in 
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Drosophila is played in mammalian neurons by BICD2 and not BICD1.  
7.2.2 BICD1 depletion does not affect axonal retrograde transport. 
 Wanschers and colleagues hypothesised a role for mammalian BICD1 in 
retrograde transport on the basis of their finding that BICD1 – RAB6B double positive 
vesicles underwent bidirectional movements in neurites of differentiated SK-N-SH 
neuroblastoma cells (Chapter 5, section 5.4.5, (Wanschers et al., 2007)). It is tempting 
to speculate that BICD1 might have a role in axonal transport because it is an adaptor 
for the dynein-dynactin complex, which is essential for neurotrophin and HC axonal 
retrograde transport (Hafezparast et al., 2003, Lalli et al., 2003) (LaMonte et al., 2002). 
However, the increased accumulation of HC after knockdown of Bicd1 was unlikely to 
be related to defects in axonal retrograde transport, as a decreased accumulation of the 
probe travelling from the periphery of the neuronal network would be expected in this 
case.  
 Axonal retrograde transport of HC or NGF-stimulated p75NTR in wild type, 
Bicd1gt/+ and Bicd1gt/gt MNs was analysed. However, no difference in the speed 
distribution curves of these probes was noticeable (Figure 6.3). This finding also offers 
a further confirmation that the neuronal populations derived from ES cells from the 
three genotypes were indeed similar. Consequently, it does not appear that BICD1 has a 
role in axonal retrograde transport, unless the residual levels of this protein were 
sufficient to support this process. Alternatively, the increased levels of BICD2 might be 
able to compensate for the lack of BICD1 in this context. Interestingly, BICD2 has been 
related to the anterograde transport of RAB6A positive vesicles (Grigoriev et al., 2007), 
however no interaction with the neuronal RAB6B isoform has been described to date.  
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7.2.3 BICD1 depletion induces accumulation of HC and p75NTR and HC 
accumulates in immature MVB in Bicd1gt/gt MNs 
 The HC accumulation phenotype observed in the siRNA screen was confirmed 
in Bicd1gt/gt MNs (Figure 6.4 A). Interestingly, Bicd1gt/+ MNs also showed a tendency 
to accumulate HC at higher levels than the wild type cells, but this was not statistically 
significant (Figure 6.4 A). Strickingly, the p75NTR antibody when co-incubated with HC, 
was also found to accumulate more in Bicd1gt/+ and Bicd1gt/gt MNs (Figure 6.4 B). This 
result is not consistent with what was observed during the siRNA screen, where the 
knockdown of BICD1 did not affect the trafficking of the p75NTR antibody. This 
difference might be the result of a greater depletion of BICD1 in the case of the gene-
trapped model compared to the siRNA knockdown.  
 In order to make a comparison with the trafficking of p75NTR triggered by a 
physiological ligand, the intracellular accumulation of the antibody upon BDNF 
stimulation was tested, and it was found to be 3 fold higher in Bicd1gt/gt than in wild 
type MNs (Figure 6.5 B). This finding suggests that BICD1 might play a role in the 
intracellular trafficking of the p75NTR upon stimulation with its physiological ligand in 
MNs. After internalisation, p75NTR is thought to prevalently recycle back to the PM 
((Bronfman et al., 2003) (Deinhardt et al., 2006b), Figure 7.1), while TeNT undergoes 
sorting in MN cell bodies and is redirected to the plasma membrane to be transcytosed 
((Salinas et al., 2010), Figure 7.1). It is possible that BICD1 depletion causes an 
accumulation of the two probes because of a modification of a normal endosomal 
sorting mechanism. In this light, our EM data demonstrated an increased accumulation 
of gold-labelled HC in immature MVBs, with a low content of intraluminal vesicles, in 
Bicd1gt/gt MNs (Figure 6.6). The number and the size of these immature MVBs were 
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increased in Bicd1gt/gt MNs, suggesting that the depletion of BICD1 inhibited the 
maturation of this organelle (Figure 7.2), causing the intracellular accumulation of 
these structures and of the probe inside them. Interestingly, HC displayed a polarised 
distribution inside Bicd1gt/gt MVBs, clustering on one side of the delimiting membrane. 
This distribution is maybe an indication of the probe accumulating in preparation for a 
potential sorting back to the plasma membrane (Figure 7.2).  
Although the EM data have been obtained using HC, it is possible to speculate 
that what appears to be a general inhibition of the maturation of MVBs would also 
affect the intracellular trafficking of p75NTR and TrkB. TrkB has been described to 
mainly be sorted to the degradative route, while a smaller pool of the receptor enters the 
recycling pathway ((Chen et al., 2005)  (Bronfman et al., 2007, Huang et al., 2009), 
Figure 7.1). Depletion of BICD1 might prevent the maturation of the MVBs resulting 
in an inhibition of the degradative pathway and a consequent intracellular accumulation 
of the pool of TrkB receptor destined for degradation. In the absence of ligands, p75NTR 
has been described to mainly undergo recycling back to the plasma membrane in PC12 
cells (Bronfman et al., 2007) and in neurons ((Deinhardt et al., 2007), Figure 7.1). 
However, p75NTR internalisation becomes clathrin-dependent upon binding with its 
ligand or when incubated with HC and in MNs this results in the retrograde transport of 
the receptor in the same compartment as HC ((Deinhardt et al., 2007), Figure 7.1). It is 
therefore possible that p75NTR accumulation upon stimulation with NGF in Bicd1gt/gt 
MNs is caused by an MVB maturation defect caused by the depletion of BICD1, which 
might prevent p75NTR from undergoing its physiological trafficking and sorting (Figure 
7.2). Interestingly, MVBs have been found to be the main endosomal population in 
sympathetic neuron cell bodies labelled with iodinated NGF (ligand of both TrkA and 
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p75NTR) (Claude et al., 1982), and Trk receptors were found associated with MVBs 
(Valdez et al., 2005). 
7.2.4 BICD1 depletion affects the levels of TrkB and p75NTR on the PM 
and alters TrkB signalling  
Ligand-bound p75NTR and TrkB, which are unable to progress along the 
degradative route in Bicd1gt/gt MNs are likely to be redirected on the PM. To confirm 
this hypothesis, the levels of TrkB and p75NTR exposed at the PM were indeed found to 
be significantly higher in Bicd1gt/gt MNs (Chapter 6, section 6.8.3, Figure 6.9 and 6.10). 
This is particularly relevant for TrkB, because it is expressed at lower levels in Bicd1gt/gt 
MNs than in wild type cells (Figure 6.2 C), which indicates that a higher proportion of 
TrkB must be redirected to the PM in mutant cells. In the case of p75NTR, the depletion 
of BICD1 is expected to affect only the pool of the receptor that undergoes ligand-
triggered internalisation, because this receptor is already thought to undergo mainly the 
recycling route to the PM in the absence of ligands. Surprisingly, though, p75NTR levels 
on the PM in Bicd1gt/gt MNs were double that of wild type cells even without the 
addition of BDNF. However, MN cultures also contain glial cells, which are likely to 
secrete neurotrophins into the medium (Levi-Montalcini et al., 1996) (Roux and Barker, 
2002), and neurons themselves secrete neurotrophins (Roux and Barker, 2002). 
Consequently, p75NTR ligand-triggered internalisation and redirection to the degradative 
route might happen normally in culture, resulting in a increased exposure of the receptor 
on the Bicd1gt/gt MN surface compared to wild type cells, determined by the redirection 
of the ligand-bound pool of the receptor (Figure 6.9). This hypothesis could be tested 
by analysing the conditioned media from MN cultures for secreted neurotrophins such 
as BDNF. Intriguingly, p75NTR protein levels of at steady state were higher in Bicd1gt/gt 
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MNs (Figure 6.2 B), yet the gene was expressed at wild type levels (Figure 6.2. C), 
supporting the idea that the degradative pathway of the receptor is impaired. 
Interestingly, RAB7 was found to induce increased accumulation of the p75NTR 
antibody in the siRNA screen (section 7.1.6), suggesting that blocking late endosome 
maturation does indeed cause the intracellular accumulation of p75NTR. No further 
characterization was done for RAB7, but it will be important to check whether RAB7 
knockdown phenocopies BICD1 depletion in terms of an increased exposure of the 
p75NTR on the PM.  
I wanted to test if the altered intracellular distribution of p75NTR and TrkB in 
Bicd1gt/gt MNs would also affect TrkB signalling. In collaboration with Matthew 
Golding in the laboratory, we assessed the phosphorylation kinetics of Akt and ERK1/2 
upon BDNF stimulation. A decrease in activation of these proteins was observed in 
Bicd1gt/gt MNs compared to the wild type control (Figure 6.11 and 6.12). An alteration 
of TrkB signalling due to changes in its intracellular localisation is reported in the 
literature: overexpression of hepatocyte growth factor-regulated tyrosine kinase 
substrate (Hrs) in PC12 cells causes the redirection of TrkB to the recycling route, 
determining a more sustained ERK1/2 activation upon BDNF stimulation (Huang et al., 
2009). A similar behaviour has also been described for another Trk receptor, TrkA, in 
that inhibiting the degradative pathway of the receptor resulted in endosomal 
accumulation of TrkA with a consequent increase in ERK1/2 activation (Saxena et al., 
2005a, Saxena et al., 2005b). The difference between our data and what has been 
reported in the literature might be due to different signalling mechanics in PC12 cells 
compared to neurons. In favour of this hypothesis, work from a colleague in the 
laboratory, Guillermo Menedez, showed that in DRG neurons the knockdown of RAB7 
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or the overexpression of a dominant negative form of this protein reduces the activation 
of CREB induced by NGF (Guillermo Menendez, Ph.D thesis). CREB phosphorylation 
is induced by the activation of TrkA, and this suggests that inhibiting the degradative 
pathway of TrkA might have the opposite effect on signalling in neurons than what has 
been previously described for PC12 cells (Saxena et al., 2005a, Saxena et al., 2005b). In 
addition, a potential reduction of the survival signal elicited by TrkB could explain the 
decreased viability of Bicd1gt/gt MNs in culture (Chapter 6, section 6.4.1).  
An interesting observation is that, while the exposure of p75NTR at the PM is two 
folds higher in Bicd1gt/gt MNs compared to wild type cells (Chapter 6, Figure 6.9), 
TrkB is only 45% more exposed at the PM in of Bicd1gt/gt MNs (Chapter 6, Figure 
6.10). This difference might result in an excess of p75NTR, which would then sequester 
BDNF preventing it from activating TrkB. Alternatively, an altered ratio between 
p75NTR and TrkB at the PM might affect the integration of the signals coming from 
these receptors. Hyperactivation of p75NTR, for example, could give rise to a feedback 
loop, which might decrease TrkB signalling. In order to test this hypothesis the 
signalling of p75NTR through NF-kB and JNK (Roux and Barker, 2002) (Chen et al., 
2009) would need to be tested; the prediction would be that the signalling through these 
pathways should be increased in Bicd1gt/gt MNs. 
An increased binding of HC was also observed in Bicd1gt/gt MNs, which could be 
explained by the increased levels of the polysialogangliosides GD1b on the PM, to 
which HC binds ((Halpern and Neale, 1995, Schiavo et al., 2000, Rummel et al., 2003), 
Figure 6.8). I have not yet investigated whether the depletion of BICD1 affects the 
intracellular trafficking of this molecule or if the overall content of GD1b in these cells 
is increased. In future experiments I plan to attempt to purify these lipids using thin 
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layer chromatography (TLC) to quantify the GD1b content of Bicd1gt/gt MNs. The only 
indirect data we have in this regard is that the expression level of the enzyme 
responsible for the synthesis of this lipid, GalNacT, is the same in the two genotypes 
(Figure 6.2 C). 
7.3 Conclusion and future experiments 
BICD1 is a microtubule associated protein and a dynein adaptor, which has been 
associated with several cellular functions (Figure 5.1), the best known in mammalian 
cells being the Golgi to ER COPI-independent retrograde transport (Matanis et al., 
2002). I have identified a novel role of this molecule in MNs. Notably, the only study 
linking a BICD protein to neurons was performed in Drosophila (Li et al., 2010), while 
BICDR-1, a BICD related protein, was found to be involved in neurite extension in 
hippocampal neurons (Schlager et al., 2010). In this thesis work, I have shown that the 
depletion of BICD1 alters the intracellular trafficking of neurotrophin receptors, 
possibly by impairing MVB maturation, resulting in an increased recycling of p75NTR 
and TrkB back to the PM (Figure 7.2). The recycling of p75NTR could be assayed by 
incubating Bicd1gt/gt MNs with a fluorescently conjugated version of the p75NTR 
antibody for an amount of time sufficient to allow receptor internalisation, followed by 
a brief acid-wash and then allow enough time for p75NTR to recycle back to the PM. The 
recycled receptor could then be visualised by staining with a differently coloured 
fluorescent secondary antibody (Deinhardt et al., 2007).  
The signalling induced by BDNF via TrkB was decreased in Bicd1gt/gt MNs. It 
should be established whether this is also the case for p75NTR signalling through NF-kB 
and JNK. In addition, it would be interesting to verify whether the initial defect in Akt 
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and ERK1/2 activation in p75NTR MNs translates to a defect in the activation of a 
downstream effector of the MAPK pathway, like the transcriptional factor CREB. The 
knockdown of RAB7, another candidate of the siRNA screen, gives a similar phenotype 
in terms of p75NTR intracellular accumulation and TrkA signalling in DRG neurons 
(Guillermo Menendez, PhD thesis) and should also be tested. Finally, the opportunity of 
using the Bicd1gt/gt ES cells to generate a homozygous mouse should be explored, in 
order to determine the in vivo phenotype. The heterozygous ES cells never gave rise to 
any offspring, suggesting that the gene is haploid insufficient, even though no obvious 
defect were noted in heterozygous embryos up to E14.5, which was the latest 
development stage analysed. Interestingly, while Bicd1gt/+ MNs mostly behaved like 
wild type MNs, they showed a behaviour similar to Bicd1gt/gt cells in the assays 
involving HC internalisation (Figure 6.4) and binding (Figure 6.7). A possible 
explanation could be provided by the observation that the levels of GD1b on the PM, a 
major determinant of HC binding to the neuronal surface, are similar in Bicd1gt/+ and 
Bicd1gt/gt MNs (Figure 6.8). The level of depletion of BICD1 in Bicd1gt/+ MNs seems 
sufficient to cause an increased exposure of GD1b at the PM, while not affecting the 
behaviour of p75NTR and TrkB. Further studies will be needed to unravel the mechanism 
underlying this observation. 
In conclusion this thesis work has demonstrated that a high content screen 
approach can be applied to motor neurons, which are notoriously difficult to handle and 
transfect. This approach has been successful in unravelling a new role for BICD1 in 
mammalian neurons. I was also able to show the pattern of expression of Bicd1 in E12.5 
and E13.5 mouse embryos, and gather data that points to a role for this protein in the 
trafficking and signalling of neurotrophin receptors, which might be extremely relevant 
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during the development of the nervous system. 
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Figure 7.1 Intracellular trafficking of HC, TrkB and p75NTR 
Schematic representation of the trafficking of neurotrophin receptors and HC in wild type MNs. In 
conditions of non stimulation TrkB is mainly directed to a degradative route (lysosome), while p75NTR 
mostly recycles back on the PM (Chen et al., 2005, Deinhardt et al., 2007). Upon neurotrophin binding 
both receptors undergo clathrin-mediated endocytosis, similar to HC, and are redirected to a common 
retrograde axonal transport route. This process is dependent on Rab5 and Rab7, because dominant 
negative forms of these two proteins prevent HC, p75NTR and TrkB axonal retrograde transport (Deinhardt 
et al., 2006b). After axonal transport to the cell body HC is found in multivescicular bodies (MVB). It is 
likely that p75NTR and TrkB also end up in MVBs, since they are transported together with HC. From this 
sorting platform HC, p75NTR and TrkB can undergo recycling or degradation. From the data gather in this 
thesis work BICD1 is likely to play a role in MVB maturation (Figure 7.2). Modified from (Deinhardt et 
al., 2006b). 
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Figure 7.2 Model of the putative function of BICD1 in the intracellular trafficking of TrkB and 
p75NTR 
Schematic representation of the possible role of the BICD1 protein in the trafficking of neurotrophin 
receptors based on the evidence gathered in this thesis work. The depletion of BICD1 by inhibiting the 
maturation of the MVBs could interfere with the degradation of endocytosed TrkB and p75NTR. This 
might result in a redirection of both receptors to the PM, with the net effect of increasing their 
concentration on the PM. 
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